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Abstract
Parkinson’s disease is a neurodegenerative disorder, characterised by the progressive
degeneration of midbrain dopaminergic neurons, and the intracellular aggregation of the
α-synuclein protein in neurons throughout the nervous system. These changes result in
the characteristic motor impairments in Parkinson’s disease. Current treatments are solely
symptomatic and therefore there is an unmet clinical need to develop new diseasemodifying therapies that can alter disease progression.
For over 25 years, one proposed experimental therapy has focused on the delivery
of proteins called neurotrophic factors to the brain to prevent dopaminergic neuron
degeneration. However, to date, clinical trials using the most well-known neurotrophic
factors have not met their primary endpoints, likely as a result of the down regulation of
their signalling receptor called Ret. Therefore, the aim of this thesis was to investigate
the efficacy of two Ret-independent neurotrophic factors called GDF5 and BMP2 using
in vitro and in vivo models of PD.
The main findings of this thesis were that GDF5 and BMP2 protected dopaminergic
neurons and their axons from neurotoxin- and α-synuclein-induced degeneration, which
is the protein that accumulates in the brains of people with Parkinson’s disease.
Moreover, intranigral delivery of an AAV vector carrying the human GDF5 transgene
protected dopaminergic neurons and their terminals from α-synuclein-induced
degeneration in vivo. This thesis has also identified two clinically approved drugs that
were capable of modulating the signalling pathway used by GDF5 and BMP2 to exert
their effects on dopaminergic neurons. These compounds, called Quinacrine and
Niclosamide, promoted dopaminergic neuron survival, and protected these neurons from
neurotoxin- and α-synuclein-induced axonal degeneration.

1

The wider implications of these findings are that they support the conclusion
that neurotrophic factor therapy remains a viable therapeutic approach for patients with
PD, and they have identified new therapeutics for the future development of neurotrophic
factor therapy in Parkinson’s disease.
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SDS-PAGE

SDS-Polyacrylamide Gel Electrophoresis

SEM

Standard error of the mean

Smad

Signalling mothers against decapentaplegic

SN

Substantia nigra

SNP

Sodium nitroprusside

SNpc

Substantia nigra pars compacta

STR

Striatum

STRAP

Serine threonine receptor-associated protein kinase

SYN1

Synapsin-1

TBS

Tris-Buffered Saline

TGF

Transforming Growth Factor

TH

Tyrosine hydroxylase

TH+

TH-positive

TXTBS

TBS containing 0.02% Triton-X100

UPDRS

Unified Parkinson's Disease Rating Scale

VMAT2

Vesicle monoamine transporter

VTA

Ventral Tegmental Area

WPRE

Woodchuck hepatitis virus post‐transcriptional regulatory element

WT

Wild type

Zeb

Zinc finger E-box-binding homeobox
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General Introduction
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1.1 Foreword
Neurological disorders are the leading cause of disability worldwide. Parkinson’s disease
(PD) is continuously growing in prevalence, disability, and deaths and is second only to
Alzheimer’s disease in terms of global incidence (Dorsey et al., 2018). There is no cure
for PD and available therapies are solely symptomatic (Poewe et al., 2017).
Consequently, there is an unmet clinical need to develop disease-modifying therapies that
can slow down, stop or even reverse the disease progression.
1.2 Epidemiology of PD
PD is a chronic idiopathic neurodegenerative disorder, first described over 200 years ago
by James Parkinson in his work ‘An Essay on the Shaking Palsy’ (Parkinson, 1817,
Parkinson, 2002). PD currently affects more than 6 million people worldwide and almost
2% of the global population over the age of 65 (Dorsey et al., 2018), increasing to over
3% above the age of 80 (Pringsheim et al., 2014). The incidence of PD in 2016 was more
than twice that in 1990 and is set to double by 2030, due in part to changing demographics
leading to longer disease duration, and exposure to possible environmental risk factors
(Dorsey et al., 2013). The estimated economic burden of PD in the US in 2017 was $51.9
billion (Yang, 2019.), while in Europe the annual cost was estimated at €13.9 billion in
2013 (Dorsey et al., 2013).
The aetiology of PD is still largely unknown, however certain genetic and
environmental influences have been linked to the onset of the disease. The leading risk
factor is age, with the average age of onset occurring above 60 years (Beitz, 2014,
Schapira and Jenner, 2011). However, PD can also manifest itself in persons younger
than 50 years, in what is known as Early Onset PD (EOPD) (Schrag and Schott, 2006).
Furthermore, PD can affect persons under the age of 20, recognised as Juvenile PD,
however this is not common (Klein and Westenberger, 2012). Gender is also implicated
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in PD with males being twice as likely to develop the disease than females (Poewe et al.,
2017). Other notable risk factors include ethnicity, exposure to environmental pesticides,
obesity, β-blockers, previous head injuries, agricultural employment, well-water drinking
and rural living (Beitz, 2014, Dick et al., 2007, Van Den Eeden et al., 2003). In contrast,
smoking and caffeine have been associated with a decreased risk of developing PD (Li et
al., 2015, Hernán et al., 2002).
While over 90% of PD cases are sporadic in origin, approximately 5-10% of cases
can be attributed to hereditary genetic mutations (Klein and Westenberger, 2012,
Toulouse and Sullivan, 2008). To date, six genes have been explicitly linked to inherited
monogenic forms of PD. These include mutations in SNCA and LRRK2, both of which
cause autosomal-dominant forms of PD and whose symptoms typically align with those
of sporadic PD, while mutations in PRKN, PINK1, DJ-1 and ATP13A2 are attributed to
autosomal-recessive patterns of inheritance and are linked with EOPD and slow disease
progression (Klein and Westenberger, 2012, Farrer, 2006, Toulouse and Sullivan, 2008).
In addition, changes in several other genes are considered to be risk factors for developing
PD including UCHL1, GYGYF2, HTRA2, PLA2G6, FBXO7, PARK16, GAK, MAPT,
GBA, NAT2, INOS2A, GAK, HLA-DRA and APOE (Klein and Westenberger, 2012,
Billingsley et al., 2018, Reed et al., 2019)
1.3 Pathophysiology of PD
PD is a progressive degenerative neurological disorder, the signature pathologies of
which include the extensive loss of dopaminergic neurons and their axons from the
substantia nigra pars compacta (SNpc) and the abnormal aggregation of the α-synuclein
protein inside neuronal cell bodies and their presynaptic nerve terminals, known as Lewy
bodies or Lewy neurites (Gibb and Lees, 1988, Kordower et al., 2013, Dickson, 2018,
Spillantini et al., 1997).
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1.3.1 Midbrain dopaminergic neurons
Dopaminergic neurons within the midbrain are categorised into three subpopulations –
A8 in the retrorubral field (RRF), A9 in the substantia nigra and A10 in the ventral
tegmental area (VTA) (German and Manaye, 1993) (Fig. 1.1). A9 midbrain dopaminergic
neurons in the SN pars compacta (SNpc) project to the dorsal striatum (or caudate
putamen) via the nigrostriatal pathway and play a key role in the regulation of voluntary
movement and motor control as part of the basal ganglia circuitry (Luo and Huang, 2016,
Hegarty et al., 2013c). In contrast, A8 and A10 midbrain dopaminergic neurons project
to the nucleus accumbens (ventral striatum), limbic systems, and the prefrontal cortex via
the mesolimbic and mesocortical pathways. These mesocorticolimbic projections
regulate a range of behaviours, including emotion, motivation, reward, and addiction
(Tzschentke and Schmidt, 2000). Consequently, abnormalities within these A8 and A10
midbrain dopaminergic neurons have been implicated in psychiatric disorders such as
schizophrenia and depression (Meyer-Lindenberg et al., 2002). However, the
degeneration of the A9 group of midbrain dopaminergic neurons is the neuropathological
hallmark of PD (Iarkov et al., 2020). These neurons project to γ-aminobutyric acid
(GABA) neurons in the striatum to regulate motor control (Sumit and Puneet, 2019).
Therefore, it is this selective loss of dopaminergic neurons, leading to a loss of striatal
dopaminergic innervation, that forms the aetiological basis of the motor impairments
associated with the disease including; resting tremor, muscular rigidity, bradykinesia,
akinesia and postural and gait instability (Kordower et al., 2013, Goetz, 2011, Moustafa
et al., 2016). In addition, several non-motor symptoms exist in PD, which commonly
present themselves prior to the onset of the classical motor symptoms. These include
olfactory dysfunction, gastrointestinal issues, sleep disorders, cognitive impairment,
psychiatric symptoms, as well as pain and fatigue (Kalia and Lang, 2015, Pfeiffer, 2016).
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Fig. 1.1 Schema depicting the dopaminergic pathways in the neurotypical and
Parkinson’s disease brain. A9 dopaminergic neurons in the SNpc project to the
dorsolateral striatum via the nigrostriatal pathway. A10 dopaminergic neurons in the
VTA project to the prefrontal cortex and ventral striatum. A8 dopaminergic neurons in
the RRF project to the ventral striatum. In PD there is a progressive loss of A9
dopaminergic neurons from the SNpc leading to the degeneration of the nigrostriatal
pathway. Created with BioRender.com.
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1.3.2 Axonal degeneration in PD
The loss of dopaminergic neurons from the SNpc is central to the clinical manifestation
of PD, however where the degeneration initially occurs within the nigrostriatal pathway
is unclear (O'Keeffe and Sullivan, 2018, Cheng et al., 2010). As mentioned, the axons of
dopaminergic neurons extend to the dorsolateral striatum forming the nigrostriatal
pathway and there now exists an array of pre-clinical, in vivo imaging and post-mortem
evidence suggesting that early axonal degeneration is a key feature of PD that precedes
dopaminergic neuronal loss (Caminiti et al., 2017, Burke and O'Malley, 2013, Tagliaferro
and Burke, 2016, Kordower et al., 2013, Dijkstra et al., 2015). In addition, it is commonly
estimated that at the time of PD onset, over 50% of dopaminergic neurons have been lost
from the SN (Ross et al., 2004, Dauer and Przedborski, 2003, Lang and Lozano, 1998).
However, 3 independent studies using linear regression to analyse dopaminergic neurons
in the SN versus duration of PD in post-mortem brains have estimated the loss of
dopaminergic neurons at the time of clinical onset to be closer to ~30% (Greffard et al.,
2006, Ma et al., 1997, Fearnley and Lees, 1991), while the loss of striatal dopamine is
estimated to be ~70% (Riederer and Wuketich, 1976, Cheng et al., 2010, Burke and
O'Malley, 2013).
Several imaging studies have used positron emission tomography (PET) to elucidate
the relationship between striatal terminals and motor symptoms (Tagliaferro and Burke,
2016). In particular, tracers for vesicular monoamine transporter (VMAT2) or dopamine
transporter (DAT) have been used, as they are predominantly expressed in dopaminergic
axons but are also present in cell bodies (Hersch et al., 1997, Nandhagopal et al., 2008,
Fu et al., 2019). By measuring the uptake of 18F-DTBZ using PET, one study examined
the level of VMAT2 activity in both the putamen and SN of patients diagnosed with PD
five years previous and compared their findings to neurotypical age-matched controls
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(Hsiao et al., 2014). This study found a severe reduction of 63-76% VMAT2 in the
posterior putamen while in the SN the loss was much lower at 13-29% (Hsiao et al.,
2014). In support of this finding, a subsequent study examining DAT loss by measuring
the uptake of 18F-FE-PE21 using PET, found a 3-fold reduction of DAT activity in the
putamen and a 1.5-fold reduction in the SN of PD patients with a mean disease duration
of 3 years (Fazio et al., 2015). Furthermore, a study examining [11C]FeCIT PET imaging
to measure DAT activity in 36 PD patients with a mean disease duration of 22 months
found a severe loss of DAT in the putamen while the SN was shown to be less affected
(Caminiti et al., 2017). A substantial reduction in dopamine network connectivity was
also recorded between the dorsal putamen and SN (Caminiti et al., 2017). These studies
support the hypothesis that there is an extensive loss of striatal terminals and degeneration
of the nigrostriatal pathway in the early stages of PD which may be central to disease
progression.
In addition to the evidence from the imaging studies, post-mortem evaluation of
nigrostriatal integrity has also been performed (Kordower et al., 2013, Chu et al., 2012).
In this study, the brains of 28 PD patients with disease durations ranging from 1 – 27
years were analysed for tyrosine hydroxylase (TH) and DAT expression in the SN and
putamen. Their findings showed that striatal fibres were only moderately affected 1 year
post diagnosis but almost completely absent by years 4-5. In addition, quantification of
striatal innervation at 1-3 years post diagnosis revealed a 35-75% loss in TH and DAT
immunoreactivity, consistent with that seen in the Hsiao et al study above. In the SN
however, there was a loss of 50-90% TH positive (TH+) neurons from the earliest time
points with only subtle loss found thereafter (Kordower et al., 2013). Moreover, the same
lab previously reported that the number of TH+ neurons in the SN of PD patients at stage
1 on the Hoehn and Yahr scale were not significantly different to neurotypical controls.
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However, a severe loss of striatal terminals was observed (Chu et al., 2012), further
implicating the loss of dopaminergic axons as a key early event in the pathogenesis of
PD. Kordower et al noted that a residual population of TH+ neurons remained in the SN
even decades after initial diagnosis despite the complete loss of striatal fibres (Kordower
et al., 2013), suggesting that therapeutic strategies targeting these surviving dopaminergic
neurons with a goal of axonal regeneration may offer potential as a disease-modifying
therapy.
1.3.3 α-synuclein
α-synuclein is a protein encoded by the SNCA gene which is predominantly expressed in
presynaptic terminals in the central nervous system (CNS) (Burré, 2015). The role of
endogenous α-synuclein remains elusive, but increasing evidence suggests that αsynuclein is involved in synaptic plasticity and neurotransmitter release (Venda et al.,
2010). α-synuclein was first linked to PD in 1997 when a point mutation in the SNCA
gene was located on chromosome 4, in which alanine was replaced by threonine at
position 53 (later termed A53T), was discovered in families living with an autosomal
dominant inheritance of PD (Polymeropoulos et al., 1997). Since that time several other
point mutations associated with autosomal dominant PD have been discovered including
A30P (Kruger et al., 1998), E46K (Zarranz et al., 2004), H50Q (Appel-Cresswell et al.,
2013), GF1D (Lesage et al., 2013), A53E (Pasanen et al., 2014) and A53V (Yoshino et
al., 2017). In addition, duplications (Chartier-Harlin et al., 2004) or triplications
(Singleton et al., 2003) of the SNCA gene are also associated with autosomal dominant
forms of PD, while linkage and genome-wide association studies have also identified
polymeric variants in the SNCA gene in patients with idiopathic PD (International
Parkinson Disease Genomics et al., 2011, Billingsley et al., 2018). α-synuclein was
further linked to PD when it was discovered that aggregates of misfolded α-synuclein
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were the major component of abnormal protein inclusions found throughout the CNS and
peripheral nervous system (PNS) (Spillantini et al., 1997). These atypical aggregates are
found in neuronal cells and their presynaptic terminals known respectively as Lewy
bodies and Lewy neurites, which constitute major pathological hallmarks of PD
(Spillantini et al., 1997, Meade et al., 2019). However, the pathological function of these
α-synuclein inclusions remains unclear (Shults, 2006).
α-synuclein inclusions are predominately found in the neuritic processes prior to
neuronal soma in the early stages of PD (Stefanis, 2012, Orimo et al., 2008, Braak et al.,
1999, Burke and O'Malley, 2013). Thus, α-synuclein has been strongly linked to the
axonal degeneration of dopaminergic neurons in PD (O'Keeffe and Sullivan, 2018, Burke
and O'Malley, 2013). This is supported by several experimental studies, one of which
utilised a transgenic mouse model expressing truncated human α-synuclein (α-Syn120)
and showed that by 12 months of age, α-synuclein was heavily distributed in neuritic
processes which also displayed beaded and dystrophic morphologies (Tofaris et al.,
2006). In addition, there was a significant reduction in striatal dopamine levels while
there was no loss in dopaminergic neurons in the SN (Tofaris et al., 2006). In this animal
model, the pathology is also associated with an age-dependent relocation of synaptic
proteins and a decline in dopamine release (Garcia-Reitbock et al., 2010). Likewise, in
line with the pathology of human PD, transgenic mice expressing mutant A30P or A53T
α-synuclein have also shown axonal degeneration to be an early and predominant feature
of the disease in these animal models (Giasson et al., 2002, Lee et al., 2002, Gomez-Isla
et al., 2003). Additional pre-clinical evidence using adeno-associated viral (AAV)
delivery of wild-type (WT) or A30P α-synuclein into the optic nerve of rats demonstrated
accelerated axonal degeneration in those axons overexpressing α-synuclein (Koch et al.,
2015). While intranigral AAV-mediated delivery of A53T α-synuclein demonstrated
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dystrophic axons with degenerative bulbs as early as 4 weeks post-surgery (Chung et al.,
2009). In addition, significant changes in the distribution of proteins related to synaptic
transmission and axonal transport were also seen in the SN and striatum (Chung et al.,
2009), further implicating the role of α-synuclein in axonal degeneration in PD.
Additional in vitro studies investigating the effects of α-synuclein on primary
dopaminergic neurons and induced pluripotent stem cells (iPSCs) are also shedding light
on the role of α-synuclein in axonal degeneration (Koch et al., 2015, Oliveira et al., 2015).
The overexpression of WT, A30P or A53T α-synuclein in primary cultures of
dopaminergic neurons from embryonic day (E)14 Wistar rats was shown to cause
detrimental effects on neurite morphology, autophagy, vesicle transport and axonal
degeneration after only 5 days in vitro (DIV) (Koch et al., 2015). iPSCs can be generated
and reprogrammed from somatic cells and differentiated into neurons.(Takahashi et al.,
2007). Consequently, this has led to advent of somatic cells from patients with idiopathic
or familial PD being differentiated into neurons to help better understand and characterise
the disease pathology, including the role of α-synuclein in axonal degeneration (Soldner
et al., 2011, Devine et al., 2011, Singh Dolt et al., 2017). Such studies have uncovered
impaired neuronal differentiation, lower neuronal connectivity and spine formation in
iPSC derived neurons from patients with SNCA gene triplication compared to
neurotypical controls (Oliveira et al., 2015). Similarly, other studies on iPSCs with SNCA
triplication have shown anomalies in neurite length as well as axonal degeneration in the
form of axonal blebbing and fragmentation (Lin et al., 2016b).
Moreover, iPSCs derived from patients with EOPD with an A53T SNCA mutation
demonstrated Lewy-like neurites, α-synuclein aggregation and displayed varicosities
positive for α-synuclein expression, neurite swelling and fragmentation as well as a
compromised ability to form synapses (Kouroupi et al., 2017). These findings are
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consistent with previous studies showing knockdown of α-synuclein results in increased
neurite length and neurite number in iPSCs derived from PD patients with SNCA
triplication (Oliveira et al., 2015). Moreover, transgenic mice expressing human αsynuclein exhibit synaptic dysfunction in striatal dopaminergic terminals and a reduction
in dopamine release over time (Garcia-Reitbock et al., 2010, Hunn et al., 2015).
Collectively, these studies demonstrate a fundamental link between α-synuclein
pathology and synaptic and axonal degeneration.
1.4 Management of PD
Despite decades of intense investigation, there is no cure or disease-modifying therapy
available for the treatment of PD. Currently, existing pharmacological treatments are
solely symptomatic and centre around replenishing dopamine levels or delaying its
metabolism (Raza et al., 2019, Schapira et al., 2014). Therefore, these interventions do
not halt the progression of the disease nor do they reverse or restore the neuronal loss
seen in the SNpc or the loss of dopaminergic axon terminals from the striatum. Since its
discovery in the 1960’s, systemic delivery of Levodopa, the precursor to dopamine,
remains the most potent and effective symptomatic treatment strategy for PD (Olanow,
2008, LeWitt and Fahn, 2016). Unlike dopamine, Levodopa can cross the blood brain
barrier (BBB) where it is converted to dopamine and acts to alleviate the motor symptoms
associated with PD (Fig. 1.2). However, prolonged treatment with Levodopa causes
unwanted adverse effects such as motor response oscillations and chronic dyskinesia,
which can be worse than the disease itself (Olanow, 2008). These side effects are believed
to be result of discontinuous drug delivery due to the rapid half-life of Levodopa and the
variability associated with its gastrointestinal absorption and transport across the BBB
(Abbott, 2010). Therefore, in clinical practice Levodopa is usually withheld from the
patient until all other viable options have been exhausted. However, novel sustained-
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release or continuous delivery formulations of Levodopa have been developed to address
these issues (Abbott, 2010).
Additional or alternative pharmacological treatment options available include
aromatic amino acid decarboxylase (AADC) inhibitors such as Benserazide or Carbidopa
as well as Catechol-O-methyltransferase (COMT) inhibitors including Entacapone which
act to inhibit the metabolism of Levodopa in the PNS in order to maximise the level of
Levodopa reaching the CNS (Jankovic and Aguilar, 2008, Connolly and Lang, 2014). In
addition, oxidation by monoamine oxidase (MAO) type B (MAOB) in glial cells plays a
major role in the breakdown of synaptically released dopamine. Therefore, inhibitors of
MAOB, such as Selegiline and Rasagiline, act to prolong synaptic dopamine
concentrations and increase pre-synaptic reuptake of dopamine (Poewe et al., 2017).
Furthermore, dopamine agonists, such as Pramipexole and Apomorphine, mimic
endogenous dopamine and directly target and activate pre- and post-synaptic dopamine
receptors. Dopamine agonists also have a long half-life and are often used to allow for
the delayed administration of Levodopa (Jankovic and Poewe, 2012). In addition, several
non-dopaminergic pharmacological therapies are also available for the treatment of motor
symptoms in PD (Poewe et al., 2017).
Other treatment options accessible to PD patients include physiotherapy, speech
therapy, diet therapy, exercise (Yang et al., 2015, Jankovic and Poewe, 2012). Surgical
interventions are also available to alleviate motor symptoms including; Deep Brain
Stimulation (DBS), which involves the targeted delivery of electrical impulses to
stimulate areas of the brain involved in motor control, namely the subthalamic nucleus
(Groiss et al., 2009), Thalamotomy, which involves the surgical ablation of a portion of
the ventrolateral nucleus of the thalamus (Speakman, 1963) and Pallidotomy, whereby a
small area in the Globus Pallidus is surgically destroyed (Lozano and Lang, 1998).
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Fig. 1.2 Dopaminergic drug targets in Parkinson disease. Presynaptic targets include
Levodopa substitution in combination with peripherally active inhibitors of AADC or
COMT. MAOB inhibitors act to increase the synaptic availability of dopamine while
dopamine agonists act post-synaptically. Dashed arrow from blood to brain designates
BBB transport of Levodopa. Dashed arrow through the DAT denotes reuptake of
dopamine from the synaptic cleft. 3-O-M-DOPA = 3-O-methyl-DOPA; D1R = dopamine
D1 receptor; DOPAC = 3,4-dioxy-phenylacetic acid. Adapted figure and legend (Poewe
et al., 2017).
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1.5 Emerging therapies under investigation
Given the distinct degeneration of the A9 population of dopaminergic neurons in PD,
several lines of research are being investigated to combat this specific loss. Some of the
most promising potential strategies include a) Cell replacement therapy which involves
the transplantation of new dopaminergic neurons, generated from foetal tissue or stem
cells, to the brain to replace those that have been lost (Wijeyekoon and Barker, 2009,
Ganz et al., 2011, Fan et al., 2020) and b) Neurotrophic factor therapy to protect the
remaining dopaminergic neurons in the SN and to regenerate the nigrostriatal
dopaminergic pathway (Sullivan and O’Keeffe, 2016) (Fig. 1.3). The focus of this thesis
will be on Neurotrophic factor therapy.

Fig. 1.3 The potential of Neurotrophic factor therapy in PD. A Showing the
progressive degeneration of the nigrostriatal pathway in PD due to the loss of
dopaminergic neurons innervating the striatum. B The administration of neurotrophic
factors has the potential to protect dopaminergic neurons as well as maintain and
regenerate the innervation of the nigrostriatal pathway. Adapted figure and legend
(Hegarty et al., 2014b).
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1.6 Neurotrophic factors – a history
Neurotrophic factors (NTFs) are naturally occurring, small secreted proteins or cytokines
that regulate neuronal differentiation and maturation during development and adulthood
(Sullivan and O’Keeffe, 2016, Holtzman and Mobley, 1994). Within the SN, NTFs for
dopaminergic neurons are intrinsically involved in the generation of the dopaminergic
transmitter phenotype, the proliferation of dopaminergic cells and their subsequent
migration to the striatum (Krieglstein et al., 1995, Hefti, 1994). During this migration,
NTFs are required to support axon elongation for successful innervation of their target.
Neurotrophic support is therefore crucially involved in all aspects of the development,
growth, proliferation, survival, migration and maturation of dopaminergic neurons
(Unsicker et al., 1996). Given the loss of dopaminergic neurons in PD, the disease lends
itself to NTF therapy (Hefti, 1994, Sullivan and Toulouse, 2011). Thus, the goal of NTF
therapy is the application of growth factors that can protect the remaining dopaminergic
neurons from degeneration and promote re-innervation of the striatum through the
regeneration of the nigrostriatal pathway (Hegarty et al., 2014b, Sullivan and O’Keeffe,
2016).
However, there are several problems associated with the administration of NTFs.

Systemic delivery of NTFs is not feasible due to poor bioavailability and their large
molecular weight, which prevents their transportation across the BBB (Pardridge, 2007).
In addition, exogenous delivery of NTFs to the brain is hampered by rapid metabolism
by endogenous enzymes within the brain (Sullivan and Toulouse, 2011). Gene therapy
using viral vectors to deliver neurotrophic factors to targeted areas of the brain offers the
potential to evade these issues. Viral vectors have many attractive attributes which make

them suitable for gene transfer including targeted delivery to specific areas of the brain
reducing unwanted off-target effects, the ability to transduce neuronal cells causing long-
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term transgene expression and the relatively small titre and volume needed which avoids
the circulation of immunogenic material (Bartus, 2015, Kirik et al., 2017). While several
approaches exist for NTF delivery, the typical strategy is the use of engineered nonreplicating viral vectors including adenoviruses (AV), lentiviruses (LV) and AAV (Kelly
et al., 2015, Lin et al., 2017). AAVs are predominately used to target neurons in the CNS
in neurological disorders such as PD due to their natural tropism for neurons, their low
rates of pathogenicity and toxicity and their ability to provide long-term targeted
transgene expression (Burger et al., 2005, Lundstrom, 2018, Mijanović et al., 2020).
AAVs belong to the parvovirus family and are single stranded viruses with a genome size
of 4.7kb (Naso et al., 2017, Mandel et al., 2008). AAVs are replicative defective as all
viral sequences are removed except for the inverted terminal repeats (ITRs), which are
required for genome packaging into the AAV capsid (Mandel et al., 2006, Weitzman et
al., 2003). Consequently, AAVs incite very little host immune responses. A limitation of
AAV compared to AV or LV is its limited packaging capacity of 4.7kb (Kelly et al.,
2015, Grieger and Samulski, 2005). However, even with this small genome size, AAVs
are capable of encoding most NTFs (Shevtsova et al., 2005). AAV2 represents the
prototypical AAV serotype of choice and has been used extensively in preclinical and

clinical studies of PD (White, 2012, Shevtsova et al., 2005, Gasmi et al., 2007, Ren et al.,
2013, Kordower et al., 2006, Marks et al., 2010, Warren Olanow et al., 2015, Bäck et al.,
2013, Richardson et al., 2011, Gombash et al., 2013, Bartus et al., 2011, Su et al., 2009,
Bartus et al., 2013, Herzog et al., 2007, Decressac et al., 2011, Quintino et al., 2019). A
brief history of the most prevalent NTFs under review for the treatment of PD will now
be discussed.
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1.7 The GDNF Family
The glial cell-line derived neurotrophic factor (GDNF) family of ligands (GFLs) is a
distant and distinct member of the transforming growth factor beta (TGF-β) protein
superfamily comprised of four NTFs including GDNF, Neurturin, Artemin and Persephin
(Airaksinen and Saarma, 2002). Unlike most members of the TGF-β family which signal
via the Smad pathway, GFLs activate signalling through binding to different
glycosylphosphatidylinositol (GPI)-anchored GDNF family receptor alpha (GFRα)
complexes which then signal through a transmembrane receptor RET (REarranged during
Transfection) tyrosine kinase (Mulligan, 2019). The GFL-GFRα complexes interact with
RET’s extracellular domain which promotes dimerization and activation of its
intracellular kinase domain, causing the activation of multiple downstream pathways
including mitogen-activated protein kinase (MAPK) and PI3 (Creedon et al., 1997).
GFLs are known to play a number of roles in cell survival and differentiation as well as
neurite growth and migration in several neuronal populations. Specifically, GDNF and
Neurturin have shown potent neurotrophic ability for dopaminergic neurons affected in
PD (Kordower and Bjorklund, 2013)

1.7.1 Glial Cell-Line Derived Neurotrophic Factor
GDNF is a glycosylated, disulfide-bonded homodimer and was discovered and
characterised in 1993 after demonstrating promising results in promoting the survival of
cultured midbrain dopaminergic neurons (Lin et al., 1993). These findings were
consistently mirrored in subsequent in vitro studies including cellular models of PD
(Clarkson et al., 1995, Eggert et al., 1999, Widmer et al., 2000, Clarkson et al., 1997). In
addition, GDNF has been shown to promote neurite growth in primary midbrain
dopaminergic neurons (Lin et al., 1993, Hegarty et al., 2014c). Consequently, GDNF was
tested in adult rodent and primate models where it was found to reliably improve the
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survival of embryonic ventral mesencephalic (VM) dopaminergic neuronal grafts to the
striatum (Apostolides et al., 1998, Espejo et al., 2000, Granholm et al., 1997, Yurek,
1998, Sullivan et al., 1998, Tomac et al., 1995, Kholodilov et al., 2004, Eslamboli et al.,
2005, Dowd et al., 2005). Given such promising results in vivo, GDNF was subsequently
tested in clinical trials (Nutt et al., 2003, Gill et al., 2003, Lang et al., 2006, Patel et al.,
2005, John T. Slevin et al., 2005, Whone et al., 2019a, Whone et al., 2019b). However,
despite initial triumphs in open-label trials (Gill et al., 2003, John T. Slevin et al., 2005),
GDNF has thus far failed to reach its primary endpoints in randomised placebo-controlled
studies. In addition, AAV-mediated or LV-mediated delivery of GDNF was found to be
unable to protect dopaminergic neurons from α-synuclein-induced degeneration in the αsynuclein pre-clinical model of the disease (Decressac et al., 2011). A phase I open-label
safety trial delivering AAV2-GDNF to patients with advanced PD is currently ongoing
and will be completed in 2022 (ClinicalTrials.gov identifier: NCT01621581).

1.7.2 Neurturin
Neurturin is a naturally occurring analogue of GDNF and has been shown to demonstrate
comparable neurotrophic action on midbrain dopaminergic neurons in vitro (Horger et
al., 1998, Akerud et al., 1999). In addition, Neurturin is also highly potent in vivo against
animal models of PD (Tseng et al., 1998, Hoane et al., 1999, Oiwa et al., 2002, Herzog
et al., 2007, Kordower et al., 2006). This evidence led to the first clinical trials using
AAV-mediated delivery of Neurturin to targeted areas of the brain (Bartus et al., 2013,
Marks et al., 2010, Marks et al., 2008, Bartus et al., 2011). However, despite
demonstrating safety and success in open label trials, the therapy failed to reach its
primary endpoint in double-blind, randomised, controlled trials (Warren Olanow et al.,
2015).
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The failure of the GDNF and Neurturin clinical trials to date is speculated to be
attributable to factors surrounding patient age and selection, catheter design and
positioning as well as drug dosage and diffusion (Kordower et al., 1999, Salvatore et al.,
2006, Decressac et al., 2011). Additionally, from a molecular point of view, accumulation
of α-synuclein in PD (Spillantini et al., 1997, Kontopoulos et al., 2006, Stefanis, 2012),
has been shown to cause downregulation of Nurr1 and its downstream effector protein,
RET, the co-receptor for GDNF and Neurturin signalling (Decressac et al., 2012a,
Drinkut et al., 2016). This may offer an explanation as to why both NTFs have shown
limited efficacy in clinical trials, as RET has also been shown to be downregulated in PD
(Decressac et al., 2012a), however evidence to the contrary has also been reported (Su et
al., 2017). Therefore, it has been proposed that RET-independent NTFs should be
considered in the study of NTF therapy for PD and pre-clinical evaluation of NTFs should
include the α-synuclein model of PD (Warren Olanow et al., 2015).

1.8 Brain Derived Neurotrophic Factor
Brain Derived Neurotrophic Factor (BDNF) belongs to the Neurotrophin family and is
produced in the endoplasmic reticulum of neural cells throughout the CNS (Palasz et al.,

2020). Here, BDNF and other Neurotrophins support neuronal differentiation and
maturation as well as serving as potent inhibitors of apoptosis-mediated cell death
through the activation of BDNF-TrkB and IP3K/Akt kinase signalling cascades (Yoo et
al., 2017). BDNF has been found to be downregulated in the blood serum and brain of
PD patients, which is correlated with a greater loss of dopaminergic neurons from the SN
(Huang et al., 2018, Scalzo et al., 2010, Ventriglia et al., 2013, Wang et al., 2016). BDNF

has been trialed in animal models of PD through direct injection (Hung and Lee, 1996,
Tsukahara et al., 1995), viral vector delivery, including transgenes to enhance

27

endogenous BNDF expression in the brain (Klein et al., 1999, Nam et al., 2015, Sun et
al., 2005, Tronci et al., 2017, Kim et al., 2012) or non-viral vehicles (Hernandez-Chan et
al., 2015, Razgado-Hernandez et al., 2015). While several studies have found BDNF to
be protective of dopaminergic neurons when administered prior to neurotoxic insult (Nam
et al., 2015, Kim et al., 2012, Tsukahara et al., 1995, Klein et al., 1999), others have
reported no therapeutic protection of dopaminergic neurons when delivered after the
insult has occurred (Hernandez-Chan et al., 2015, Kim et al., 2012, Yoshimoto et al.,
1995). Yet despite the lack of effect on dopaminergic cell numbers, others have noted
improved striatal dopaminergic levels (Hernandez-Chan et al., 2015) as well as better
behavioural output (Kim et al., 2012, Klein et al., 1999, Hernandez-Chan et al., 2015,
Razgado-Hernandez et al., 2015).
To date, BDNF has not been trialed in humans for PD but has been trialed for patients
with amyotrophic lateral sclerosis (ALS), however the study failed to reach statistical
significance, despite positive findings in phase I/II trials (Bradley, 1999, Ochs et al.,
2000). Notably, BDNF expression and trafficking has been shown to be negatively
affected by α-synuclein through the impairment of the BDNF-TrkB signalling pathway,
leading to dopaminergic neuronal cell death (Fang et al., 2017, Kang et al., 2017). This

raises important questions concerning the use of cellular models and animal models to
mimic synucleinopathies. Investigating potential NTFs using an α-synuclein model of PD
in pre-clinical studies is needed to overcome this issue and to highlight discrepancies
early in the discovery phase.
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1.9 Cerebral Dopamine Neurotrophic Factor and Mesencephalic astrocytederived neurotrophic factor
Cerebral Dopamine Neurotrophic Factor (CDNF), formerly known as Conserved
Dopamine Neurotrophic factor, and Mesencephalic Astrocyte-derived Neurotrophic
Factor (MANF) form a novel evolutionary conserved family with selective neurotrophic
potential for dopaminergic neurons (Lindholm and Saarma, 2010). MANF is the founding
member of the family and was originally identified from the culture medium of rat Type1 astrocyte ventral mesencephalic cell line 1 when it was found to selectively promote
dopaminergic neuronal survival in embryonic neuronal cultures (Petrova et al., 2003).
Interestingly, MANF expression in drosophila flies is known to be crucial for the
maintenance of dopaminergic neurites and dopamine levels (Palgi et al., 2009). CDNF
was then later discovered as a specific paralogue to MANF (Lindholm et al., 2007). Both
CDNF and MANF have been shown to reduce motor deficits and protect dopaminergic
neurons in the SN and their axonal terminals in the striatum in animal models of PD
(Lindholm et al., 2007, Voutilainen et al., 2009, Airavaara et al., 2012).
In addition, several studies have used viral vectors to deliver CDNF or MANF in
pre-clinical models of PD and have achieved encouraging results (Bäck et al., 2013, Ren

et al., 2013, Cordero-Llana et al., 2015, Hao et al., 2017). Striatal delivery AAV2-CDNF
has demonstrated neuroprotection of dopaminergic neurons and restoration of
behavioural deficits when delivered to the striatum in animal models of PD (Bäck et al.,
2013, Ren et al., 2013). Similarly, AAV9-MANF has been shown to halt
neurodegeneration and regenerate lost nerve terminals in the striatum of lesioned animals
(Hao et al., 2017). An additional study investigated the combined effect of LV-mediated

delivery of both CDNF and MANF to the nigra and found significant synergistic effects
that resulted in a robust reduction in behavioural deficits and protection of dopaminergic
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neurons and striatal fibres in lesioned animals (Cordero-Llana et al., 2015). The first
clinical trial using CDNF was started in 2017 (Huttunen and Saarma, 2019). In this study,
patients with moderately advanced PD were given intermittent monthly bilateral
intraputamenal infusions of CDNF in randomized placebo-controlled phase I–II clinical
studies (ClinicalTrials.gov identifier: NCT03295786) (Huttunen and Saarma, 2019).
Preliminary results indicate that the therapy is safe for human use and comprehensive
results are expected to be published shortly.

1.10 Platelet-derived Growth Factor-BB
Platelet-derived growth factor BB (PDGF-BB) is a homodimer of PDGF isoform B which
has been demonstrated to have significant restorative effects on the nigrostriatal pathway

in animal models of PD (Mohapel et al., 2005, Zachrisson et al., 2011). These results led
to randomized, placebo-controlled phase I–IIa clinical studies in which continuous
intracerebroventricular infusion of PDGF-BB was given to patients with moderate PD
over a 14-day period (Paul et al., 2015). The initial results found this treatment to be safe
and well received. However, no differences were found in the Unified Parkinson's
Disease Rating Scale (UPDRS) scores between treatment groups in a follow up after 3

months. Although patients who received high doses of the treatment exhibited significant
increases in DAT ligand binding in PET scans compared with patients who received the
placebo (Paul et al., 2015). However, after significant delays in initiating subsequent
clinical trials and problems relating to the medical device and commercialisation of the
therapy, the continued development of PDGF-BB therapy by Newron Pharmaceuticals
SpA was discontinued in 2015 (Huttunen and Saarma, 2019).
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1.11 The Bone Morphogenetic Protein family
The bone morphogenetic protein (BMP) family is the largest subgroup of the TGF-β
superfamily of proteins and is comprised of at least 20 growth factors, including the
Growth and Differentiation factor (GDF) family (Kawabata et al., 1998, Chen et al.,
2004). BMPs were first identified by their presence in extracts of demineralized bone
(Wozney, 1992) and have since been shown to induce a sequential developmental cascade
of cartilage and bone formation (Nishimura et al., 2012, Miyazono et al., 2010, Wu et al.,
2016), as well as playing roles in various other developmental processes (Chen et al.,
2004). Much experimental evidence has demonstrated that BMPs are involved in many
biological processes across various cell types, including monocytes, epithelial cells,
mesenchymal cells, and importantly, neuronal cells (Miyazono and Shimanuki, 2008,
Wang et al., 2014). Within these cells, BMPs are known to regulate growth,
differentiation, chemotaxis and apoptosis, while also playing vital roles in the
morphogenesis of almost all organs and tissues throughout embryogenesis (Hogan, 1996,
Wang et al., 2014). Additionally, BMPs are crucial regulators of axonal growth in many
distinct neuronal populations (Gratacos et al., 2002, Parikh et al., 2011, Hegarty et al.,
2013a).

1.11.1 BMP Signalling
BMPs signal through a canonical pathway that involves transcription factors known as
Smads. In this pathway, BMPs bind to a heterotetrameric complex of cell surface
transmembrane type I and type II serine/threonine kinase receptors, causing the
subsequent activation of Smad signalling (Weiss and Attisano, 2013, Nohe et al., 2004)
(Fig. 1.4). Depending on the cellular context, BMP signalling can also occur via noncanonical pathways involving the activation of many intracellular pathways, including
GTPases, MAPK and PI3K pathways (Zhang, 2009). To date, there are seven identified
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type I receptors, the activin receptor-like kinases (ALK) 1–7, and five type II receptors
(Hegarty et al., 2013a, Sieber et al., 2009, Miyazono and Shimanuki, 2008). There are
eight distinct Smad proteins, which constitute three separate functional groupings. These
include the receptor-regulated Smads (R-Smads) -1, -2, -3, -5, and -8/9, the commonmediator Smad (Co-Smad) 4 and the inhibitory Smads (I-Smads) 6 and 7 (Wrana and
Attisano, 2000, Heldin et al., 1997). Following ligand binding to the heterotetrameric
receptor complex, which is composed of a type I and type II receptor dimer, the
constitutively active type II receptors intracellularly transphosphorylates the type I
receptors at serine and threonine residues via a highly conserved glycine/serine (GS)
domain (Miyazono et al., 2010). The phosphorylation of type I receptors leads to the
recruitment and subsequent phosphorylation of the R-Smads, which can then form a
heterotrimer complex with Co-Smad 4. The I-Smads function as major negative
regulators of BMP-Smad signalling and compete with the R-Smads for both receptor
binding and Co-Smad 4 binding. The I-Smads also target the receptors for degradation
via the proteasome (Shi and Massague, 2003, Miyazono et al., 2005). The signalling
pathway culminates with the R-Smads and Co-Smad 4 complex translocating to the
nucleus, where it binds to DNA and regulates the transcription of target genes (Wrana

and Attisano, 2000).
However, although there are many ligands of the TGF-β superfamily, there are very
few receptors available to accommodate ligand binding. Thus, the type I and type II
receptors are required to bind to more than one ligand type (Shi and Massague, 2003).
There are two known type I BMP receptors (BMPRs), BMPR1A (also known as ALK3)
and BMPR1B (also known as ALK6); however, BMPs are also capable of binding to
ALK1 and 2. Furthermore, BMPs can bind to three type II receptors: BMPR2, activin
type 2A receptor (ACVR2A) and ACVR2B (Hegarty et al., 2013a, Miyazono et al.,
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2010). Recent studies have identified dynamin-dependent endocytosis to be a crucial
regulator of the BMPRs at the surface of the cell membrane and to play a central role in
the activation, temporal kinetics and magnitude of BMP signal transduction (Hegarty et
al., 2017b).
The type I and II BMPRs can form the heterotetrameric complex required for Smad

activation in various ways; consequently, BMP ligands have varying affinities for these
combinations. For example, BMP2 binds to BMPR1A and BMPR1B with a higher
affinity than it does to BMPR2. Similarly, GDF5 binds to BMPR2 and BMPR1B with
greater affinity than to BMPR1A. In fact, the affinity of GDF5 for BMPR1B is at least
15-fold higher than it is for BMPR1A, signifying the fundamental importance of
BMPR1B for GDF5 signalling (Nickel et al., 2005). Such varying affinities for multiple

receptor complexes is relevant when studying the effects of potential NTFs in different
cell lines. In addition, various studies on the structural and functional features of the
BMPRs have highlighted a cytoplasmic loop segment, known as the L45 loop, located
adjacent to the GS domain on type I receptors, which is involved in R-Smad binding. A
corresponding loop, the L3 loop, is also present on the R-Smads and is involved in
determining the specific Smad substrates for the type I receptor kinases. Smads 1, 5 and
8 are the pivotal effectors that are primarily linked to members of the BMP/GDF
subfamily, while Smads 2 and 3 are typically associated with TGF-βs, Activins and
Nodals (Mueller and Nickel, 2012).
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Fig. 1.4 Schematic of BMP-Smad signalling from cell membrane to the nucleus.
BMP ligands bind to a heterotetrameric complex of type I and type II serine/threonine
kinase cell surface receptors causing the constitutively active type II receptor to
intracellularly phosphorylate the type I receptors. R-Smads and I-Smads compete for
binding at the receptor complex for phosphorylation and subsequent complexation with
Co-Smad 4. The complex formed with Co-Smad 4 translocates to the nucleus where it
binds to the DNA and alters transcription (Goulding et al., 2020).
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1.11.2 BMP expression in the nervous system
Several studies have characterized the temporal expression profiles of the various BMPs
and their receptors in the developing nervous system. BMPR1 and BMPR2 are stably
expressed in the brain throughout adulthood, in several regions including the cortex,
striatum, hippocampus and SN (Chen et al., 2003, Miyagi et al., 2011). The expression
of BMPR1B and BMPR2 receptors in the rat VM is present from E11 onwards, after
which it is continuous right through to adulthood to at least post-natal day (P) 90 (Hegarty
et al., 2014a). Similarly, BMPR1B and BMPR2 transcripts are expressed in the mouse
VM from E12 onwards (Hegarty et al., 2017c). Notably, this BMPR temporal expression
profile parallels the growth of nigrostriatal dopaminergic projections as TH, a key marker
of dopaminergic neurons, is expressed at E13 and peaks at E15 (O'Keeffe et al., 2004b).
In addition, both BMPR1b and BMPR2 are found to be colocalised with TH in VM
dopaminergic neurons (Hegarty et al., 2014a). These findings suggest that BMP-Smad
signalling plays an active role in regulating nigrostriatal projections towards their target,
the dorsal striatum. Indeed, BMP-Smad signalling has been shown to be involved in
neural crest formation, modelling of the dorsal spinal cord, and has been heavily
implicated in neuronal and glial development (Hegarty et al., 2013a). The sustained
expression of the BMPRs through to adulthood would also suggest their role in the
maintenance of dopaminergic neurons. In strong support of this, a study using BMPR2
dominant negative (BMPR2DN) adult male mice highlighted a significant 20% reduction
in the number of VM dopaminergic neurons and a radical loss of almost 90% in striatal
innervation. These mice also displayed lower locomotor ability when compared WT
controls (Chou et al., 2008a). Therefore, it would appear that a neurotrophic role for
endogenous BMP-Smad signalling exists in dopaminergic neuronal development and
maintenance.
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It is now also known that the initial blocking of BMP-Smad signalling in
embryonic and adult iPSCs can lead to high rates of dopaminergic neuronal generation
(Chambers et al., 2009, Cai et al., 2013). Yet, the role of BMP-Smad signalling in the
later stages of midbrain dopaminergic development, until very recently, remained
unclear. Jovanovic et al (Jovanovic et al., 2018) have now described experimental
evidence to support BMP-Smad signalling as a critical regulator of mammalian
dopaminergic neurogenesis in vivo, through modulating the proliferation and
differentiation of progenitor cells. Here, they found that Smad 1 inactivation in the neural
stem cells (NSCs) of mice in vivo caused an obstruction to progenitor cells differentiating
into dopaminergic neurons, through the prevention of cell cycle exit of SN neurons
(Jovanovic et al., 2018).
In addition to the BMPRs, transcripts for the ligands BMP2- 8 are expressed from
E12 to E19 in several pivotal regions in the CNS (Jordan et al., 1997) while transcripts
for BMP2, -4, -5, -6 and -7 are shown to continually express throughout the cortex,
hippocampus, striatum and nigrostriatal system in the adult rat brain (Jordan et al., 1997,
Soderstrom and Ebendal, 1999, Chen et al., 2003). Likewise, GDF5 (also known as
BMP14) mRNA and protein expression begins at E12 in the VM and striatum, where it
reaches a peak at E14 and continues through to adulthood (Gavin et al., 2014, Krieglstein
et al., 1995, O'Keeffe et al., 2004b). Furthermore, mRNA transcripts for BMPs -2, -3, -4,
-6, -7 and GDF-5 have shown to be heavily abundant in the E14 rat dorsal root ganglia
(DRG) and are implicated in the modulation of neurotrophins on sensory neurons (Farkas
et al., 1999). Interestingly, like the BMPRs, transcripts for BMP2, BMP6 and GDF5 are
found to be expressed in the developing midbrain floor region during dopaminergic
neurogenesis, a time when neurotrophic support is crucial, prior to target innervation
(Jordan et al., 1997, Hegarty et al., 2014c). Given that the temporal expression profiles
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for several BMPs evolve in the VM and coincide with the generation of dopaminergic
neurons, this suggests that BMPs are neurotrophic factors for this specific neuronal class.
In support of this, several BMPs have been shown to possess potent neurotrophic
potential for midbrain dopaminergic neurons (Table 1.1). Within the BMP family, the
most promising and extensively studied members include GDF5 and BMP2. Therefore,
the focus of this thesis will be on these two ligands. Evidence for the neurotrophic action
of both GDF5 and BMP2 in vitro and in vivo will be discussed below.

Table 1.1 The effect of BMP ligands on dopaminergic neurons in vitro and
in vivo
BMP

Study

Effect on

Ligand

Type

dopaminergic neurons

BMP2

Promotes survival and
differentiation of midbrain
dopaminergic neurons
In vitro

Reference
(Jordan et al., 1997,
Stull et al., 2001, Reiriz
et al., 1999, Hegarty et
al., 2014a)

Increases differentiation of
NSCs into dopaminergic

(Yan et al., 2016)

neurons
Promotes differentiation of
SH-SY5Y cells

(Hegarty et al., 2013b)

Increases survival of
dopaminergic neurons in 6In vivo

OHDA lesioned rat model

(Espejo et al., 1999)

Decreases rotational behaviour
in 6-OHDA lesioned rat model
BMP4

Promotes survival of
In vitro

dopaminergic neurons
Induces dopaminergic
differentiation
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(Jordan et al., 1997)

(Stull et al., 2001)

BMP5
In vitro

Promotes survival of

(Jordan et al., 1997,

dopaminergic neurons

Brederlau et al., 2002)

Increases the number of TH+
neurons in iPSCs and NSCs

In vivo
BMP6
In vitro

Promotes dopaminergic
neurogenesis

(Jovanovic et al., 2018)

Promotes survival of

(Jordan et al., 1997,

dopaminergic neurons

Brederlau et al., 2002)

Induces dopaminergic
differentiation

BMP7

(Jovanovic et al., 2018)

(Stull et al., 2001)

Promotes survival of

(Jordan et al., 1997,

dopaminergic neurons

Brederlau et al., 2002)

Antagonises effects of
In vitro

Methamphetamine

(Chou et al., 2008b)

neurotoxicity
Increases the number of TH+
neurons in iPSCs and iNSCs

(Jovanovic et al., 2018)

Decreases rotational behaviour
in 6-OHDA lesioned rat
models
Restores KCl evoked
dopamine release to striatum
In vivo

(Harvey et al., 2004)

Partially protects dopaminergic
neurons after 6-OHDA
administration
Antagonises effects of
Methamphetamine
Promotes dopaminergic
neurogenesis

BMP12

GDF5

In vitro

In vitro

Promotes survival of
dopaminergic neurons

(Chou et al., 2008b)

(Jovanovic et al., 2018)

(Jordan et al., 1997)

Increases survival of

(Krieglstein et al., 1995,

dopaminergic neurons

Jaumotte and Zigmond,
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2014, Wood et al.,
2005, O'Keeffe et al.,
2004a, O'Sullivan et al.,
2010)
Protects dopaminergic neurons

(Krieglstein et al.,

against MPP+ neurotoxic insult

1995)

Promotes differentiation of

(Hegarty et al., 2014a,

dopaminergic neurons

O'Keeffe et al., 2004a)

Promotes survival and
differentiation of SH-SY5Y
cells
Protects SH-SY5Y cells
against 6-OHDA neurotoxicity
Protects dopaminergic neurons
against iron toxicity
Protects dopaminergic neurons
against 6-OHDA neurotoxicity
Decreases rotational behaviour
in 6-OHDA lesioned rat
models

In vivo

(Toulouse et al., 2012,
Hegarty et al., 2013b)

(Toulouse et al., 2012)

(Lingor et al., 1999)

(O'Sullivan et al., 2010)
(Sullivan et al., 1998,
Hurley et al., 2004,
O'Sullivan et al., 2010,
Costello et al., 2012)

Increased survival of

(Sullivan et al., 1998,

dopaminergic neurons in 6-

Hurley et al., 2004,

OHDA lesioned rat models

Costello et al., 2012)

Promotes survival of
dopaminergic neurons after 6-

(Hurley et al., 2004)

OHDA lesion
Increases mean somal area and
total neurite length in TH+

(O'Sullivan et al., 2010)

neurons
Increases total neurite length of
dopaminergic neurons
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(Costello et al., 2012)

GDF15

Increases dopaminergic
neuronal survival
In vitro

Protects dopaminergic neurons

(Strelau et al., 2000)

against iron intoxication
Protects dopaminergic neurons
against 6-OHDA neurotoxicity

(Machado et al., 2016)

Decreases rotational behaviour
in 6-OHDA lesioned rat
models
Promotes survival of
In vivo

(Strelau et al., 2000)

dopaminergic neurons 6OHDA lesioned rat models
Contributes to dopaminergic
neuronal rescue after

(Machado et al., 2016)

neurotoxic insult

1.11.3 Evidence for GDF5 and BMP2 as neurotrophic factors for
dopaminergic neurons
1.11.3.1 Evidence for the neurotrophic effects of GDF5 in vitro
GDF5 and its signalling receptors share a co-expression pattern with TH in VM
dopaminergic neurons, suggesting that GDF5 may offer trophic support to these neurons
to promote their survival and growth. Many studies have investigated this premise, the
first of which examined the effect of 20ng/ml of GDF5 in its active dimeric form on E14
VM cultures for up to 8 DIV and found there was a 1.6-fold increase in the survival of
TH+ neurons compared to untreated controls (Krieglstein et al., 1995). Consistent with
this, additional studies using 1ng/ml or 10ng/ml GDF5 induced a 3.1- and 2.6-fold
increase in TH+ neurons, respectively (O'Keeffe et al., 2004a), while also significantly
increasing axon length and branching. Furthermore, both doses of GDF5 led to
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noteworthy increases in the number of astrocytes present in the culture, suggesting a
possible association between astrocytes and GDF5 induced signalling, as also
documented in previous studies (Krieglstein et al., 1995, Wood et al., 2005). However,
the positive effects of GDF5 on TH+ neuron can also occur independently of astrocytes
indicating that GDF5 acts directly on dopaminergic neurons themselves, as has been
shown in glial depleted E14 VM cultures (Wood et al., 2005). In this study, the authors
aimed to compare the neurotrophic effects of GDF5 with that of GDNF using E14 VM
cultures. Here, 1, 10 or 100ng/ml doses of GDNF or GDF5 were added to normal cultures
and to glial depleted cultures every 48 hours for a period of 8 DIV. GDF5 increased the
survival of TH+ neurons at all doses up to 6 DIV, while 100ng/ml was also effective at 8
DIV. The same results were achieved for GDNF (Wood et al., 2005). In glial depleted
cultures, 1ng/ml GDF5 was tested as this dose was shown to significantly increase both
TH+ neurons and GFAP-positive (GFAP+) astrocytes. Here, the authors found no
significant difference in the number of TH+ neurons compared with normal cultures at
any time point. GDNF was not tested in these cultures as no significant increases in
GFAP+ astrocytes were found for any dose of GDNF. These results illustrate that while
treatment of GDF5 may contribute to astroglial proliferation, indicating a role for GDF5
in the regulation of neural progenitors, this is independent of its trophic effects on
dopaminergic neurons. Interestingly, the authors also investigated a co-treatment of E14
VM cultures with 1ng/ml GDNF and 1ng/ml GDF5 and found a substantial increase of
11.6% in TH+ cell number compared to cultures treated with GDF5 (5.1%) or GDNF
(4.9%) alone (Wood et al., 2005). The reason for this additive effect was postulated to be
due to the differential expression patterns of the receptors required by these NTFs to elicit
signalling, indicating that a combination therapy of NTFs may warrant investigation.
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Given that GDF5 is capable of promoting TH+ survival in mesencephalic cultures,
the question remained of whether GDF5 could also protect these TH+ neurons from
neurotoxic insult. To answer, one study employed E14 VM cultures treated with 20ng/ml
GDF5 one day prior to the administration of 0.5mM of the selective dopaminergic toxin
1-methyl-4-phenylpyridinium (MPP+) for 4 DIV (Krieglstein et al., 1995). MPP+ was
found to reduce TH+ neuronal survival by 67% while co-treatment with GDF5 saw a
reduction of just 30%, indicating a partial protective effect of dopaminergic neurons
(Krieglstein et al., 1995). An additional study investigated the potential of GDF5 to
protect against free radical damage given the evidence of their role in neurodegenerative
disorders (Lingor et al., 1999). Here, E14 VM cultures were given 10ng/ml GDF5 for
one week prior to addition of 30uM FeCl2 or 10uM sodium-nitroprusside (SNP) on day
7 for 24 h. Treatment with GDF5 induced a significant 1.7-fold increase in TH+ cell
survival compared to controls. However, no protection was achieved against SNP (Lingor
et al., 1999). The suggested reason for this was due to a difference in cell death pathway
between FeCl2 and SNP, where GDF5 may not be effective. However, this study was the
first of its kind to highlight the potential of GDF5 in rescuing dopaminergic neurons from
free radical injury and death. This is important given the evidence of elevated iron
deposits in the brains of PD patients (Hirsch et al., 1991, Sofic et al., 1991).
In contrast to these positive findings, other research groups have reported
unfavourable outcomes. One particular study treated E14 VM cultures with 30uM of the
selective dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA) for 6 DIV, prior to
the addition of GDF5 on day 7 (Brederlau et al., 2002). After assessing thymidine
incorporation, immunohistochemistry and immunofluorescence, GDF5 was found to
have had no protective or survival promoting effects on these cells. However, the authors
note that caution is needed when making conclusions about 6-OHDA work in vitro, as
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glial cells, which offer potent protective effects, can also be affected. While, in vivo, this
compound is known to act more selectively on dopaminergic neurons (Brederlau et al.,
2002). To coincide with this work, a recent study employed cultures of the SN isolated
from P0 pups and investigated the effects of five different NTFs against exposure to 10500µM MPP+ (Jaumotte et al., 2016). Here, cultures were exposed to MPP+ and treated
either 1 h prior to MPP+ exposure, during MPP+ exposure or 48 h after MPP+ exposure
with 100ng/ml GDNF, BDNF, TGF-β, fibroblast growth factor 2 (FGF-2) or GDF5.
However, no survival enhancing effects were seen for any of the NTFs when tested alone.
However, given in combination, a significant increase in survival of TH+ cells in the SN
cultures was seen at 32.6 ± 5.13% after exposure to 10µM MPP+ for 30 minutes, and 29.1
± 8.56% after exposure to 500µM MPP+ for 30 minutes (Jaumotte et al., 2016). This
apparent synergy could be as a result of elevated NTF receptor ‘hits’ on dopaminergic
cells, altered signalling cascades and the fact that each NTF not only acts on
dopaminergic neurons, but also non-dopaminergic cells whose paracrine signalling may
serve as a critical influence to dopaminergic neuron survival (Jaumotte et al., 2016). The
fact that no NTF alone was found to promote survival in this study may be due to
oversaturation of the relevant receptors above certain doses of each NTF (Jaumotte et al.,
2016), rendering high concentrations of these factors null and void. Still, these results
again reiterate the potential of a combination therapy using a cocktail of NTFs for the
treatment of PD.

1.11.3.2 Evidence for the neurotrophic effects of GDF5 in vivo
To complement the neurotrophic effects of GDF5 seen in vitro, the actions of GDF5 in
vivo are also quite compelling. The first group to investigate GDF5 in vivo examined both
the monomeric (inactive) and dimeric (active) form of the protein in the 6-OHDA rat
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model of PD (Sullivan et al., 1997). Here, 50ug of the monomer or dimer was injected
into the left SN and left lateral ventricle prior to a 6-OHDA lesion into the left median
forebrain bundle (MFB). One-week post-surgery, animals underwent behavioural testing
in the form of amphetamine induced rotations. Animals which had received the 6-OHDA
lesion as well as animals receiving the lesion combined with the monomeric form of
GDF5 displayed a rotation rate indicative of a 95% depletion of the nigrostriatal pathway.
In contrast, control animals and animals who had been administered the dimeric form of
GDF5 with 6-OHDA did not rotate at all, inferring an intact nigrostriatal system (Sullivan
et al., 1997). A subset of each experimental group also underwent PET scanning using a
dopaminergic transporter tracer to measure binding potential (BP). Again, animals which
had received the 6-OHDA lesion and animals receiving the lesion combined with the
monomeric form of GDF5 had a BP suggestive of a complete loss of dopaminergic uptake
within the striatum. While control animals and animals administered the dimeric form of
GDF5 with 6-OHDA exhibited an intact striatum (Sullivan et al., 1997). Post-mortem
High Performance Liquid Chromatography (HPLC) analysis examining dopamine and
its metabolites, 3,4-Dihydroxyphenylacetic acid (DOPAC) and Homovanillic acid
(HVA), found similar levels between the control group and GDF5 dimer with 6-OHDA
group while the 6-OHDA group and 6-OHDA with GDF5 monomer group had a marked
decrease across all 3 metabolites. Furthermore, TH immunostaining confirmed that the
6-OHDA and GDF5 monomer with 6-OHDA had extensive losses of TH+ neurons within
the SN and VTA while TH+ neurons in the GDF5 dimer with 6-OHDA group were largely
spared (Sullivan et al., 1997). These results demonstrate that GDF5 promotes survival
against dopaminergic toxins in vivo and can protect not only the nigral cell bodies of
dopaminergic neurons but their striatal nerve terminals too. These effects are also
corroborated in a functional capacity, as demonstrated by the behaviour testing and
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dopaminergic reuptake. Thus, establishing GDF5 early on as a strong candidate for NTF
therapy for treatment of PD.
In a follow up study, the group investigated the effectiveness of GDF5-treated
foetal mesencephalic grafts in the 6-OHDA lesioned rat model versus GDNF-treated or
untreated transplants (Sullivan et al., 1998). Here, rats were lesioned in the MFB 4 weeks
prior to grafting. Rats received untreated mesencephalic transplants or transplants which
had been suspended in solutions containing 500ug of GDNF or GDF5 (monomer or
dimer) in buffer, prior to transplantation into the striatum. Amphetamine-induced rotation
rates were assessed over an 11-week period. The mean rate for lesion-only animals was
12.6 ± 2.8, graft-only animals was 2 ± 0.4, GDF5 monomer-treated animals was 1.6 ± 0.3
while animals receiving GDF5 dimer-treated or GDNF-treated grafts displayed no
rotations (Sullivan et al., 1998). Furthermore, PET scans were undertaken to assess the
BP in the striatum. Intact control rats had a BP of 0.71 ± 0.07, while all 6-OHDA lesioned
animals prior to transplant had a mean BP of 0.3 ± 0.04. Post-graft, animals receiving the
graft only had a mean BP of 0.4 ± 0.04, GDF5 monomer-treated grafts had a mean BP of
0.36 ± 0.04, GDF5 dimer-treated grafts had a mean BP of 0.65 ± 0.04 while GDNFtreated grafts had a mean BP of 0.67 ± 0.06 (Sullivan et al., 1998). In terms of TH+ cell
survival, a deposit of TH+ cells was visible in all groups who had received a VM
transplant. However, the grafts pre-treated with GDF5 dimer or GDNF displayed a
significant increase in number and density of TH+ neurons compared with the graft alone
or the GDF5 monomer treated graft (Sullivan et al., 1998). This work was the first of its
kind to show the neurotrophic and neuroprotective effect of GDF5 on treated foetal
mesencephalic transplants. Notably, this study also highlighted that GDF5 treatment is
equally as beneficial as GDNF which is important in the pursuit of new functional
therapies given the failures of GDNF in clinical trials thus far.
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While GDF5 has been shown to be effective in protecting TH+ neurons from
intrastriatal 6-OHDA lesioning when administered concurrently, the question of whether
GDF5 is restorative post-lesion, is a major area of interest. In an effort to answer this, one
study administered 25ug/5ul GDF5 into the left striatum or left SN, one or two weeks
post 6-OHDA lesion into the left striatum (Hurley et al., 2004). Amphetamine-induced
rotation testing showed all 6-OHDA lesioned animals rotated at least 5 turns/minute after
lesioning, indicative of a partial striatal lesion. Animals receiving GDF5 to the striatum
at one-week post-lesion, but not at two weeks, had significantly reduced rotations.
Animals receiving GDF5 into the SN at one and two weeks post-lesion also had
significantly decreased rotation rates to 6-OHDA alone, three weeks post-surgery (Hurley
et al., 2004). Post-mortem analysis of the left SN showed a 60% loss of TH+ neurons in
the 6-OHDA group in comparison to its contralateral side, while animals injected with
GDF5 one-week post lesion into the SN or striatum had a 30-35% loss of TH+ neurons
from the SN. However, animals injected with GDF5 two weeks post lesion into the SN
or striatum conferred no protection to nigral dopaminergic neurons. In the striatum of 6OHDA animals, dopaminergic fibre density was reduced to 50% of the contralateral side,
and animals injected with GDF5 one or two weeks post lesion into the SN or striatum
were not significantly different to 6-OHDA animals (Hurley et al., 2004). The partial
lesion model used in this study is more reflective of the pathological degeneration seen
in PD, compared to complete lesion via the MFB. However, the fact that GDF5, delivered
via the SN or striatum, was ineffective in sparing striatal fibres is not entirely surprising
considering when 6-OHDA is injected into the striatum, the degeneration of axons begins
immediately and is complete within 24 h (Rosenblad et al., 1999). Therefore,
administration of GDF5 one or two weeks post-lesion, is most likely too late for axonal
protection using this model of PD, a result also found with intranigral delivery of GDNF
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(Kirik et al., 2001). The fact remains however that a single dose of GDF5 injected into
the SN or striatum, can significantly protect nigral cell soma from injury or death induced
by 6-OHDA lesioning weeks prior - a major breakthrough.
Given that NTFs are rapidly metabolised in vivo, one study has looked at the
overexpression of GDF5 in E13 VM tissue using cationic lipid-mediated gene delivery
(O'Sullivan et al., 2010). Here, cells were transfected with plasmids for enhanced green
fluorescent protein (EGFP) as the control, GDF5 or pcDNA (mock transfection). Twenty
four h post transfection, cells were treated with 50uM 6-OHDA for 30 minutes, then
processed for immunocytochemistry. Analysis of the cultures revealed that the cells
transfected with the GDF5 plasmid had significantly lower levels of TH+ cell death. The
number of TH+ cells was also significantly higher than the control or mock transfected
cultures (O'Sullivan et al., 2010). Given the efficacy of this system, the authors tested
these GDF5 transfected E13 VM cultures in the 6-OHDA model of PD. Animals received
a 6-OHDA lesion to the striatum two weeks prior to receiving the GDF5 transfected cells,
mock-transfected cells or freshly dissected tissue. Amphetamine induced rotations were
used to assess motor function (O'Sullivan et al., 2010). Post-lesion, all animals rotated
ipsilaterally with 8 turns per minute. Two weeks post-graft, those receiving the GDF5
transfected transplant displayed significantly lower rotation rates than that of 6-OHDA
alone, control animals or mock transfected animals. Moreover, post-mortem analysis
showed the presence of TH+ cells in all rats who had received a graft. While somal area
and total neurite length were significantly higher in animals receiving GDF5 transfected
cell transplants compared to mock transfected or freshly dissected transplant groups
(O'Sullivan et al., 2010). This study was the first to demonstrate the feasibility of
transfections prior to transplantation of foetal tissue, which could easily be applied to
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other cell types such as neural progenitors or stem cells, given the quantity of the foetal
tissue required for viable grafts.
In an additional study, a Chinese hamster ovary (CHO) cell line was stably
transfected with the human GDF5 gene in order to examine the effects of GDF5
production after transplantation into the rat striatum (Costello et al., 2012). Here, E14
VM cultures were supplemented with concentrated medium from GDF5-CHO cells or
Mock-CHO cells. In E14 VM cultures with GDF5-CHO medium, GDF5 precursors and
mature GDF5 were secreted for at least 15 days. There was also a 2-fold increase in the
number of TH+ cells. For E14 VM cells with Mock-CHO medium, there was no GDF5
secretion and no increase to TH+ cell number (Costello et al., 2012). To test these cells in
vivo, rats received a 6-OHDA lesion to the MFB. GDF5-CHO or Mock-CHO cells were
then delivered in three ways: injected into the striatum at the same time as 6-OHDA
lesion, injected into the striatum one week after 6-OHDA lesion, or injected into the SN
one week after 6-OHDA lesion. Rats receiving GDF5-CHO transplants expressed GDF5
for at least one week. Amphetamine-induced rotation testing revealed 6-OHDA animals
and 6-OHDA+Mock-CHO (same time) animals rotated at a rate of 8 turns/minute. 6OHDA+GDF5-CHO (same time) animals had significantly lower rotations than both 6OHDA alone and 6-OHDA+Mock-CHO animals (Costello et al., 2012). Animals
receiving GDF5-CHO into the striatum or SN 7 days post-lesion also displayed
significantly decreased rotations compared with 6-OHDA or 6-OHDA+Mock-CHO.
Four weeks post-surgery, animals who had received GDF5-CHO transplants at the same
time as the 6-OHDA lesion or one week post-lesion into the striatum or SN, had
significantly higher numbers of TH+ neurons in the SN compared to 6-OHDA alone or
6-OHDA+Mock-CHO (Costello et al., 2012). This data once again highlights the
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protective and restorative effects of GDF5 and shows that sustained, targeted and longterm delivery of GDF5 can be achieved.

1.11.3.3 Evidence for the neurotrophic effects of BMP2 in vitro
The first evidence for a neurotrophic effect of BMP2 came in 1997 when recombinant
human (rh)BMP2 was demonstrated to exert neurotrophic effects on cultured E13-15 rat
VM midbrain dopaminergic neurons (Jordan et al., 1997). Specifically, treatment with
10ng/ml rhBMP2 increased the survival of TH+ midbrain dopaminergic neurons, by 1.5fold compared to that in controls, after 8 DIV. The same study demonstrated that BMP2
treatment of midbrain dopaminergic cultures resulted in increased numbers of 5bromodeoxyuridine (BrdU)-positive and GFAP+ cells, markers of cell proliferation and

astrocytes, respectively. These early findings indicated not only does BMP2 promote the
survival of midbrain dopaminergic neurons, but that it also appears to play a selective
role in the proliferation and differentiation of neural progenitors. A further study also
demonstrated positive effects of BMP2 treatment on midbrain dopaminergic neurons in
E14 VM cultures. Specifically, cultures treated with BMP2 displayed a concentrationdependent increase in the number of midbrain dopaminergic neurons, reaching a

maximum increase of 237% after treatment with 10ng/ml, compared to vehicle-treated
controls after 7 DIV (Reiriz et al., 1999). In addition, BMP2 treatment increased the
number of primary neurites and neurite branching in TH+ cells in a concentrationdependent manner, reaching a maximal effect with 1ng/ml rhBMP2 (Reiriz et al., 1999).
Similarly, other studies have shown a significant increase in the neurite length of TH+
neurons in E14 rat VM primary cultures after treatment with 200ng/ml rhBMP2 (Hegarty
et al., 2014a).
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One study investigated whether BMP2-induced effects were mediated by astroglial
cells and reported that addition of 10ng/ml BMP2 had no effect on the number or
morphology of astroglial cells in E14 VM cultures (Reiriz et al, 1999). They further
showed that BMP2-induced increases in TH+ cell numbers were not altered in the
presence of 30µM α-aminoadipic acid, a gliotoxin that eliminates GFAP-immunoreactive
astrocytes (Reiriz et al., 1999). Interestingly however, this study did report that treatment
with 100ng/ml BMP2 led to significant increases in both the number and morphology of
astrocytes (Reiriz et al., 1999). These findings suggest that, at low doses, BMP2 treatment
promotes both the number and morphological differentiation of midbrain dopaminergic
neurons, while at higher doses, it also influences the number and phenotype of astroglial
cells (Reiriz et al., 1999). Several studies have reported that the neurotrophic effects of
BMP2 and BMP signalling often occur in tandem with, and are amplified by, other NTFs.
For example, BMP2-induced signalling in E19 rat striatal neurons was found to be
facilitated by co-administration of either BDNF or Neurotrophin-3 (NT-3) (Gratacos et
al., 2001). However, there is limited data available on the interactions of BMPs with other
NTFs in the context of dopaminergic neurons, and this will be an important point to
consider in future research.
In addition to the neurotrophic effects of BMP2 reported in studies on primary VM
cultures, similar effects have been demonstrated in SH-SY5Y cells, a cell line which,
despite some limitations, is a widely-used in vitro model of human midbrain
dopaminergic neurons (Xie et al., 2010, Hegarty et al., 2016b, Xicoy et al., 2017,
Goulding et al., 2019). Specifically, SH-SY5Y cells treated with 200ng/ml rhBMP2 for
4 DIV displayed an increase in total neurite length (Hegarty et al., 2013b). This supported
additional studies which showed that BMP2 treatment induced neuronal differentiation
of midbrain dopaminergic neurons (Hegarty et al., 2014a, Reiriz et al., 1999). Treatment
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with BMP2 was also found to activate the canonical Smad 1/5/8 signalling pathway in
SH-SY5Y cells to induce neurite growth (Hegarty et al., 2013b). A causal link between
neurite growth and BMP signalling was demonstrated when it was shown that
pretreatment with dorsomorphin, a selective small molecule inhibitor of BMPR1
receptors (Yu et al., 2008, Hegarty et al., 2013b), completely prevented BMP2-induced
differentiation of SHSY5Y cells (Hegarty et al., 2013b). In addition, dorsomorphin
treatment completely blocked BMP2-induced Smad activation. Similar experiments on
E14 VM cultures showed that dorsomorphin blocked both morphological differentiation
of midbrain dopaminergic neurons and activation of the Smad pathway, which had been
induced by BMP2 treatment (Hegarty et al., 2013b, Hegarty et al., 2014a). Collectively,
these studies show that the phenotypic effects exerted by BMP2 are directly dependent
on the activation of the Smad 1/5/8 signalling pathway in midbrain dopaminergic
neurons.(Hegarty et al., 2013b, Hegarty et al., 2014a).

1.11.3.4 Evidence for the neurotrophic effects of BMP2 in vivo
To support the positive neuroprotective effects of BMP2 seen in the in vitro studies, there
are some promising data regarding its in vivo effects. One study reported that pretreatment

with 50ng/ml rhBMP2 could maintain cell viability in cultures of E14 VM for up to 6 h,
compared to untreated control cultures which demonstrated a 25% decrease in cell
viability over the same period (Espejo et al., 1999). A subsequent in vivo study showed
that treatment of E14 rat VM with 50ng/ml rhBMP2 prior to grafting into the striatum of
6-OHDA-lesioned rats resulted in a significant increase in the survival of the grafted
dopaminergic neurons (Espejo et al., 1999). This neuroprotective effect of BMP2

pretreatment in vivo was substantial at one week after grafting, and remained, although
at a lower level, after four weeks (Espejo et al., 1999). After one week, the rats that had
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received BMP2-treated VM grafts showed no difference in motor impairment, as
measured by apomorphine-induced rotations, than those that had received untreated VM
grafts; however after four weeks, rats with BMP2-treated VM grafts displayed significant
reductions in rotations, compared to those with untreated grafts. Furthermore, the
morphology of the grafted dopaminergic neurons was notably more differentiated in the
rhBMP2 pre-treated group than in the untreated graft group at four weeks post-grafting
(Espejo et al., 1999). In light of these studies showing the in vivo potential of BMP2
treatment, it will be important to test both recombinant BMP2 and viral vectors carrying
the BMP2 transgene in neurotoxin and α-synuclein in vivo models of PD.
As well as the neurotrophic effects of BMP2 described above, another study has
highlighted the potential of BMP2 to induce differentiation of neural stem cells (NSCs)

in vitro (Yan et al., 2016). This is an important finding, given the low survival rate, and
considering the ethical and logistical difficulties involved, of human foetal VM tissue
grafts for treatment of PD (Olanow et al., 2003, Ishii and Eto, 2014). Specifically, the
Yan study employed five doses of BMP2 (that is 0.1, 1, 10, 20 and 100 ng/ml) over a 14day period, to treat NSCs harvested from E14 VM cells. This study found that 20 and 100
ng/ml doses of BMP2 induced the highest increases in the number of dopaminergic
neurons, while also increasing their neurite length (Yan et al., 2016). This effect of BMP2
on NSC differentiation was induced via miR-145-mediated upregulation of Nurr1, a key
player in the maintenance of dopaminergic neurons (Yan et al., 2016). NSCs offer a
viable therapeutic approach to PD therapy as the cells are self-renewing and can be
differentiated into all neural lineage cells, therefore showing promising potential to be
used for replacement of those midbrain dopaminergic neurons that are lost from the PD
brain.
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Collectively, GDF5 and BMP2 have been shown to be potent neurotrophic factors
for dopaminergic neurons and have demonstrated neuroprotective capabilities against
several commonly used dopaminergic neurotoxins including MPP+ and 6-OHDA. The
substantial evidence reviewed here in support of these morphogens would suggest that
their neurotrophic properties warrant further investigation as novel therapeutic agents
against PD. In addition, the fact that both GDF5 and BMP2 mediate their neurotrophic
effects exclusively via the BMP-Smad signalling is also important as the authors of the
recent Neurturin clinical trial have suggested that “better results might be achieved with
other trophic factors that are not RET dependent” (Warren Olanow et al., 2015).
However, there has been little evidence to date on the neurotrophic effects of GDF5 and
BMP2 on promoting dopaminergic axon growth and protecting these axons against
neurotoxin induced axonal degeneration. In addition, there is no evidence to date on the
potential neuroprotective action of GDF5 and BMP2 against α-synuclein-induced
degeneration in vitro or translational models of PD. Moreover, whether α-synuclein
disrupts the BMP-Smad signalling pathway is currently unknown. These issues are
important to address in order to justify the further development of GDF5 and BMP2, or
any other BMP ligand, as therapeutic interventions for PD.

1.12 Small molecule activators of the BMP signalling pathway
Currently, the only practical method of delivering NTFs to the brain is via direct injection.
While this approach is safe for patients and clinically feasible (Bartus et al., 2014, Marks
et al., 2008, Bartus et al., 2013), it is dependent on the remaining dopaminergic neurons
in the SN expressing the full complement of proteins needed to respond to the specific
NTF being administered. The consequences of this requirement were highlighted by the
failure of GDNF to protect against α-synuclein in vivo due to the down regulation of the

53

RET receptor required for pathway activation (Decressac et al., 2012a, Decressac et al.,
2011). One way to circumvent this challenge is by identifying small molecule drugs or
biologics that are can cross the BBB and that are capable of selectively activating the
signalling pathway of the desired NTF or their downstream effectors, which would
bypass the need for the NTF itself and allow for the advent of non-invasive therapies
(O'Keeffe et al., 2017).
In this regard, small molecule activators of the BMP-Smad signalling pathway have
previously been identified. CTPB ((N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6pentadecyl-benzamide) is a small molecule activator of p300/CBPs, which are histone
acetyltransferases (HATs) known to interact with Smad effectors to modulate BMPSmad mediated gene transcription (Pouponnot et al., 1998, Pearson et al., 1999,
Balasubramanyam et al., 2003). In SH-SY5Y cells, CTPB has been shown to promote
neurite growth to a similar extent to that of GDF5 and BMP2 and promotes survival
against 6-OHDA-induced cell death (Hegarty et al., 2016a). In addition to HATs, histone
deacetylase (HDACs) inhibitors (HDIs) are potent transcriptional regulators whose
neurotrophic effects on dopaminergic neurons have been widely characterised (Gardian
et al., 2004, Kidd and Schneider, 2011, St Laurent et al., 2013, Kontopoulos et al., 2006,
Outeiro et al., 2007). Class-IIa HDIs have recently been shown to promote neurite length
in SH-SY5Y cells and E14 cultures of dopaminergic neurons and protects these cells
from neurotoxin-induced degeneration (Collins et al., 2015). Moreover, HDIs have been
demonstrated as activators of the BMP-Smad pathway and regulators of neurite growth
via BMP signalling (Collins et al., 2015, Mazzocchi et al., 2019). Pre-clinical testing of
HDACs in animal models of PD is currently underway and will further elucidate the
potential use of HDACs to target dopaminergic neurons as a therapeutic approach in PD.
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In addition to downstream transcriptional regulators of the BMP-Smad pathway,
modulators of BMP expression have also been discovered. A recent study has identified
Quinacrine and Niclosamide, both of whom are Food and Drug Administration (FDA)
approved medicinal drugs, as potent modulators of BMP2 expression in cultures of
human tendon tissue and in a BMP2 reporter cell line (Ghebes et al., 2017). Quinacrine
is an acridine derivative that has previously been used as an antimalarial compound but
has since been superseded by Chloroquine in recent years (Ehsanian et al., 2011).
Quinacrine has also been used as an anthelmintic and as a therapy for giardiasis. In
addition, Quinacrine has been used to treat connective tissue diseases, including lupus
erythematosus and rheumatoid arthritis and was once used as a form of
contraception/sterilisation (Macfarlane and Manzel, 1998, Gurova, 2009, Chumanevich
et al., 2016, Gardner and Hill, 2001, Wozniacka et al., 2002, Lippes, 2015). Quinacrine
has been shown to activate p53 and superoxide dismutase and is an inhibitor of NF-κB
and phospholipase A2 (Gurova et al., 2005, Gasparian et al., 2011, Al Moutaery and
Tariq, 1997, Kara et al., 2014, Jani et al., 2010). Consequently, these anti-inflammatory
and anti-cancer properties have led to Quinacrine being used in the treatment of several
cancers (Jani et al., 2010, Dermawan et al., 2014, Fasanmade et al., 2001, Preet et al.,
2012). Importantly, Quinacrine has been shown to protect dopaminergic neurons against
neurotoxic insult in animal models of PD (Tariq et al., 2001).
Niclosamide is a salicylamide derivative and an anthelmintic drug, most widely
used to treat tapeworm infections (Kadri et al., 2018). The mechanism of action of
Niclosamide is poorly understood however several studies have discovered that
Niclosamide is a potent uncoupler of oxidative phosphorylation and can modulate Wnt/βcatenin, mTORC1, STAT3, NF-κB and Notch signalling pathways (Chen et al., 2018,
Frayha et al., 1997, Satoh et al., 2016, Li et al., 2014). Consequently, there is growing
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interest in the therapeutic potential of Niclosamide for a range of diseases and disorders
including Type 2 Diabetes Miletus, Bacterial Infections, Viral Infections, Cancer,
Neuropathic pain, Endometriosis and Rheumatoid Arthritis (Chen et al., 2018, Kadri et
al., 2018, Arend et al., 2016, Tao et al., 2014, Lin et al., 2016a, Lu et al., 2011, Sack et
al., 2011, Rajamuthiah et al., 2015, Wu et al., 2004, Prather et al., 2016). Niclosamide
has also been investigated for potential use in the treatment of PD, as Niclosamide
activates PTEN-induced kinase 1 (PINK1) signalling in cultured cortical neurons (Barini
et al., 2018). This is important given that mutations in PINK1 are linked with autosomal
recessive EOPD (Valente et al., 2004).
Given that Quinacrine and Niclosamide have been found to be potent modulators
of BMP2 expression in primary tendon cells, together with the evidence for BMP2mediated neurotrophic action in dopaminergic neurons, this suggests that Quinacrine and
Niclosamide may also demonstrate neurotrophic action in dopaminergic neurons through
the upregulation of BMP2 expression and/or the activation of the BMP-Smad signalling
pathway. Therefore, these compounds warrant further investigation for their potential use
as a treatment for PD.

.
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1.13 Conclusion and Objectives
Neurotrophic factor therapy holds significant promise as a disease-modifying therapy in
PD, however clinical trials to date using GFLs has yielded disappointing outcomes. In
light of this, it has been suggested that better results may be realised using RETindependent NTFs. GDF5 and BMP2 are members of the BMP family which activate the
RET-independent, canonical Smad signalling pathway. GDF5 and BMP2 have shown
potent potential as NTFs in dopaminergic neurons against in vitro and pre-clinical models
of PD but have not yet been investigated against α-synuclein-induced degeneration either
in vitro or in vivo. In addition, experimental therapies to date, both protective and
restorative, have notoriously targeted dopaminergic cell loss with no focus on the
degeneration of axons. Therefore, the initial aim of this thesis is to identify the specific
neurotrophic effects of GDF5 and BMP2 on dopaminergic neurons and their axons in
vitro against cellular models of PD, including α-synuclein. Following these experiments,
the second objective will be to evaluate the neuroprotective effect of viral mediated
delivery of GDF5 and BMP2 against α-synuclein-induced degeneration in vivo in the αsynuclein rat model of PD. The final objective of this thesis will be to investigate the
therapeutic potential of the FDA approved small molecule drugs, Quinacrine and
Niclosamide, in dopaminergic neurons as a novel therapeutic approach for the treatment
of PD.
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Chapter 2.0

Materials & Methods
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2.1 Cell culture
All experiments were performed in a sterile laminar flow Class II Microflow Biological
Safety cabinet, wearing appropriate garbing and gloves and using aseptic techniques. All
materials used were of tissue culture grade or had been sterilised via autoclaving at 121°C
or filtered through a 0.20μm filter.
2.1.1 Harvesting and dissociation of the SH-SY5Y cell line
SH-SY5Y cells were stored in vials of freezing medium consisting of 70% Dulbecco’s
modified Eagle’s medium (DMEM) F-12 Ham (Sigma), 20% foetal bovine serum (FBS)
(Sigma) and 10% dimethyl sulfoxide (DMSO) (Sigma), under liquid nitrogen. For use in
cell culture experiments, cells were thawed at room temperature (RT) and immediately
centrifuged at 500 rotations per minute (rpm) for 5 minutes (min). The supernatant was
then discarded, and cells were resuspended in 20 ml of fresh SH-SY5Y cell culture
medium. The culture medium used was DMEM F-12 Ham, supplemented with 10% FBS,
100nM L-glutamine (Sigma) and 100U/ml penicillin and 10µg/ml streptomycin (Sigma).
The cells were grown in T75 flasks and incubated in a humidified atmosphere containing
5% CO2 at 37°C. At 80-90% confluency the cells were passaged. Cells were passaged
three times prior to use in experiments. To passage the cells, the spent medium was
removed; the cells were briefly washed with 3 ml of Hank’s Balanced Salt Solution
(HBSS) to remove residual media before enzymatic cleavage of the cells in 3 ml of 0.2%
Trypsin for 5 min at 37°C. 7 ml of serum-containing fresh media was added to the flask
to neutralise the trypsin and was mixed to ensure homogeneity using a pipette. The cell
solution was transferred into a 15 ml sterile tube and was centrifuged at 500 rpm for 5
min to pellet the cells. The supernatant was then removed, 1 ml of fresh media was added
to the sterile tube and the cells were resuspended using a flame polished Pasteur pipette.
A sample of the cell solution was then diluted 1:10 in fresh culture medium. 10 μl of this
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solution was then used to count the cells using a haemocytometer and the following
formula:
𝐶𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 × 10 (𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟) × 104 (ℎ𝑎𝑒𝑚𝑜𝑐𝑦𝑡𝑜𝑚𝑒𝑡𝑒𝑟 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡)
= 𝑐𝑒𝑙𝑙𝑠/𝑚𝑙
5 (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑔𝑟𝑖𝑑𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑)

The cells were cultured such that each T75 flask contained 4 million cells in 20 ml fresh
medium. For experiments in 24 well plates, 500 µl of the required cell solution was added
per well. In 12 well plates, 1 ml was added per well and in 6 well plates 2 ml was added
per well. This process was repeated as required. Where indicated, SH-SY5Y cultures
were treated with 0-200ng/ml rhBMP2 (Gibco), 0-200ng/ml rhGDF5 (Peprotech), 010nM Niclosamide (Sigma), 0-10nM Quinacrine (Sigma), 0-15µM 6-OHDA (Sigma) or
0-1.5mM MPP+ (Sigma) or pre-treated with 1µg/ml dorsomorphin (Sigma) 30 min prior
to the addition of rhBMP2, rhGDF5, Niclosamide or Quinacrine. Virkon solution was
added to SH-SY5Y cells, spent media and other cell culture waste prior to discarding into
an autoclave waste bin.
2.1.2 Poly-D-lysine coating of culture plates
24-well plates were coated using 130 µl of a 0.1mg/ml solution of Poly-D-lysine (Sigma)
and incubated in the cell culture hood for 15 minutes. The solution was then removed,
and the surface of each well was washed 3 times with sterile water. The coated plates
were allowed to dry for 1-2 hours (h) before experimental use or were stored at -20ºC
until required. Prior to use, coated plates were incubated at 37ºC for 30 min and placed
in the cell culture hood to evaporate any condensation before introducing cells and media.

2.1.3 Harvesting of the E14 rat VM
Time-mated Sprague-Dawley (SD) rats (Biological Services Unit, UCC) were terminally
anaesthetised using isoflurane (Abbott Laboratories Ltd.) in a fit-for-purpose bell jar
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inside a Class I laminar flow cabinet. Once anaesthetised, the rats were decapitated using
a guillotine. The E14 embryos were removed from the pregnant rat via laparotomy and
placed in a 90mm petri dish containing HBSS and kept on ice. This procedure was carried
out under license with full ethical approval. The embryos were then removed from their
yolk sac and their crown-to-rump length was measured to verify the correct age with a
1.0-1.2cm crown-to-rump length indicative of E14. The mesencephalon was dissected
out by incision at the midbrain-hindbrain boundary, and at the forebrain-midbrain
boundary. The dorsal mesencephalon was then cut along the midline, and the
mesencephalon was then levelled out to display the VM in the centre. A cut at a point
between the lateral to medial VM was then made on both sides to isolate the VM. The
meninges were removed, leaving the VM intact. Dissected VMs were stored in a sterile
15 ml Eppendorf tube in HBSS on ice until all the embryos were dissected. Primary
cultures of the E14 rat VM were then established immediately upon completion of the
VM dissection.
2.1.4 Primary cultures of the E14 rat VM
E14 VM tissue was immediately centrifuged post dissection at 1100 rpm for 5 min. The
HBSS was removed and the pelleted tissue pieces were enzymatically dissociated in
1.5ml Trypsin-HBSS and incubated for 5 min at 37°C with 5% CO2. 1ml of the TrypsinHBSS was removed and replaced by 1ml FBS to neutralise the trypsin. The tissue pieces
were then centrifuged at 1100 rpm for 5 min. The supernatant was discarded, and the
pellet of tissue was then mechanically dissociated in 1ml of DMEM F-12 containing
100nM L-Glutamine, 6mg/ml D-Glucose, 100 U/ml Penicillin, 10μg/ml Streptomycin,
with 2% B-27 supplement, and 1% FBS, using a p1000 pipette, followed by a 25 gauge
needle and 1 ml syringe. Cell density was calculated as per section 2.1.1. To allow the
cells to adhere to the wells, 50 μl of the required cell suspension was added to each well
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of a poly-D lysine coated plate and incubated for 1h at 37ºC and 5% CO2. The wells were
then ‘flooded’ with 450μl of fresh medium and incubated at 37ºC and 5% CO2 for the
length of the experiment. Fresh medium was applied to the cells every 2-3 days.
2.2 Fixation, blocking and immunocytochemical staining of cultured cells
Spent media was aspirated from each well and SH-SY5Y cells were fixed in 4%
Paraformaldehyde (PFA; Sigma) for 15 min at RT. E14 VM cultures were fixed in ice
cold methanol, or 4% PFA in the case of transfections or viral infections, for 15 min at
RT. The cells were then washed using 0.02% Triton X-100 (Sigma) in 10mM phosphate
buffered saline (PBS-Tx), 3 times for 5 min per wash. The cells were blocked using 5%
bovine serum albumin (BSA) in 10mM PBS for 1 h at RT. Depending on the experiment,
the cells were then incubated overnight at 4°C in the appropriate primary antibodies
including; TH (1;2000; Abcam or Merck Millipore), α-synuclein (1:2000; Merck
Millipore), Phospho-Smad (1:200; Cell Signalling Technologies), Total-Smad (1:200;
Abcam), BMPR1A (1:200; R&D Systems or Thermo Fisher), BMPR1B (1:200; R&D
Systems or Thermo Fisher), BMPR2 (1:200; R&D Systems or Thermo Fisher), GDF5
(1:200; Abcam) or BMP2 (1:200; Abcam) diluted in 1% BSA. The cells were then
washed 3 times with PBS-Tx for 5 min each. The appropriate fluorescent secondary
antibodies: Goat anti-Mouse igG H&L Alexa Fluor® 488 or 594 (1:500; Invitrogen) or
Goat anti-Rabbit igG H&L Alexa Fluor® 488 or 594 (1:500; Invitrogen) were diluted
1:500 in 1% BSA in 10mM PBS and applied to the cells for 2 h in the dark at RT.
Following three 5 min washes in PBS-Tx, 4'-6-Diamidino-2-phenylindole (DAPI) was
diluted (1:3000) in 10mM PBS and applied to the cells to stain the nuclei for 5 min at RT
in the dark. The cells were then washed with PBS, for three 5 min washes. PBS was added
to each well to prevent dehydration and the plates were stored at 4°C until visualised
using the Olympus IX71 inverted microscope.
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2.3 MTT Cell Viability Assay
SH-SY5Y cells were plated at a density of 5×104 cells per well and treated for 3 DIV prior

to performing the assay. Media was slowly aspirated and 300μL of 0.5 mg/ml solution of 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) in HBSS was
added to each well and the cells were incubated for 3 h at 37°C in 5% CO2. The MTT-HBSS
solution was then carefully aspirated and 100μL of DMSO was added to each well to
permeabilise any formazan produced by the cells. 75μL of the DMSO/formazan solution in
each well was pipetted into a 96 well plate and the absorbance of each sample was measured
at 620nm using an A600 plate reader (Thermo Fisher).

2.4 Transfection of cultured cells
SH-SY5Y cells and E14 VM cultures were transfected with 0.5–1 μg of plasmid
deoxyribonucleic acid (DNA) or 250ng of the Smad Binding Element (SBE)-GFP
reporter assay (Qiagen) using the TransIT-X2® Dynamic Delivery System (Mirus Bio)
according to the manufacturer's instructions. SH-SY5Y cells were seeded at a density of
2.5×104 cells per well and allowed to reach ≥80% confluency prior to transfection. E14
VM cultures were seeded at a density of 1.5×105 cells per well. The TransIT-X2:DNA
complex was prepared according to the manufacturer's specifications using serum-free
medium, TransIT-X2 reagent and 0.5–1μg/μl stock of a control EGFP plasmid (ControlGFP)

or

EGFP-α-synuclein-WT

(αSynWT-GFP)

or

EGFP-α-synuclein-A53T

(αSynA53T-GFP) plasmids. These were a kind gift from David Rubinsztein (Addgene
plasmids #40822 and #40823). The transfection efficiency for SH-SY5Y cells and E14
VM cells was 31% and 3%, respectively.
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2.5 Phospho-Smad Enzyme Linked Immunosorbent Assay (ELISA)
Activation of the Smad pathway by rhBMP2 was shown using the SMAD1
(Total/Phospho) Human InstantOne™ ELISA Kit (Invitrogen). In brief, SH-SY5Y cells
were seeded at a density of 5×104 cells per well and treated with 50ng/ml rhBMP2 or
rhGDF5, 1µg/ml dorsomorphin or pre-treated with 1µg/ml dorsomorphin 30 min prior to
treatment with rhBMP2 or rhGDF5 for 2 h. Cells were then lysed and prepared for the
ELISA as per the manufacturer’s instructions.
2.6 Transduction of E14 VM cultures
E14 VM cultures were plated at a density of 1.0×105 per well of a 24 well plate and
transduced with AAV2/5-GDF5, AAV2/5-BMP2, AAV2/6-GFP or AAV2/6-α-synuclein
to achieve a multiplicity of infection (MOI) of 5.0×104 to 2.0×105, as indicated in the text.

2.7 Analysis of neuronal complexity and nuclear intensity
5 randomly-selected cell bodies or neurites were measured in no less than 15 randomlyselected fields per N, yielding at least 225 cell bodies or neurites analysed per experiment.
To verify the number of TH+ cells and total cells, TH and DAPI counts were completed
in 15 randomly-selected fields and the numbers of TH+ cells were expressed as
percentages of the total DAPI-stained cells. All experiments were repeated at least 3 times
and all analyses were performed using Image J software.

2.8 Western Blotting
2.8.1 Protein extraction from SH-SH5Y cells and E14 VM Cells
Spent medium was aspirated from 24-well plates containing SH-SY5Y cells or E14 VM
cultures. The cells were then washed with 1 ml PBS to remove residual media. 200 µl of
RIPA lysis buffer (50 mM Tris pH 7-8, 150 mM sodium chloride (NaCl), 0.1% SDS,
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0.5% sodium deoxycholate, 1 mM Sodium Fluoride, 1mM Sodium Orthovanadate) was
added to each well and the plate. The adhered cells were scraped from each well using a
cell scraper and aliquoted into eppendorf tubes, which were incubated on ice for 1 h. The
eppendorf tubes were then centrifuged at 16000 rpm for 10 min to pellet any cell debris
and the supernatant was stored at -80°C.

2.8.2 BCA assay
This was performed using the Pierce™ Bicinchoninic acid (BCA) Protein Assay Kit
(Thermo Fisher) as per the manufacturer’s instructions. Briefly, to prepare the BCA
working reagent, 10 ml of Reagent A and 200 µl of Reagent B were added to a centrifuge
tube and mixed thoroughly using a pipette. 2 mg/ml BSA was then diluted in series using
500 µl dH2O to prepare a set of standards. The final concentrations of the standards were
as follows: 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, 0.0625 and 0.03125 mg/ml.
20 µl of each standard was added in duplicate to a 96 well plate. 20 µl of each protein
sample of interest were also added in duplicate. 200 µl of the BCA reagent was added to
each well, the plate was then covered and incubated at 37°C for 30 mins. The absorbance
of each well was measured at 562nm using a plate reader. The protein concentration of
each sample was determined using Microsoft Excel.

2.8.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDSPAGE) and western blotting
Using the Bio-Rad Discontinuous System approach, SDS-PAGE was performed using a
10% resolving gel and 5% stacking gel in 1X Running buffer (80% deionised (d)H2O,
20% 5X Running buffer (7.2% Glycine, 1.5% Tris Base, 0.5% SDS in 1L dH20)) on the
Power-Pac Basic (Bio-Rad, USA). The protein samples were prepared in 2X Sample

65

Loading Buffer (40mM Tris-Hydrochloric Acid (HCl) pH 6.8, 2% SDS, 15% Glycerol,
6% 2-Mercaptoethanol (β-ME), 0.025% Bromophenol blue in dH20) and loaded onto the
gel and electrophoresed at 80V for 30 min, followed by 120V for 1 h 30 min. The proteins
were transferred from the gel using Transfer buffer (60% dH2O, 20% Methanol, and 20%
5X Transfer Buffer (7.2% Glycine, 1.5% Tris Base)) onto a methanol pre-soaked
polyvinylidene difluoride (PVDF) membrane at 100V for 1 h. Prior to transfer, the PVDF
membrane was soaked in methanol for 15-30 seconds to activate the membrane, followed
by immersion in dH2O for 5 min and finally soaking in transfer buffer for 15 min. Post
transfer, the membrane was stained using the Ponceau S removable stain in order to
visualise the protein bands. The membrane was then washed with Phosphate Buffered
Saline containing 0.1% Tween® 20 (PBS-T) 3 times for 10 min per wash. The membrane
was blocked in PBS-T containing 3% BSA for 1 h at RT or overnight at 4°C. The
membrane was then incubated in primary antibody for: GAPDH (1:1000; SCBT) and αsynuclein (1:5000; Merck Millipore), diluted in 1% BSA, for 1 h at RT or overnight with
shaking at 4°C. The primary antibody was removed, and the membrane was washed 3
times with PBS-T for 10 min per wash. The membrane was then incubated with the
appropriate secondary antibody for 1 h, with shaking, at RT. The membrane was washed
3 times with PBS-T for 10 min per wash and protein bands were visualised using
enhanced chemiluminescence.

2.8.4 Enhanced Chemiluminescence (ECL)
The Pierce™ ECL Western Blotting Substrate kit was utilised as per the manufacturer’s
instructions (Thermo Fisher). Briefly, each detection reagent was added at a 1:1 ratio to
an eppendorf and mixed thoroughly using a pipette. The membrane was then coated with
the mixed solution for 1 min. The excess solution was then removed, and the membrane
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was covered with a clear plastic sheet for protection. The membrane was then exposed
to an AGFA CP1000 film which was developed using an automatic developer.

2.9 Bacterial transformations and plasmid purification
2.9.1 Bacterial transformations
100ng of plasmid DNA (EGFP, EGFP-α-synuclein-WT or EGFP-α-synuclein-A53T)
was added to 50µl of competent DH5α cells (Sigma) on ice 30 min. The bacteria and
plasmid mixture was then heat shocked at 42ºC for 45 seconds and replaced on ice for 2
min. 250µl of Luria-Bertani (LB) Broth (Sigma) without antibiotic was added to each
bacteria and the plasmid mixture was incubated at 37ºC shaking at 250 oscillations per
min for 45 min. The bacteria and plasmid mixture was then spread on an LB Agar (Sigma)
96 mm petri dish containing 100μg/ml ampicillin (Sigma) or 50μg/ml kanamycin
(Sigma), depending on the plasmid, and incubated upside-down at 37ºC overnight.

2.9.2 Isolation and culture of transformed bacteria
A single colony of transformed bacteria was isolated from the LB Agar petri dish using
a pipette tip to inoculate a starter culture containing 5ml of LB broth containing the
appropriate antibiotic. This culture was incubated at 37ºC, with vigorous shaking (~250
oscillations per min) for 8 h. 1ml of starter culture was then aseptically transferred into a
conical flask of 200ml LB Broth containing the appropriate antibiotic as indicated in
section 2.9.1 and incubated at 37ºC shaking (~250 oscillations per min) overnight.

2.9.3 Plasmid DNA purification
Plasmid purification was carried out using the Plasmid Midi Kit (Qiagen) as per the
manufacturer’s instructions. Briefly, the bacterial cells were harvested by centrifugation
at 6,000 relative centrifugal force (rcf) for 15 min at 4ºC. The bacterial pellet was re-
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suspended and lysed using the buffers provided, for the specified time. Lysis buffer was
added for 5 min and the resulting mixture was incubated at RT before the addition of the
neutralisation buffer to precipitate out the genomic DNA, proteins and cell debris. This
mixture was incubated on ice for 15 min before centrifugation at 20,000 rcf for 30 min at
4ºC. The supernatant was then removed and centrifuged at 20,000 rcf for 30 min at 4ºC.
The clear supernatant was then passed through the Qiagen anion-exchange tip where the
plasmid DNA selectively bound to the resin and impurities in the flow-through were
discarded. The resin was washed twice with 10 ml of QC buffer before the plasmid DNA
was eluted in 5 ml of QF elution buffer. 3.5 ml of isopropanol (Sigma) was added to
precipitate the DNA, and the precipitate was centrifuged at 15,000 rcf for 30 min at 4ºC.
The supernatant was removed, and the pellet was washed with 2 ml of 70% ethanol. The
pellet was re-dissolved in 200 μl of nuclease-free water, and the DNA concentration in
ng/μl was determined using a Nanodrop.

2.10 Bioinformatics
Human SN gene expression data from healthy controls (GSE:60863) (Ramasamy et al.,
2014) and age-matched control and PD patients (GSE:49036) (Dijkstra et al., 2015) were
analysed separately using the R2: Genomics Analysis and Visualization Platform
(http://r2.amc.nl). Pearson correlation analysis with a false discovery rate (FDR) multiple
testing correction was used to identify all genes that were co-expressed with five
dopaminergic neuronal markers: ALDH1A1, NR4A2, KCNJ6, TH and LMX1B in the SN,
and four markers enriched in Purkinje cells in the cerebellum: PDE1A1, CBLN1, PDE9A,
CALB1 (GSE:60863).

68

2.11 GDF5 and BMP2 In Vivo Studies
2.11.1 Ethical approval
Procedures concerning live animals were performed under licence in accordance with
Irish and European directive 2010/63/EU following full ethical approval by University
College Cork Animal Experimentation Ethics Committee and a personal and project
license issued from the Health Products Regulatory Authority (HPRA) (AE19130/P057).

2.11.2 Animal Husbandry and Study Design
Adult female SD rats were purchased from Envigo, UK, and maintained on a 12h:12h
light:dark cycle with access to food and water ad libitum. In the case of the GDF5 study,
animals were assigned to one of the following four experimental groups: AAV-Control
(n=20), AAV-α-synuclein (n=20), AAV-GDF5 (n=20) or AAV-α-synuclein+AAVGDF5 (n=20). In the case of the BMP2 study, animals were assigned to one of the
following four experimental groups: AAV-Control (n=20), AAV-α-synuclein (n=20),
AAV-BMP2 (n=20) or AAV-α-synuclein+AAV-BMP2 (n=20). Rats were housed in
groups of four in standard housing cages containing environmental enrichment. All
experiments were conducted fully in accordance with the European Directive
2010/63/EU and under an authorisation granted by the HPRA.

2.11.3 Virus Preparation
An α‐Synuclein plasmid was generously donated from Dr Eilis Dowd (National
University of Ireland, Galway) and Professor Deniz Kirik (Lund University, Sweden).
AAV2/6-α-synuclein, AAV2/5-GDF5, AAV2/5-BMP2, AAV2/5-Null and AAV2/6Null viral vectors were produced by Vector Biosystems Inc, Philadelphia, USA. Briefly,
AAV2 ITRs coding for human WT α‐synuclein or human GDF5 or BMP2 were packaged
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using AAV6 or AAV5 capsid proteins, to produce AAV2/6 and AAV2/5 viral vectors
and the corresponding empty control vectors. Transgene expression was driven by
synapsin‐1 promoter (SYN1) and enhanced using woodchuck hepatitis virus post‐
transcriptional regulatory element (WPRE). The final titre for AAV2/5-Null was
1.0×1013 gc/ml, for AAV2/6-Null it was 5.3×1012 gc/ml, for AAV2/6-α-synuclein it was
5.2×1013 gc/ml, for AAV2/5-GDF5 it was 1.3×1013 gc/ml and for AAV2/5-BMP2 it was
5.0×1012 gc/ml.

2.11.4 Stereotaxic Surgery
All surgeries were performed using aseptic procedures, including sterile gloves, masks,
sterile instruments and aseptic techniques. Aseptic surgery was performed using
procedures that limit microbial contamination to lessen the possibility of any significant
infection or suppuration. This included preparation of the animal, preparation of the
person performing the procedure, sterilisation of instruments, supplies, and implanted
materials, and the use of operative techniques to reduce the likelihood of infection. Good
surgical technique included asepsis, gentle tissue handling, minimal dissection of tissue,
appropriate use of instruments, effective haemostasis, and correct use of suture materials
and patterns. Aseptic technique was followed through for all procedures. Preoperative
analgesia was administered by the non-steroidal anti-inflammatory analgesic drug
carprofen (Rimadyl®, 5mg/kg) in the animals’ drinking water. Stereotaxic surgery was
conducted under general anaesthesia induced by the inhalation agent isoflurane. Once
anaesthetised, the head was shaved, the animals were positioned in a stereotaxic frame
and the scalp was sterilised using 70% ethanol and betadine. Local anaesthetic
(Lidocaine) was applied to the incision site. Using a sterile scalpel, a small incision
(approximately 1.5-2 cm) was made in the midline of the scalp. The skin was gently
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retracted to expose the skull surface. Once bregma was located and with the aid of a
stereotaxic guide and the use of a small electric drill, a small hole of approximately 1 mm
in diameter was made through the skull over the brain region of interest.
All vector combinations were given unilaterally into the SN at coordinates
anteroposterior (AP) ‐5.3, mediolateral (ML) ± 2.0, and dorsolateral (DV) ‐7.2 relative to
bregma, at an infusion rate of 1µl/min with an additional 2 min for diffusion. At the end
of surgery, the skull was gently swabbed with sterile physiological saline and the skin
sutured closed. The sutured wound was then cleaned with sterile saline. Animals then
received the Carprofen subcutaneously and 5% glucose solution via intraperitoneal
injection. Following surgery, the animals were transferred to clean cages which were kept
on heating pads until the animals were moving normally about the cage. Animals were
treated with oral carprofen once daily for a further two days following surgery. The
animals were closely monitored for any signs of pain, infection or distress for 7 days postsurgery and once weekly thereafter for 6 weeks using a HPRA-approved scoring rubric.

For the GDF5 study:
AAV-Control animals were administered 2 µL AAV2/5-Null (1.0×1010 vg/µL) +
AAV2/6-Null (5.3×109 vg/µL). AAV-α-synuclein animals were administered 2 µL
AAV2/6-α-synuclein (5.2×1010 vg/µL) + AAV2/5-Null (1.0×1010 vg/µL). AAV-GDF5
animals received 2 µL AAV2/5-GDF5 (1.3×1010 vg/µL) + AAV2/6-Null (5.3×109
vg/µL). AAV-α-synuclein+AAV-GDF5 animals received 2 µL AAV2/6-α-synuclein
(5.2×1010 vg/µL) + AAV2/5-GDF5 (1.3×1010 vg/µL).
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For the BMP2 study:
AAV-Control animals were administered 3 µL AAV2/5-Null (1.0×1010 vg/µL) +
AAV2/6-Null (5.3×109 vg/µL). AAV-α-synuclein animals were administered 3 µL
AAV2/6-α-synuclein (5.2×1010 vg/µL) + AAV2/5-Null (1.0×1010 vg/µL). AAV-BMP2
animals received 3 µL AAV2/5-BMP2 (5.0×109 vg/µL) + AAV2/6-Null (5.3×109
vg/µL). AAV-α-synuclein+AAV-BMP2 animals received 3 µL AAV2/6-α-synuclein
(5.2×1010 vg/µL) + AAV2/5-BMP2 (5.0×109 vg/µL).

2.12 Behavioural Testing
Motor function was assessed using the Stepping Test of forelimb akinesia (Olsson et al.,
1995), the Whisker Test of sensorimotor integration (Schallert et al., 2000), the Corridor
Test of lateralised response (Dowd et al., 2005) or the Cylinder Test of independent
forelimb use (Schallert et al., 2000). Each of which will be described below.

2.12.1 Stepping Test
The stepping test of forelimb akinesia was performed as previously described (Olsson et
al., 1995). Animals were held with both hindlimbs and one forelimb restrained with the
remaining free forelimb resting on the countertop. The animal was then moved sideways
across a countertop at a steady pace (90cm in 15 seconds) and the numbers of adjusting
steps taken with the unrestrained forelimb over both directions was counted.

2.12.2 Whisker Test
The Whisker Test measures sensorimotor integration and has been previously
characterised (Schallert et al., 2000). This test is based on the sensorimotor reflex
underlying vibrissae-elicited movement whereby the animal’s whiskers are brushed
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against a surface (e.g. corner of a table) and this elicits a reflex which causes the rat’s
ipsilateral limb to move, which results in the animal placing its paw on the table surface.
During testing, the animal’s whiskers on one side of the body were gently brushed off the
corner of the table, triggering the animal to place their paw on the tabletop (“vibrissaeelicited forelimb placings”). This was performed 10 times for each side of the body and
the number of placings were recorded.

2.12.3 Cylinder Test
The Cylinder test was used to assess forelimb use, as previously described (Schallert et
al., 2000). The test measures a rat’s forepaw use while exploring a novel cylindrical
environment. Since this test takes advantage of an animal’s drive to explore a novel
environment by standing on the hindlimbs and leaning towards the enclosing walls of a
cylinder, no habituation to the test itself was required. To perform this test, animals were
placed individually into a glass cylinder (4L beaker: 17cm diameter and 27cm height).
The number of wall contacts performed independently with the left and the right forepaw
were counted per rat. The test was deemed complete once a total of 20 wall contacts had
been made or until an allotted time of 5 min had elapsed. The number of wall contacts
per forelimb and the time taken were recorded. The number of times the rat touched the
side walls with its contralateral paw was then expressed as a percentage of the total
touches made.

2.12.4 Corridor Test
The Corridor Test measures contralateral sensorimotor neglect and was devised and
characterised as previously described (Dowd et al., 2005). As is a normal part of this
procedure, rats were food restricted to 85-90% of their free feeding body weight by being
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deprived of food for 12 h prior to testing. The corridor apparatus consisted of two long,
narrow chambers (length 50 cm, height 24.5 cm, width 7 cm). The test involved a
habituation and testing period. During the habituation period (5 min), animals were
allowed to freely explore the first empty corridor with CocoPops® scattered on the floor.
During the testing period, 10 pairs of pots were placed adjacently and at equal intervals
along the floor edge of the second corridor and 2-3 CocoPops® were placed in each of
these. Animals were placed in the test corridor and allowed to freely retrieve CocoPops®
from pots on either side. The trial finished after either 5 min s had elapsed, or the animal
had retrieved 20 food rewards.

2.13 Tissue Processing
Animals were sacrificed 20 or 24 weeks post-surgery by either decapitation under
isoflurane anaesthesia (5% in O2) for quantitative real-time polymerase chain reaction
(RT-qPCR) and HPLC analyses, or transcardially perfused with 10mM PBS followed by
4% PFA under terminal pentobarbital anaesthesia (50 mg/kg) for immunohistochemical
analyses. For RT-qPCR, the SN were microdissected from each brain and stored at -80ºC
until needed. For HPLC analyses, the striata were microdissected from each brain and
stored in the appropriate buffer at -20º until required. For immunohistochemical analyses,
the brains were post-fixed in 4% PFA for 24 h and cryoprotected in 30% sucrose solution
containing 0.1% sodium azide. Coronal sections (30 μm thickness) were cut on a freezing
stage sledge microtome and were then processed for immunohistochemistry.
2.14 HPLC
HPLC analysis was performed on striatal samples, as previously described (Clarke et al,
2013). Dissected striatal brain tissue was sonicated in 1 ml of chilled mobile phase, spiked
with 2ng/20ul of N-Methyl 5-HT (Sigma, UK) as internal standard. The mobile phase
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contained 0.1M citric acid, 0.1M sodium dihydrogen phosphate, 0.01mM ethylene
diamine tetra acetic acid (EDTA) (Alkem/Reagecon, Cork, Ireland), 5.6mM octane-1sulphonic acid (Sigma) and 9% (v/v) methanol (Alkem/Reagecon), and was adjusted to
pH 2.8 using 4N sodium hydroxide (Alkem/Reagecon). Homogenates were then
centrifuged at 14,000 rpm for 20 min at 4C and 20μl of the supernatant injected onto the
HPLC system which was coupled to an electrochemical detector. A reverse-phase column
(Kinetex 2.6u C18 100 x 4.6mm, Phenomenex, UK) maintained at 30C was employed
in the separation (Flow rate 0.9ml/min), the glassy carbon working electrode combined
with an Ag/AgCL reference electrode (Shimdazu) was operated at +0.8V and the
chromatograms generated were analysed using Class-VP 5 software (Shimadzu).
Dopamine was identified by its characteristic retention time as determined by standard
injections which were run at regular intervals during the sample analysis.
Analyte:Internal standard peak height ratios were measured and compared with standard
injections to calculate the results.
2.15 RT-qPCR
Total ribonucleic acid (RNA) was extracted from samples using the Qiagen RNeasy
Universal Plus kit according to the manufacturer’s instructions. Levels of Th, Dat, NeuN,
Ret, Bmp2 Bmpr2, Bmpr1b and Smad1 messenger (m)RNAs were quantified by real-time
PCR relative to a geometric mean of mRNAs for the reference genes glyceraldehyde
phosphate dehydrogenase (Gapdh), ubiquitin C (Ubqc) and tata binding protein (Tbp). 5
μl of SN total RNA was reverse-transcribed for 1 h at 45°C using the AffinityScript kit
(Agilent, Berkshire, UK) in a 25 µl reaction according to the manufacturer’s instructions.
2 µl of cDNA was amplified in a 20 µl reaction volume using Brilliant III ultrafast qPCR
master mix reagents (Agilent Technologies). PCR products were detected using dual-
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labelled (FAM/BHQ1) hybridization probes specific to each of the cDNAs
(MWG/Eurofins, Ebersberg, Germany). The PCR primers used were as follows:
Th Forward: 5'-AGA GAT TGC CTT CCA GTA-3'

Reverse: 5'-CCT TCA GCG TGA CAT ATA C-3';

Dat Forward: 5′-CAC CAC CTC CAT TAA CTC-3′

Reverse: 5′-CAG GAT AGA TGATGA AGA TGA G-3′;

NeuN Forward: 5’-CAC TCT CTT GTC CGT TTG-3’

Reverse: 5′-CCG ATG GTA TGA TGG TAG-3′;

Ret Forward: 5′-TGT TCT CTT CCT CCA TTT CA-3′

Reverse: 5′-AGT TCT CCA CGC AAA CTT-3′;

Bmp2 Forward 5’ -GGA GAT TCT TTA ATT TAA G-3

Reverse: 5’ -ACT GCT ATT GTT TCC TAA-3’

Bmpr2 Forward: 5′-CAA CTT CAC TGA GAA CTT C-3′ Reverse: 5′-GCT AAT ACA GAA ACC GAT G-3′;
Bmpr1b Forward: 5’-AAA GGT AGC TGT GAA AGT-3’ Reverse: 5′-ATG ATA GTC TGT GAT GAG G-3′;
Smad1 Forward: 5’-TCG GAG GAG AGG TGT ATG-3’ Reverse: 5′-GCG AAC TCT TGG TTG TTG-3′;
Gapdh Forward: 5′-TGG TCA TCA ACG GGA AAC-3′

Reverse: 5′-CCA CGA CAT ACT CAG CAC-3′;

Ubqc Forward: 5′-TTC TCA CCA CAG TAT CTA G-3′

Reverse: 5′-AGT GCA ATG AAA CTT GTT A-3′;

Tbp Forward: 5’-CAC CAA TGA CTC CTA TGA-3’

Reverse: 5’-TGG GAT TAT ATT CAG CAT TTC-3’.

Dual-labelled probes used were:
Th:

5'-FAM-AAG CAC GGT GAA CCA ATTCC-BHQ1-3';

Dat:

5'-FAM-CTT CTC CTC TGG CTT CGT CGT-BHQ1-3';

NeuN:

5'-FAM-ATC AGC AGC CGC ATA GAC TC-BHQ1-3';

Ret:

5'-FAM-CGT GTC TGT GCT GCC TGT C-BHQ1-3';

Bmp2

5’ -FAM-CCC ACG GAG GAG TTT ATC ACC-BHQ1-3’

Bmpr2:

5'-FAM-CAC CTC CTG ATA CAA CAC CAC TC-BHQ1-3';

Bmpr1b:

5'-FAM-TCA CCA CGG AGG AAG CCA-BHQ1-3';

Smad1:

5'-FAM-CAG TGA CAG CAG CAT CTT CGT G-BHQ1-3';

Gapdh:

5′-FAM-CAT CAC CAT CTT CCA GGA GCG AGA-BHQ1-3;

Ubqc:

5′-FAM-CCT TCT TGT GCT TGT TCT TGG-BHQ1-3,

Tbp:

5’-FAM-TCC TGC CAC ACC AGC CTC TG -BHQ1-3’.

Forward and reverse primers were used at a concentration of 150 nM and dual-labelled
probes were used at a concentration of 200 nM. PCR was performed using the Mx3000P
platform (Agilent) using the following conditions: 95°C for 3 min followed by 40 cycles
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of 95°C for 12 s and 60°C for 35 s. Standard curves were generated for each cDNA for
every real-time PCR run, by using serial threefold dilutions of reverse-transcribed adult
rat brain total RNA (Zyagen, San Diego, USA). Relative mRNA levels were quantified
in SN dissected from 5 separate animals for each experimental condition. Primer and
probe sequences were designed using Beacon Designer software (Premier Biosoft, Palo
Alto, USA).

2.16 Immunohistochemistry
Sections were washed for 10 min using tris-buffered saline (TBS) solution. To remove
endogenous peroxidase activity, sections were quenched using 3% Hydrogen Peroxide
(H2O2)/10% Methanol in distilled water for 5 min followed by 3 x 5 min washes with
TBS. Non-specific antibody binding was blocked for 1 h using 3% Goat, Horse or Rabbit
serum as required diluted in TBS containing 0.02% Triton-X100 (TXTBS). Sections were
incubated overnight at RT with primary antibody diluted in TXTBS containing 1%
serum. Primary antibodies were TH (1:1000, Merck Millipore), DAT (1:200, SCBT), αsynuclein (1:1000, Millipore), and pSer129-α-synuclein (1:1000, Abcam). Following 3 x
5-min TBS washes, sections were incubated in secondary antibody diluted in TXTBS
containing 1% serum for 2 h. For chromogen staining, biotinylated goat-anti-rabbit IgG
(1:200, Jackson Immunoresearch Lab), horse-anti-mouse IgG (1:200, Vector Labs) or
rabbit-anti-goat IgG (1:200, Vector Labs) secondary antibodies were used. Following 3
x 5-min TBS washes, sections were incubated in a Streptavidin–biotin–horseradish
peroxidase solution (Vector Labs) for 2 h. Sections were then washed 3 x 5 min with TBS
before developing with 3,3'-Diaminobenzidine (DAB) (Vector Labs). The sections were
dehydrated using increasing concentrations of Ethanol, cleared in Xylene and coverslipped using DPX mounting media (BDH Chemicals). Images of the sections were taken
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using the Olympus BX53 Upright Microscope and the Olympus FV1000 Confocal Laser
Scanning Biological Microscope.

2.17 Immunofluorescence
Sections were washed for 10 min using TBS solution. Non-specific antibody binding was
blocked for 1 h using 3% Goat, Horse or Rabbit serum as required diluted in TXTBS.
Sections were incubated overnight at RT with primary antibody diluted in TXTBS
containing 1% serum. Primary antibodies used include TH (1:1000, Merck Millipore or
Abcam), GDF5 (1:100, Abcam), BMP2 (1:200, Abcam), α-synuclein (1:1000, Millipore)
and Phospho-Smad (1:100, Cell Signalling Technology). Following 3 x 5-min TBS
washes, sections were incubated in secondary antibody diluted in TXTBS containing 1%
serum for 2 h. For immunofluorescence, Alexa Fluor 488- or 594-conjugated secondary
antibodies (1:200; Invitrogen) were used. Sections were washed for 3 x 5-min using TBS
and cover-slipped using fluorescent mounting media (Dako Diagnostics). Images of the
sections were taken using the Olympus BX53 Upright Microscope and the Olympus
FV1000 Confocal Laser Scanning Biological Microscope.

2.18 Statistical Analysis
Statistical analysis was performed using GraphPad Prism 8 (©2020 GraphPad Software,
CA USA). An Unpaired Student’s t-test or one-way analysis of variance (ANOVA) or
two-way ANOVA with post hoc Dunnett’s, Tukey’s, Bonferroni, or Holm-Sidak’s test
or Uncorrected Fisher’s LSD test, were used as indicated to determine significant
differences between groups. Results were deemed to be significant when p < 0.05. All
data are presented as mean ± SEM.
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Chapter 3.0

GDF5 protects midbrain dopaminergic neurons
against MPP+, 6-OHDA and α-synuclein induced axon
degeneration.

3.1 Aims of Study
• Identify the most effective concentration of rhGDF5 for promotion of neurite length
• Establish the neurotrophic effect of rhGDF5 against cellular models of PD in SH-SY5Y
cells

• Determine the neurotrophic effect of rhGDF5 against cellular models of PD in primary
VM cultures

• Evaluate the potential neurotrophic effects of AAV2/5-GDF5 in primary dopaminergic
neurons
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3.2 Abstract
Introduction: PD is a chronic neurological disorder causing the progressive loss of
dopaminergic neurons from the SN and consequently a loss of striatal innervation.
Current therapies are solely symptomatic and do not stop or slow the dopaminergic
degeneration. One strategy to combat this loss is the targeted delivery of neurotrophic
factors in an effort to protect remaining dopamine neurons and regenerate the nigrostriatal
pathway. GDF5 is a member of the TGF-β protein superfamily and has previously been
shown to harbour neurotrophic potential for dopaminergic neurons.
Methods: In this study, SH-SY5Y cells and primary VM cultures were used to evaluate
the effect of rhGDF5 on neurite length in cultures treated with either 6-OHDA or MPP+,
or overexpressing WT -synuclein.
Results: rhGDF5 demonstrated a significant increase in neurite length in both SH-SY5Y
cells and E14 VM cells. In addition, while MPP+, 6-OHDA and the overexpression of
WT α-synuclein had a detrimental effect on neurite length, co-treatment with rhGDF5
significantly protected SH-SY5Y and primary cell terminals against the neurotoxic and
α-synuclein-induced axon degeneration. Moreover, GDF5 signalling mediators were
found to be unaffected by α-synuclein overexpression. Finally, AAV2/5-GDF5 was
shown to proficiently infect TH+ neurons and markedly increase the neurite length of
these cells.
Conclusion: These findings are particularly noteworthy given the increasing evidence of
axon degeneration preceding dopaminergic neuronal cell loss in PD, potentially mediated
by α-synuclein. Taken together with previous findings, these results justify the further
investigation of GDF5 in an α-synuclein translational model of PD.
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3.3 Introduction
PD is a progressive neurodegenerative disorder, characterised by the progressive
degeneration of nigrostriatal dopaminergic neurons from the SN and their axonal
terminals in the striatum (Kalia and Lang, 2015). Dopaminergic neurons in the SN project
to the dorsal striatum via the nigrostriatal pathway and play a key role in the regulation
of voluntary movement and motor control as part of the basal ganglia circuitry (Luo and
Huang, 2016). It is this selective loss of dopaminergic neurons, and hence a loss of striatal
dopaminergic innervation, that gives rise to the motor impairments associated with the
disease including; bradykinesia, resting tremor, rigidity and postural instability
(Kordower et al., 2013). However, despite decades of intensive research, no disease
modifying therapy exists and clinical therapies currently available are purely
symptomatic. Therefore, there is an urgent clinical need for disease-modifying therapies
that offer long term neuroprotection and/or neuroregeneration of the remaining
dopaminergic neurons in the SN (Hegarty et al., 2014b). One promising approach is the
targeted delivery of NTFs to protect the remaining dopaminergic neurons and their axons
and to regenerate the nigrostriatal pathway (Sullivan and O’Keeffe, 2016).
The TGF-β protein superfamily holds several members known to be potent NTFs
for dopaminergic neurons (Hegarty et al., 2014c). Indeed, the most well-known NTFs to
date, GDNF and Neurturin, are distant members of the TGF-β superfamily (Saarma,
2000). However, despite promising results in pre-clinical models of PD, to date both
NTFs have failed to reach their primary endpoints in clinical trials (Decressac et al., 2011,
Gill et al., 2003, Granholm et al., 1997, Lang et al., 2006, Nutt et al., 2003, Patel et al.,
2005, Herzog et al., 2007, Kordower et al., 2006, Marks et al., 2010, Marks et al., 2008,
Warren Olanow et al., 2015, Whone et al., 2019b, Whone et al., 2019a). Recently, the
lack of clinical efficacy of GDNF and Neurturin has been postulated to be caused by the
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downregulation of their common co-receptor, Ret, by α-synuclein (Decressac et al.,
2012a). It has therefore been suggested that NTFs that are Ret independent, may achieve
better clinical results (Warren Olanow et al., 2015). The BMP family is the largest
subgroup of the TGF-β protein superfamily (Chen et al., 2004). Members of the BMP
family play key roles in the development and function of a variety of tissues, and were
initially discovered as inducers of bone and cartilage formation (Nishimura et al., 2012)
and for their role in skeletal development (Miyazono et al., 2010, Wu et al., 2016). Since
then, BMPs have emerged as key regulators of neuronal function in a host of neuronal
populations (Gratacos et al., 2002, Parikh et al., 2011, Hegarty et al., 2013a). Crucially,
members of the BMP family signal in a Ret independent manner, through the activation
of the canonical Smad signalling pathway (Weiss and Attisano, 2013, Hegarty et al.,
2013a).
GDF5 is among the most extensively studied NTF in the BMP family and has been
shown to promote dopaminergic survival and protect dopaminergic neurons from
neurotoxin-induced degeneration both in vitro and in vivo (Krieglstein et al., 1995,
O'Keeffe et al., 2004a, Wood et al., 2005, Lingor et al., 1999, O'Sullivan et al., 2010,
Costello et al., 2012, Sullivan et al., 1998, Sullivan et al., 1997). However, to date the
protective effect of GDF5 against neurotoxin-induced axonal degeneration remains
unclear. In addition, the effect of GDF5 on neuronal cells in an α-synuclein model of PD
are unknown. This is important given that α-synuclein is the principle component of
Lewy bodies and Lewy neurites (Spillantini et al., 1997) and α-synuclein overexpression
has been shown to induce axonal degeneration in cultured dopaminergic neurons (Koch
et al., 2015, Kouroupi et al., 2017). Therefore, in this study, SH-SY5Y cells and E14 VM
cultures were used to assess the ability of GDF5 to protect dopaminergic neurons and
their axons from neurotoxin and α-synuclein based degeneration.
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3.4 Results
3.4.1 rhGDF5 promotes neurite growth in SH-SY5Y cells in a dosedependent manner and activates Smad signalling.
In order to determine the most effective concentration of rhGDF5 for this study, SHSY5Y cells, a commonly used model of midbrain dopaminergic neurons (Xicoy et al.,
2017), were treated with 0-200ng/ml concentrations of rhGDF5 for 24h (Fig. 3.1A) or
48h (Fig. 3.1B, D). Total neurite length was then used as a readout of neurotrophic action.
Statistical analysis showed that rhGDF5 promoted neurite growth at 10ng/ml or 50ng/ml
concentration after 24h. After 48hr, 50ng/ml or 200ng/ml significantly promoted neurite
growth relative to the untreated control. Given that 50ng/ml induced the greatest increase
in neurite length at both time points, this concentration was chosen for further
experiments. To investigate whether 50ng/ml rhGDF5 was capable of activating the
Smad signalling pathway, a phospho-Smad ELISA kit was used whereby an increase in
phospho-Smad expression was indicative of the activation of the Smad pathway (see Fig.
1.4 in chapter 1.0). Treatment of SH-SY5Y cells with 50ng/ml rhGDF5 for 2h led to a
significant increase in phospho-Smad levels (Fig. 3.1C).

3.4.2 rhGDF5 partially protects SH-SY5Y cells against MPP+- and 6OHDA-induced axon degeneration.
Given that rhGDF5 can promote neurite growth in SH-SY5Y cells, the next question was
whether rhGDF5 could also promote neurite growth in cellular models of PD. SH-SY5Y
cells were treated with the dopaminergic neurotoxins MPP+ and 6-OHDA at doses known
to elicit neurite degeneration and were treated with and without 50ng/ml rhGDF5 daily for
72h after which neurite length was measured. rhGDF5 significantly increased neurite
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growth compared to untreated controls while 1mM MPP+ and 15µM 6-OHDA had a
significant detrimental effect (Fig 3.2A, B). However, co-treatment with rhGDF5 for 72h
led to a significant increase in neurite length compared to each neurotoxin alone. Yet, when
compared to the untreated control, the neurite length of the co-treated groups was still
significantly different. These results demonstrate that rhGDF5 can partially protect against
MPP+- and 6-OHDA-induced axon degeneration in SH-SY5Y cells.

3.4.3 rhGDF5 protects against WT α-synuclein overexpression in SHSY5Y cells.
While 6-OHDA and MPP+ are very useful models of distinct aspects of the cellular
pathology of PD, they do not model the -synuclein accumulation which is central to the
disease progression. Therefore, to investigate whether rhGDF5 could protect SH-SY5Y
cells against α-synuclein-induced neurite degeneration, SH-SY5Y cells were transfected
with a control-GFP or a WT α-synuclein-GFP (αSynWT-GFP) overexpression plasmid
for 24h (Fig 3.3). SH-SY5Y cells were then immunocytochemically stained for αsynuclein to show overexpression relative to control-GFP cultures (Fig 3.3A). After 24h,
control-GFP and αSynWT-GFP expressing cells were treated with or without 50ng/ml
rhGDF5 daily for a further 72h. Quantification of GFP-positive neurites demonstrated
that rhGDF5 increased neurite growth while α-synuclein overexpression significantly
decreased neurite growth relative to GFP alone group (Fig. 3.3B, C). However, cotreatment of αSynWT-GFP with rhGDF5 prevented the degenerative effects of αsynuclein. These results show for the first time a neuroprotective effect of rhGDF5
against α-synuclein-induced axon degeneration in SH-SY5Y cells.
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3.4.4 rhGDF5 protects E14 dopaminergic neurons against MPP+- and 6OHDA-induced degeneration.
Although SH-SY5Y cells are widely used as in vitro model of human dopaminergic
neurons (Xicoy et al., 2017, Xie et al., 2010) they do not recapitulate all the features of
midbrain dopaminergic neurons. For this reason, the effects of rhGDF5 were next
examined on primary cultures harvested from the E14 rat VM to determine whether
rhGDF5 could protect against the effects of 6-OHDA and MPP+ in primary dopaminergic
neurons. E14 VM cultures were treated with 5µM 6-OHDA or 5µM MPP+ and cultured
with or without 50ng/ml for 72 h. Here, MPP+ and 6-OHDA significantly reduced neurite
length relative to the untreated control group (Fig. 3.4A). Treatment with rhGDF5 led to
a significant increase in dopaminergic neurite length (Fig. 3.4A, B). Moreover, cotreatment with rhGDF5 protected against the neuritotoxic effects of both 6-OHDA and
MPP+ (Fig. 3.4A, B). In addition, somal area was analysed and found that MPP+ and 6OHDA had a significantly reduced somal area compared with untreated controls while
rhGDF5 treatment increased soma size (Fig. 3.4C). In addition, when co-treatment with
rhGDF5 returned somal area to control levels. Furthermore, the number of TH+ neurons
in the culture was used as a readout of cell survival (Fig. 3.4D). Here, MPP+ and 6-OHDA
treated cells had a significantly reduced number of TH+ neurons compared to control
cells, while co-treatment with rhGDF5 prevented this. These data show that rhGDF5 can
protect primary dopaminergic neurons against 6-OHDA and MPP+.

3.4.5 rhGDF5 protects E14 VM cultures against WT α-synuclein
overexpression.
To investigate if rhGDF5 treatment could also protect against -synuclein-induced
neuritotoxicity in primary cultures, E14 VM cells were transfected with a Control-GFP
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or a WT--synuclein-GFP overexpression plasmid. Representative photomicrographs
revealed strong expression of -synuclein in cells transfected with the WT--synucleinGFP compared to cells transfected with the control-GFP plasmid (Fig. 3.5A). Firstly, to
assess the effect of α-synuclein on cell bodies, the somal area of transfected cells was
analysed from both groups. Here, no difference was found in αSynWT-GFP cells
compared to Control-GFP cells after 72 h (Fig. 3.5B). Next, neurite length was analysed
and showed that cells overexpressing SynWT-GFP exhibited a significant decrease in
neurite length compared to Control-GFP (Fig. 3.5C, D); this decrease was prevented by
co-treatment with rhGDF5.

3.4.6 α-synuclein overexpression does not affect canonical Smad
signalling in E14 VM cultures.
In view of the evidence relating to the downregulation of the RET receptor required for
GDNF and Neurturin mediated signalling by α-synuclein (Decressac et al., 2012a), a
critical factor for NTFs is that the effector molecules required for their signalling are not
affected by α-synuclein. GDF5 signals through the canonical Smad signalling pathway
through preferential binding to the BMPR1B and BMPR2 receptors (Fig. 3.6A).
Therefore, to determine the effect, if any, of α-synuclein on the expression of BMPRs
and Smad1/5 effector molecules, SH-SY5Y cells were transfected with Control-GFP and
αSynWT-GFP

overexpression

plasmids

for

72h.

The

cells

were

then

immunocytochemically stained for BMPR2, BMPR1B and Smad1/5 and GFP positive
cells were analysed for their expression (Fig. 3.6B). Here, while the expression of
BMPR2 was significantly downregulated in αSynWT-GFP cells compared to ControlGFP cells, the expression of BMPR1B and Smad1/5 remained unchanged (Fig. 3.6B).
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Furthermore, to determine if α-synuclein overexpression in primary cultures would affect
rhGDF5 induced Smad signalling, E14 VM cells were again transfected with ControlGFP and αSynWT-GFP overexpression plasmids for 24h. The cultures were then treated
with or without 50ng/ml rhGDF5 for 2h and immunocytochemically stained and analysed
for phospho-Smad activation. Here, αSynWT-GFP cells maintained a similar expression
of phospho-Smad as Control-GFP, while cultures co-treated with 50ng/ml rhGDF5
significantly increased phospho-Smad expression in both Control-GFP and αSynWTGFP cells (Fig. 3.6C). These data shows that GDF5-Smad signalling is not impacted by
the overexpression of α-synuclein in primary VM cultures.

3.4.7 AAV2/5-GDF5 co-expresses with TH+ neurons and promotes
neurite growth.
Taking into consideration the problems associated with the delivery of recombinant
proteins to the brain, viral mediated delivery of genes coding for neurotrophic proteins
has become a promising therapeutic approach. Therefore, to assess the ability of AAVGDF5 to integrate into TH+ neurons in primary VM cultures, E14 VM cells were infected
with AAV-GDF5 using a multiplicity of infection (MOI) rate of 5×104 for 10 DIV.
Immunocytochemistry revealed strong expression of the AAV-GDF5 vector throughout
the culture and importantly, inside TH+ neurons (Fig. 3.7A). It was also found that AAVGDF5 significantly increased neurite length compared to AAV-GFP (Fig. 3.7B, C). In
addition, AAV-GDF5 had no adverse effect on TH+ cell survival compared to AAV-GFP
cells (Fig. 3.7D). These results indicate that the AAV-GDF5 viral vector can successfully
target and integrate into TH+ neurons and elicit neurotrophic effects on neural projections
without any adverse effects on cell survival.
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3.5 Figures and Figure Legends

Fig. 3.1 rhGDF5 promotes neurite growth in SH-SY5Y cells in a dose-dependent
manner and activates Smad signalling. Graphs showing the neurite length of SH-SY5Y
cells treated with 0-200ng/ml rhGDF5 for A 24h and B 48h. C Graph showing phosphoSmad expression in SH-SY5Y cells after treatment with 50ng/ml rhGDF5 for 2h. D
Representative photomicrographs of SH-SY5Y cells treated with 0-200ng/ml rhGDF5
for 48h. Scale bar = 50µm. All data are presented as mean ± SEM from at least three
experiments. (* p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as indicated. One-way
ANOVA with Tukey’s post hoc test (A, B,) or Student’s t-test (C)).
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Fig. 3.2 rhGDF5 partially protects SH-SY5Y cells against MPP+- and 6-OHDAinduced axon degeneration. A Graph and B Representative photomicrographs of SHSY5Y cells treated with 1mM MPP+ or 15µm 6-OHDA with or without 50ng/ml rhGDF5
for 72h. Scale bar = 50µm. All data are presented as mean ± SEM from at least three
experiments. (** p < 0.01, *** p < 0.001 vs. control. ### p < 0.001 vs MPP +. $$$ p <
0.001 vs 6-OHDA. One-way ANOVA with Tukey’s post hoc test).
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Fig. 3.3 rhGDF5 protects against WT-α-synuclein overexpression in SH-SY5Y cells.
A Representative photomicrographs of SH-SY5Y cells transfected with constructs
expressing

GFP

(Control-GFP)

or

WT

α-synuclein-GFP

(αSynWT-GFP)

immunocytochemically stained for α-synuclein after 24h. Scale bar = 25µm. B Graph and
C Representative photomicrographs of SH-SY5Y cells expressing Control-GFP or
αSynWT-GFP and treated with or without 50ng/ml rhGDF5 for 72h. Scale bar = 50µm.
All data are presented as mean ± SEM from at least three experiments. (* p < 0.05 vs.
control. # p < 0.05 vs αSynWT-GFP. One-way ANOVA with Tukey’s post hoc test).
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Fig. 3.4 rhGDF5 protects E14 VM dopaminergic neurons against MPP+- and 6OHDA-induced degeneration. A Graph of neurite length and B Representative
photomicrographs C Graph of Somal Area and D Graph of TH+ neurons expressed as a
percentage of the control in E14 VM dopaminergic neurons treated with 5µm MPP+ or
5µm 6-OHDA with or without 50ng/ml rhGDF5 for 72h. Scale bar = 50µm. All data are
presented as mean ± SEM from at least three experiments. (* p < 0.05, ** p < 0.01, ***
p < 0.001 vs. control. # p < 0.05, ### p < 0.001 vs MPP+. $ p < 0.05, $$$ p < 0.001 vs 6OHDA. One-way ANOVA with Tukey’s post hoc test).
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Fig. 3.5 rhGDF5 protects E14 VM cultures against WT-α-synuclein overexpression.
A Representative photomicrographs of E14 VM cells transfected with constructs
expressing Control-GFP or WT αSynWT-GFP immunocytochemically stained for αsynuclein after 24h. Scale bar = 25µm. B Graph of Somal Area C Graph of Neurite
Length and D Representative photomicrographs of E14 VM cultures expressing ControlGFP or αSynWT-GFP and treated with or without 50ng/ml rhGDF5 for 72h. Scale bar =
50µm. All data are presented as mean ± SEM from at least three experiments. (** p <
0.01, *** p < 0.001 vs. control. ### p < 0.001 vs αSynWT-GFP. Unpaired Student’s ttest (B) One-way ANOVA with Tukey’s post hoc test (C)).
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Fig. 3.6 α-synuclein overexpression does not affect canonical Smad signalling in E14
VM cultures. A Schema showing GDF5 mediated activation of Smad signalling. B
Graph of BMPR2, BMPR1B and Smad1/5 effector molecules in SH-SY5Y cells
overexpressing Control-GFP or αSynWT-GFP. C Graph of phospho-Smad expression in
E14 VM cultures overexpressing Control-GFP or αSynWT-GFP. All data are presented
as mean ± SEM from at least three experiments. (* p < 0.05, *** p < 0.001 vs. control.
### p < 0.001 vs αSynWT-GFP. Student’s t-test). n.s. = no significance.
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Fig. 3.7 AAV2/5-GDF5 co-expresses with TH+ neurons and promotes neurite
growth. A Representative photomicrographs of AAV-GDF5 expression in TH+ neurons.
Scale bar = 25µm. B Graph of neurite length C Representative photomicrographs D
Graph of total TH+ neurons expressed as a percentage of total cells after transduction with
either AAV-GFP or AAV-GDF5 for 10 DIV. Scale bar = 50µm. All data are presented
as mean ± SEM from at least three experiments. (* p < 0.05 vs. control. Student’s t-test).
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3.6 Discussion
In this study, SH-SY5Y cells were initially used to assess the neurotrophic effect of
rhGDF5. rhGDF5 increased neurite length in a concentration dependent manner and
activated the canonical Smad signalling pathway, consistent with previous findings in
SH-SY5Y cells (Hegarty et al., 2013b) and dopaminergic neurons (O'Keeffe et al., 2004a,
Hegarty et al., 2014a, Costello et al., 2012). In addition, rhGDF5 was found to be partially
neuroprotective against MPP+ and 6-OHDA-induced reductions in neurite length in SHSY5Y cells. Considering the emerging evidence of α-synuclein-mediated axon
degradation in dopaminergic neurons (Koch et al., 2015, Kouroupi et al., 2017), rhGDF5
was evaluated for neurotrophic potential against the overexpression of WT α-synuclein
in SH-SY5Y cells which found rhGDF5 prevented the α-synuclein induced axon
degeneration.
While SH-SY5Y cells are an excellent resource for use in initial testing of
neurotrophic potential, since they are catecholaminergic they do not replicate all
properties of dopaminergic neurons. Therefore, primary cultures of the E14 rat VM were
used to investigate the neuroprotective potential of rhGDF5 in vitro. rhGDF5 led to a
significant increase in neurite length relative to the untreated control, which is consistent
with previous studies (Hegarty et al., 2014a, Costello et al., 2012). In addition, rhGDF5
protected dopaminergic neurons from MPP+ and 6-OHDA-induced somal and axon
degeneration and increased the dopaminergic neuron survival. The number of TH+
neurons in cultures treated with rhGDF5 alone however were not significantly different
from the control, this is in line with previous findings showing rhGDF5 predominately
works to differentiate neuronal cells rather than promoting increased survival (Hegarty et
al., 2013b). However, in contrast, several studies have found GDF5 to increase the
survival of TH+ neurons. Krieglstein et al were among the first to report a 1.6-fold
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increase in TH+ cell survival after treatment with 20ng/ml GDF5 for 8 DIV (Krieglstein
et al., 1995). While additional studies found that 1-10ng/ml GDF5 could increase
survival up to 3.1-fold after 6 DIV (O'Keeffe et al., 2004a). Furthermore, varying doses
(1, 10 or 100ng/ml) of GDF5 and GDNF were compared for their effect on dopaminergic
neuronal survival and it was found that GDF5 was as effective at promoting TH+ cell
viability as GDNF at all doses tested up to 6 DIV (Wood et al., 2005). A potential reason
for the lack of effect in this study may be due to the duration of the experiment which
was 3 DIV in comparison to that in earlier studies. In addition, this study found a
significant decrease in TH+ cell viability of 26% for MPP+ and 22% in 6-OHDA treated
cultures compared to the controls after 72h. However, co-treatment with rhGDF5
significantly attenuated this loss. This is consistent with previous findings that have
shown GDF5 to be protective against selective dopaminergic toxins including MPP+
(Krieglstein et al., 1995) and free radical induced damage induced by FeCl2 (Lingor et
al., 1999) in E14 VM cultures.
In contrast to these positive findings, GDF5 was not protective against SNP
induced free radical toxicity in E14 VM cultures (Lingor et al., 1999). This was suggested
to be in part due to the different cell death pathways induced by the SNP and FeCl2. In
addition, another study found no survival promoting effect of GDF5 in 6-OHDA treated
E14 VM cultures (Brederlau et al., 2002). However, in that study cultures were not
exposed to GDF5 until after 6DIV making the cultures E20 in nature, a time when the
expression of the GDF5 is in fact downregulated in vivo and thus neuronal cells may be
unresponsive to the effects of exogenous GDF5 (O'Keeffe et al., 2004b). Additionally, a
recent study assessed the effect of GDF5 against MPP+ treated SN cultures harvested
from postnatal day P0 pups (Jaumotte et al., 2016). However, the authors noted no
survival enhancing effects of GDF5 at any time point tested. Interestingly however, when
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a combination of NTFs was used including GDNF, BDNF, TGF-β, FGF-2 and GDF5,
the number of TH+ neurons in the SN cultures rose by 32.6 ± 5.13% after exposure to
10µM MPP+ for 30 minutes, and 29.1 ± 8.56% after exposure to 500µM MPP+ for 30
minutes (Jaumotte et al., 2016). This synergistic effect may be due to each NTF not only
acting on dopaminergic neurons, but also non-dopaminergic cells which may influence
dopaminergic neuron survival through paracrine signalling (Jaumotte et al., 2016). The
fact that GDF5 was not found to be neuroprotective in this study may again result from
the age of the culture as GDF5 is known to be downregulated at P0 (O'Keeffe et al.,
2004b).
While MPP+ and 6-OHDA are valuable neurotoxins for modelling selective
dopaminergic degeneration, they do not accurately represent the pathophysiology of PD.
The accumulation of α-synuclein protein aggregates that spread throughout the CNS
known as Lewy bodies and Lewy neurites (Spillantini et al., 1997) are a major
pathological hallmark of PD. In addition, missense point mutations in the SNCA gene
including A30P, A53T or duplications or triplications of SNCA are associated with
familial forms of PD (Kruger et al., 1998, Polymeropoulos et al., 1997, Singleton et al.,
2003, Chartier-Harlin et al., 2004, International Parkinson Disease Genomics et al.,
2011). Therefore, to investigate the effects of α-synuclein in E14 VM cultures, cells were
transfected with either a control-GFP or αSynWT-GFP expression plasmid. The
overexpression of α-synuclein had no effect on somal area, consistent with previous
findings (Koch et al., 2015) but significantly reduced neurite length, which was
attenuated by co-treatment with rhGDF5. This finding agrees with several studies
showing neuritic pathologies as important events in synucleinopathies including PD
(Kalia and Kalia, 2015, Prots et al., 2013, Furlong et al., 2020). Indeed, it is now
becoming widely accepted that axonal degeneration occurs early in PD (Kordower et al.,

97

2013, O'Keeffe and Sullivan, 2018, Hsiao et al., 2014, Caminiti et al., 2017) and may be
a consequence of α-synuclein overload (Koch et al., 2015, Oliveira et al., 2015, Prots et
al., 2013, Lin et al., 2016b, O'Keeffe and Sullivan, 2018).
Given the evidence supporting the α-synuclein mediated downregulation of RET,
the co-receptor required for GDNF and Neurturin signalling (Decressac et al., 2012a), the
effect of α-synuclein, on the regulators of BMP-Smad signalling was investigated. GDF5
is known to preferentially bind to the BMPRs, BMPR1B and BMPR2, to activate the
Smad signalling pathway (Nishitoh et al., 1996, Hegarty et al., 2013b). In this study, SHSY5Y cells overexpressing α-synuclein significantly reduced the expression of BMPR2
while the expression of BMPR1B and Smad1/5/8 remained unchanged compared to
control-GFP cells. As GDF5 is known to elicit its phenotypic neurotrophic effects
primarily through high affinity binding to BMPR1B (Hegarty et al., 2013b), this result
was promising. rhGDF5 was also shown to increase phospho-Smad expression in
dopaminergic neurons overexpressing α-synuclein, indicating that the BMP-Smad
pathway machinery are not affected by WT α-synuclein overexpression in SH-SY5Y
cells and primary VM cultures.
While NTFs are a promising therapeutic intervention, a significant problem with
delivering recombinant proteins, including GDF5, is their need for direct administration
to the brain due to rapid metabolism in the gut and moreover, the inability to cross the
blood brain barrier due their large molecular weight (O'Keeffe et al., 2017). Although
administration of recombinant NTFs to the brain is safe and clinically feasible, clinical
trials using recombinant proteins thus far failed to meet their primary endpoints (Gill et
al., 2003, Lang et al., 2006, John T. Slevin et al., 2005, Nutt et al., 2003). This is due to
low levels of the protein of interest reaching its target area due to rapid biometabolism
by endogenous enzymes. However, the advent of gene therapy using viral vectors
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bypasses this issue by incorporating the gene for the protein of interest for targeted
expression within the brain (Axelsen and Woldbye, 2018). This has led to pre-clinical
studies using recombinant LV or AAV vectors to deliver NTFs in animals models of PD
(Choi-Lundberg et al., 1997, Kordower et al., 2000, Kordower et al., 2006, Ramaswamy
et al., 2007, Herzog et al., 2007, Su et al., 2009, Decressac et al., 2011, Bäck et al., 2013,
Cordero-Llana et al., 2015, Ren et al., 2013). Translating this research into clinical trials
however favours AAV2 vectors due to higher safety profiles within the clinic (Kelly et
al., 2015, Bartus et al., 2013, Bartus et al., 2011, Marks et al., 2010, Warren Olanow et
al., 2015). E14 VM cultures transduced with AAV2-GDF5 vector for 10 DIV
demonstrated strong expression of GDF5 and co-expression with TH+ neurons in culture.
Moreover, AAV2-GDF5 significantly increased the neurite length of TH+ neurons and
dopaminergic cell viability was not impacted relative to AAV2-GFP cultures, indicating
its safe use.
Collectively, this study demonstrates for the first time that rhGDF5 protects against 6OHDA, MPP+ and α-synuclein induced axonal degeneration in SH-SH5Y cells and
primary E14 VM cultures. In addition, this study provides further evidence of rhGDF5
promoting TH+ neuronal survival against 6-OHDA and MPP+ treated primary cultures.
This study also shows that GDF5-mediated canonical BMP-Smad signalling is not
affected by the overexpression of WT α-synuclein in SH-SY5Y cells and primary VM
cultures. Finally, this study validates the efficacy of AAV2/5-GDF5 in targeting TH+
neurons and highlights the potential of AAV2/5-GDF5 to induce neurotrophic effects on
TH+ cells. Taken together, this study provides robust evidence for the potent neurotrophic
efforts of GDF5 and justifies the further investigation of AAV2/5-GDF5 in a translational
model of PD, such as the α-synuclein rat model of the disease.
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Chapter 4.0

GDF5 exerts neuroprotection in an α-synuclein rat
model of Parkinson’s disease.

4.1 Aims of Study
• Investigate the long-term effects of AAV-mediated delivery of GDF5 in vivo
• Identify the effect of AAV-mediated delivery of α-synuclein to the SN
• Determine if there is a neuroprotective effect of AAV-GDF5 against AAV-αSyn
• Evaluate the effect of α-synuclein on the expression of key mediators in the Smad
signalling pathway

• Determine the effect of α-synuclein on motor behaviour

Work featured in this chapter has been published in the following paper:
Goulding SR, Concannon RM, Morales-Prieto N, Villalobos-Manriquez F, Clarke G,
Collins LM, Wyatt SL, Sullivan AM, O'Keeffe GW. GDF5 exerts neuroprotection in an
α-synuclein rat model of Parkinson’s disease. Brain 2020 In Press.
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4.2 Abstract
Introduction: Neurotrophic factors hold significant promise as neuroprotective therapies
for PD. While viral vector-mediated delivery of neurotrophic factors to the PD brain is
safe and clinically feasible, clinical trials of two well-known neurotrophic factors, GDNF
and Neurturin, have failed to meet their primary end-points. This study sought to
determine whether viral delivery to the adult rat brain of a novel neurotrophic factor,
GDF5, could protect dopaminergic neurons from -synuclein–induced degeneration,
which is the primary neuropathological hallmark of PD.
Methods: 80 adult SD female rats were used over two experiments. In experiment 1;
animals received a unilateral injection of an AAV-Cont+AAV-Cont or AAVGDF5+AAV-Cont vector combination into the SN. In experiment 2; animals received an
AAV-Syn+AAV-Cont or AAV-Syn+AAV-GDF5 vector combination into the SN.
Behavioural tests of sensorimotor function were carried out at 8, 12, 16 and 20 weeks,
prior to post-mortem analysis of -synuclein pathology and nigrostriatal integrity at 20
weeks.
Results: Intranigral delivery of AAV-α-synuclein led to significant reductions in the
expression of transcripts for Th, Dat and Ret expression, but did not affect the expression
of Bmpr2, Bmpr1b and Smad 1. In addition, AAV-α-synuclein caused a significant loss
of TH+ and DAT+ neurons from the SN and a loss of striatal dopamine which were
prevented by AAV-mediated delivery of GDF5.
Conclusion: The observed neuroprotective effects of GDF5 in this preclinical model
support the theory that Ret-independent neurotrophic factors may have therapeutic
benefit in PD and are worthy of further exploration.

101

4.3 Introduction
The concept of NTF therapy holds significant promise as a disease-modifying therapy for
PD (Paul and Sullivan, 2019). Whone et al. have recently reported the results of a
randomized, double-blind, placebo-controlled trial of intermittent intraputamenal
convection-enhanced delivery of GDNF in PD patients (Whone et al., 2019a). Despite an
extensive body of excellent work and significant improvements to dosing and delivery,
this trial failed to reach its primary endpoint. This outcome is largely consistent with an
earlier randomized, placebo-controlled trial of GDNF in PD (Lang et al., 2006). Preclinical studies have shown that delivery of AAV-GDNF to either the striatum or SN
failed to protect dopaminergic neurons or their terminals in a rat model of PD generated
through viral-mediated overexpression of human WT α-synuclein (AAV-Syn)
(Decressac et al., 2011) or A30P mutant α-synuclein (LV-Syn) (Lo Bianco et al., 2004).
This has been suggested to be due to Syn-induced downregulation of Nurr1 and Ret in
the midbrain, measured at 2 weeks post-surgery (Decressac et al., 2012a). Similar Syninduced downregulation of Ret was reported in the SN of PD patients (Decressac et al.,
2012a). This may explain the lack of clinical efficacy of GDNF, as the Ret receptor has
been reported to be critical for the dopaminergic neurotrophic effects of GDNF in vivo
(Drinkut et al., 2016). However, others found that transgenic overexpression of human
-synuclein in mice, or intranigral administration of AAV-Syn in rats, did not
downregulate Nurr1 or TH expression after 8 weeks (Su et al., 2017). Therefore, the effect
of -synuclein on Ret expression remains an open and important question.
More generally, the lack of clinical efficacy of GDNF has raised the larger question
of whether NTF delivery as a therapeutic approach remains viable, or if this approach
requires further testing and evaluation in clinical settings (Whone et al., 2019b). Another
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consideration is that if Ret receptors are downregulated or not functioning optimally in
the PD brain, then Ret-independent neurotrophic factors may have therapeutic benefit,
assuming that -synuclein does not also affect the expression of their key signalling
mediators. Thus, a critical requirement to justify the development of Ret-independent
NTF therapy, is that these factors must display therapeutic benefit in the -synuclein
model of PD, which more closely mimics the disease pathology than other rodent models.
In chapter 3.0, GDF5 was shown to be neuroprotective against in vitro models of PD
including the overexpression of α-synuclein. Importantly, the neurotrophic effects of
GDF5 are known to be exclusively dependent on the canonical Smad signalling pathway,
which is a Ret-independent mechanism (Hegarty et al., 2014a, Hegarty et al., 2013b).
Therefore, this study investigated whether viral mediated intranigral delivery of GDF5
could protect dopaminergic neurons and their axons against the overexpression of αsynuclein in vivo.
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4.4 Results
4.4.1 Experimental Design
The approach to this study was two-fold. Firstly, in experiment 1, the safety and efficacy
of AAV-mediated delivery of GDF5 was evaluated. In this study, animals received a
unilateral injection of either an AAV2/5-Cont+AAV2/6-Cont (AAV-Cont) or an
AAV2/5-GDF5+AAV2/6-Cont (AAV-GDF5) vector combination into the SN (Fig.
4.1A). Subsequently, experiment 2 evaluated the neurodegeneration induced by the
overexpression of human WT α-synuclein and the potential neuroprotective effect of
GDF5. Here, animals were unilaterally injected with an AAV2/6-αSyn+AAV2/5-Cont
(AAV-αSyn)

or

an

AAV2/6-αSyn+AAV2/5-GDF5

(AAV-αSyn/GDF5)

vector

combination into the SN (Fig. 4.1B). In both experiments, behavioural testing was carried
out at four weekly intervals beginning 8 weeks after stereotactic surgery (Fig. 4.1C).
Animals were sacrificed at 20 weeks and analysed for α-synuclein overexpression and
nigrostriatal integrity.

4.4.2 No adverse effects of long-term AAV-GDF5 on nigrostriatal
integrity for up to 20 weeks post-surgery.
In experiment 1, the safety and efficacy of AAV-mediated transfer of GDF5 was
investigated relative to animals who had received an AAV-Cont vector unilaterally
injected into the SN. Twenty weeks post-surgery, animals sacrificed via transcardial
perfusion were immunohistochemically probed for TH to assess nigral and striatal
dopaminergic integrity (Fig. 4.2A, E). Quantification of TH in the SN displayed no
significant difference in the number of TH+ cell bodies between AAV-Cont and AAVGDF5 groups (Fig. 4.2B). To confirm this result, SN sections were also stained for DAT
and a statistical analysis showed no difference in the number of DAT-positive (DAT+)
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cell bodies in the SN between AAV-Cont and AAV-GDF5 animals (Fig. 4.2C). To
confirm the expression of the human GDF5 transgene, SN sections from AAV-GDF5
animals were stained for human GDF5 which revealed strong expression of GDF5 in TH+
cells (Fig. 4.2D). Furthermore, quantification of TH staining as a percentage of the
contralateral intact striatum revealed there was no difference in striatal TH levels in
AAV-Cont compared to AAV-GDF5 animals (Fig. 4.2.E, F). In agreement with this,
HPLC analysis of dopamine in the striatum showed consistent dopamine levels in both
AAV-Cont and AAV-GDF5 animals (Fig. 4.2G). The results of this study indicate that
long-term AAV-mediated expression of GDF5 is well tolerated in TH+ neurons and
produces no adverse effects in the SN or striatum of adult rats, at least up to 20 weeks.

4.4.3 AAV-GDF5 maintains nigrostriatal integrity and striatal
dopamine levels in the rat AAV-Syn model of PD.
In experiment 2, adult rats received a stereotaxic unilateral intranigral injection of αsynuclein vector (AAV2/6-αSyn) and concomitantly either a control vector (AAV2/5Cont) or a vector carrying the human GDF5 transgene (AAV2/5-GDF5) (Fig. 4.3A). Rats
were sacrificed 20 weeks later for analysis of transgene expression and nigrostriatal
integrity. There were no differences in α-synuclein expression levels between AAV-αSyn
and AAV-αSyn/GDF5 treated animals in the striatum (Fig. 4.3B) or SN (Fig. 4.3C). It
was then investigated whether nigral GDF5 overexpression could prevent the loss of
striatal dopaminergic terminals, which is known to occur in this model (Decressac et al.
2011). To evaluate the neurodegeneration induced by overexpression of human WT αsynuclein and the potential neuroprotective effect of AAV-GDF5, the number of TH+ and
DAT+ neurons in the ipsilateral and contralateral SN were measured. At 20 weeks post
injection of AAV-αSyn, there was ~36% loss of TH+ (Fig. 4.3D, E) and ~30% loss of
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DAT+ (Fig. 4.3F) neurons, compared to the intact side. AAV-mediated delivery of GDF5
to the SN prevented this loss of dopamine neurons (Fig. 4.3E, F). In addition, quantitative
analysis of TH+ striatal fibre innervation revealed that nigral overexpression of αsynuclein induced ~45% reduction (Fig. 4.3G, H). In contrast, nigral overexpression of
GDF5 by AAV-GDF5 had a protective effect on striatal dopaminergic terminal density
(Fig. 4.3G, H). Moreover, analysis of striatal dopamine levels using HPLC after 20 weeks
revealed that nigral overexpression of α-synuclein induced ~45% reduction in striatal
dopamine levels (Fig. 4.3I). While AAV-mediated nigral overexpression of GDF5 had a
protective effect on striatal dopamine levels (Fig. 4.3I). Collectively, these data show that
intranigral injection of AAV-GDF5 protected dopaminergic neurons and their terminals,
maintaining striatal dopamine levels in the AAV-αSyn rat model of PD.

4.4.4 α-synuclein downregulates Ret but not key mediators of BMP
signalling in vivo.
Given that α-synuclein has been shown to downregulate the Ret receptor required for
GDNF and Neurturin signalling, this study also investigated the effect of -synuclein
overexpression on the effectors of the BMP-Smad signalling pathway in the rat SN.
AAV-αSyn resulted in the strong expression of -synuclein throughout the midbrain and
high α-synuclein immunoreactivity in the axonal terminals distributed throughout the
striatum on the ipsilateral, but not contralateral side (Fig. 4.4A). In addition, pSer129-synuclein immunostaining for the pathological form of -synuclein revealed strong
expression in dopaminergic neuronal soma and neurites in the ipsilateral SN,
characteristic of Lewy bodies and Lewy neurites (Fig. 4.4B). Furthermore, intranigral
delivery of AAV-αSyn led to significant reductions in the expression of transcripts for
Th (Fig. 4.4C) and Dat (Fig. 4.4D), but not NeuN (Fig. 4.4E). AAV-αSyn also induced a
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significant reduction in Ret expression (Fig. 4.4F), but no change in the expression of
Bmpr2, Bmpr1b and Smad 1, all of which are required for the dopaminergic neurotrophic
effects of GDF5 (Fig. 4.4G). These results therefore add significant weight to the
proposed use of Ret-independent neurotrophic factors as therapeutic interventions for PD.

4.4.5

Phospho-Smad

expression

in

dopaminergic

neurons

is

substantially reduced by AAV-αSyn transduction of the SN, but not
when combined with AAV-GDF5.
Given that the overexpression of WT α-synuclein did not affect transcripts for key
mediators of canonical BMP-Smad signalling in the SN, this study also looked at the
level of phospho-Smad proteins in TH+ neurons in the ipsilateral SN of animals injected
with either AAV-αSyn+AAV-Cont or AAV-αSyn+AAV-GDF5 (Fig. 4.5). In this
experiment, SN sections were immunofluorescently stained for TH and α-synuclein and
TH+ neurons were then quantified for the level of phospho-Smad intensity. Statistical
analysis showed that the overexpression of α-synuclein caused a significant reduction in
phospho-Smad expression after 20 weeks, relative to the contralateral intact SN (Fig.
4.5A, B). However, animals injected with α-synuclein in combination with GDF5, did
not experience this marked decline and instead phospho-Smad intensity was maintained
at the level of the contralateral intact SN (Fig. 4.5C, D). These results indicate that the
overexpression of α-synuclein impacts phospho-Smad protein expression in vivo, which
can be rescued by GDF5.
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4.4.6 AAV-Syn transduction of the SN leads to subtle sensorimotor
impairments, that are attenuated by AAV-GDF5.
To determine whether the overexpression of -synuclein had any effects on motor
behaviour and whether this could be prevented by GDF5, animals underwent the whisker,
stepping and corridor tests of sensorimotor function beginning 8 weeks after stereotaxic
surgery and repeated at four weekly intervals for 20 weeks. When the effect of the AAVGDF5 viral vector on motor function were examined, no significant result for AAVGDF5 was found on performance in the whisker test (F(1, 18) = 0.1951; p=0.6639) (Fig.
4.6A), stepping test (F(1, 18) = 1.221; p=0.2838) (Fig. 4.6B) nor in the corridor test (F(1, 18)
= 0.4855; p=0.4948) (Fig. 4.6C). These data show that AAV-GDF5 did not have any
adverse effects on behaviour for up to 20 weeks suggesting that the approach is safe and
well tolerated. In contrast, a two-way repeated measures ANOVA of performance in the
whisker test revealed that there was a significant effect of AAV-Syn (F(1, 18) = 8.587; p
= 0.0089) and time (F(3, 54) = 4.227; p =0.0093) but no significant interaction between
both (F (3, 54) = 3.13; p = 0.1238). Post-hoc analysis showed that the AAV-Syn animals
performed significantly worse than controls at 16 (p < 0.05) and 20 weeks (p < 0.05) (Fig.
4.6D). In contrast however, there was no significant effects of AAV-Syn in the stepping
test (F(1, 18) = 0.0002; p =0.9644) (Fig. 4.6E) nor in the corridor test (F(1, 18) = 0.04416;
p=0.8359) (Fig. 4.6F). These data show that AAV-Syn leads to subtle impairments only
in the whisker test that only emerge 16 weeks post-surgery.
Given the effects of AAV-Syn were only seen in the whisker test, the four
groups were then directly compared at the 20 week time point (Fig. 4.6G). A one-way
ANOVA at 20 weeks revealed a significant effect in the whisker test with post-hoc testing
showing that the only group in which there was a significant reduction in performance
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was in the AAV-Syn+AAV-Cont group (Fig. 4.6G). Collectively these data show that
the while AAV-Syn leads only to subtle impairments in motor function relative to the
controls, the subtle impairments that are seen in the AAV-Syn+AAV-Cont group, are
not seen in the AAV-Syn+AAV-GDF5 group. These data show that although AAVSyn exerts only subtle effects on aspects of motor behaviour, these effects are attenuated
by AAV-GDF5.
Finally, given that weight loss has been reported as an adverse effect of GDNF
therapy (Nutt et al., 2003, Manfredsson et al., 2009), the average weight of the animals
in each group at 20 weeks was analysed by one-way ANOVA and found no differences
compared with AAV-Cont+AAV-Cont animals (Fig. 4.6H). These results indicate that
the overexpression of GDF5, or indeed α-synuclein, causes no adverse or long-term
effects on weight.
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4.5 Figures and Figure Legends

Fig. 4.1 Experimental Design. A In Experiment 1, animals received a unilateral injection
of an AAV-Cont+AAV-Cont or AAV-GDF5+AAV-Cont vector combination into the
SN. N=20 per group. B In Experiment 2, animals received a unilateral injection of an
AAV-αSyn+AAV-Cont or AAV- αSyn+AAV-GDF5 vector combination into the SN.
N=20 per group. C Schema showing the study timeline for each experimental group from
0-20 weeks, including behavioural testing and post-mortem assessment measure. IHC =
Immunohistochemistry.
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Fig. 4.2 No adverse effects of long-term AAV-GDF5 on nigrostriatal integrity for up
to 20 weeks post-surgery. A Representative photomicrographs of AAV-Control (Black)
and AAV-GDF5 (Blue) TH-stained sections through SN on the ipsilateral side. Scale bar
= 200µm. B, C Graph showing the numbers of B TH+ and C DAT+ neurons in the SN
expressed as a percentage of the intact side. D Representative photomicrographs showing
expression of the human (h)GDF5 transgene (green) in TH+ neurons (red; white arrows)
in the ipsilaterally (injected) SN at 20 weeks’ post-injection of the AAV-GDF5 vector.
Scale bar = 50µm. E Representative photomicrographs of TH-stained sections through
the striatum on the ipsilateral side and the contralateral intact side. Scale bar = 1mm. F
Graph showing the striatal TH immunoreactivity expressed as percentage of the intact
side. G Graph of HPLC data showing striatal dopamine (DA) levels expressed as a
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percentage of the intact side. All data are presented as mean ± SEM and analysed by a
Student’s t-test.

Fig. 4.3 AAV-GDF5 maintains nigrostriatal integrity and striatal dopamine levels
in the rat AAV-Syn model of PD. A Representative striatal images of -synuclein
staining in animals injected with AAV-Syn with either an AAV-Cont (purple) or AAVGDF5 (blue) vector into the SN and B, C quantification of -synuclein levels in B the
Striatum and C the SN in both experimental groups. D Representative photomicrographs
of TH-stained sections through SN on the ipsilateral side. Scale bar = 200µm. E, F
Graph showing the numbers of E TH+ and F DAT+ neurons in the SN expressed as
percentage of the intact side. G Representative photomicrographs of TH stained sections
through the striatum on the ipsilateral (injected) side and the contralateral intact side.
Scale bar = 1mm. H Graph showing striatal TH immunoreactivity expressed as
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percentage of the intact side. I Graph of HPLC data showing striatal dopamine (DA)
levels expressed as percentage of the intact side. All data are presented as mean ± SEM
and analysed by a Student’s t-test; *p < 0.05, **p < 0.01 vs control.

Figure 4.4 -synuclein downregulates Ret but not key mediators of BMP signalling
in vivo. Representative images showing A WT -synuclein (Syn) immunostaining in
rat striatum and midbrain, and B pSer129-Syn staining in SN, at 20 weeks after
unilateral stereotaxic injection of AAV-Syn vector into the SN. Blue arrows indicate
dopaminergic neuronal cell bodies and red arrows indicate processes. Scale bar = 1mm.
Real-time PCR data showing expression of transcripts for C Th (** t = 4.211, d.f. = 8, P
= 0.0029), D Dat (*** t = 5.28, d.f. = 8, P = 0.0007) E NeuN, F Ret (* t = 2.45, d.f. = 8,
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P = 0.0399) and G Bmpr2, Bmpr1b and Smad1, key mediators of BMP signalling in
animals injected with an AAV-Cont+AAV-Cont (Black) or an AAV-αSyn+AAV-Cont
(purple) vector combination (n = 5 per group). All data are presented as mean ± SEM and
analysed by Student’s t-test; *p < 0.05, **p < 0.01, ***p<0.001 vs control.

Fig. 4.5 Phospho-Smad expression in dopaminergic neurons is substantially reduced
by AAV-αSyn transduction of the SN, but not when combined with AAV-GDF5.
Quantification of phospho-Smad expression as a percentage change from the
contralateral (intact) side of animals injected with A AAV-αSyn+AAV-Cont or C AAVαSyn+AAV-GDF5 at 20 weeks. Representative photomicrographs of TH+ (red) neurons
in the SN expressing phospho-Smad (green) in the ipsilateral (injected) and contralateral
(intact) side of animals injected with B AAV-αSyn+AAV-Cont or D AAV-αSyn+AAVGDF5 at 20 weeks. (n=7 per group; ***p<0.001 vs intact control). All data are presented
as mean ± SEM and analysed by Student’s t-test. Scale = 10µm.
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Fig. 4.6 Long-term viral-mediated overexpression of WT -synuclein in the rat SN
leads to subtle sensorimotor impairments that are attenuated by AAV-GDF5. A-F
Graphs showing the results of the A, D Whisker, B, E Stepping and C, F Corridor tests
at four weekly intervals from 8 weeks up to 20 weeks after stereotactic injection with AC an AAV-Cont+AAV-Cont (Black) or AAV-GDF5+AAV-Cont (Blue) or D-F an AAVαSyn+AAV-Cont (Purple) or AAV-αSyn+AAV-GDF5 (Purple/Blue) vector into the SN.
G Graph showing the combined experimental results of the whisker test at 20 weeks post
stereotactic injection into the SN with AAV-Cont+AAV-Cont, AAV-GDF5+AAV-Cont,
AAV-αSyn+AAV-Cont or AAV-αSyn+AAV-GDF5, as indicated. H Graph showing the
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final weight of animals in all experimental groups. All data are mean ± SEM (* p < 0.05
vs control; one-way ANOVA with post-hoc (D) Bonferroni’s or (G) Tukey’s test (n=10
per group)).

4.6 Discussion
Given the recent failure of AAV-GDNF to protect dopaminergic neurons from αsynuclein overexpression in vivo, this study evaluated the effect of another potent
dopaminergic neurotrophic factor, GDF5. This study initially investigated the safety and
efficacy of viral-mediated delivery of GDF5 to the SN of adult rats. To confirm its
expression within the ipsilateral SN, immunofluorescent staining revealed strong levels
of the GDF5 transgene within TH+ neurons. Nigral integrity was assessed after 20 weeks
and revealed no significant difference in the number of TH+ and DAT+ neurons between
AAV-Cont and AAV-GDF5 animals. In addition, analysis of striatal integrity showed no
difference in TH immunoreactivity between the two groups, substantiated by HPLC
analysis of the striata which showed no difference in dopamine levels between AAVCont and AAV-GDF5 animals. Moreover, GDF5 overexpression had no adverse effect
on motor behaviour relative to AAV-Cont animals. Notably, the weight of the animals
was not affected after long-term exposure to GDF5, which is an important finding given
that anorexia and weight loss were adverse effects associated with intracerebral GDNF
delivery in monkeys (Nutt et al., 2003). These results support the conclusion that AAVmediated delivery of GDF5 to the SN is a safe and well-tolerable approach.
This study then assessed the effect of viral mediated α-synuclein overexpression in
the SN and whether AAV-GDF5 could protect dopaminergic neurons from α-synucleininduced degeneration. Here, intranigral AAV-αSyn delivery led to widespread expression
of α-synuclein throughout the midbrain and striatum on the ipsilateral side only.
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Moreover, immunostaining for pSer129-αSyn for the pathological form of α-synuclein
revealed strong expression in dopaminergic neuronal soma and neurites in the ipsilateral
SN, a key signature of Lewy bodies and Lewy neurites (Anderson et al., 2006). This
overexpression of α-synuclein led to a significant reduction in the number of TH+ and
DAT+ neurons in the SN and TH+ fibre density in the striatum, verified by HPLC
dopamine analysis. However, animals given AAV-αSyn in combination with AAVGDF5 saw a significant increase in both TH+ and DAT+ neurons in the SN and also TH+
fibre density in the striatum. However, the level of α-synuclein overexpression was
unchanged by GDF5. These results agree with previous studies showing GDF5 exerts
neuroprotection to dopaminergic neurons against commonly used neurotoxin-based
preclinical models of the disease (Costello et al., 2012, O'Sullivan et al., 2010, Sullivan
et al., 1997, Sullivan et al., 1998, Hurley et al., 2004). Of note, one study in particular
compared the efficacy of GDF5 dimer-treated, GDNF dimer-treated and untreated foetal
mesencephalic grafts in the 6-OHDA lesioned rat model of PD. In this study, rats received
the graft four weeks post-lesion to the MFB. Behavioural testing of amphetamineinduced rotation rates found the mean rate for lesion-only animals was 12.6 ± 2.8, graftonly animals was 2 ± 0.4, while animals receiving GDF5-treated or GDNF-treated grafts
displayed no rotations (Sullivan et al., 1998). In determining TH+ cell survival, a deposit
of TH+ cells was visible in all groups that had received a VM transplant. However, the
grafts pre-treated with GDF5 dimer or GDNF displayed a significant increase in number
and density of TH+ neurons compared with the graft alone (Sullivan et al., 1998). This
study was the first to show the neurotrophic and neuroprotective effect of GDF5 on
treated foetal mesencephalic transplants. Notably, this study also highlighted that GDF5
treatment was equally as beneficial as GDNF. Collectively, the in vivo evidence in
support of GDF5 to date demonstrates that GDF5 is neuroprotective against 6-OHDA
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and α-synuclein models of PD, both of which are mechanistically different models of PD
(Raza et al., 2019, Dijkstra et al., 2015). This implies that GDF5 may play a role in
alleviating oxidative stress and mitochondrial dysfunction as well as a role in regulating
axonal function.
Furthermore, given that the failure of GDNF and Neurturin has been attributed to
the downregulation of their common co-receptor, Ret (Decressac et al., 2012a), this study
also examined the effect of α-synuclein overexpression on the transcripts for mediators
of the Smad signalling pathway. In this experiment, the expression of GDF5’s receptors
and downstream transcription factor Smad1 was not affected by α-synuclein
overexpression, at least at the 20-week time point examined. The observed
neuroprotective effects of GDF5 in this preclinical model thus support the theory that
Ret-independent neurotrophic factors may have therapeutic benefit in PD and are worthy
of further exploration (Warren Olanow et al., 2015). However, in agreement with
Decressac et al (2012), this experiment found that viral-mediated overexpression of αsynuclein led to a significant reduction in Ret expression in the adult rat SN at 20 weeks
post-surgery. However, it is important to note that the reduction of 25% in this study was
observed at 20 weeks, in contrast to the much greater (~65%) reduction reported by
Decressac et al after 2 weeks. Since this study found that ~75% of Ret expression
remained in the α-synuclein-overexpressing brain, these data suggest that the signalling
capacity of GDNF may be retained, at least partially, in these animals. This is also
consistent with the significant putamenal increase in 18F-DOPA uptake in GDNF-treated
patients at Week 40 reported in the Whone et al study (Whone et al., 2019a). The key
determinant of clinical efficacy of GDNF may therefore be the level of α-synuclein
burden in the host brain. High levels of α-synuclein may lead to an early and strong
downregulation of Ret, similar to that reported in the Decressac et al. study (2012),
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whereas modest α-synuclein levels may lead in the short term to minimal reductions in
Ret, as observed by Su and co-workers after 8 weeks (2017), but more substantial
impairment of Ret expression in the longer term, as seen in this study.
Finally, to determine whether the overexpression of -synuclein had any effects on
motor behaviour and whether this could be prevented by GDF5, animals underwent the
whisker, stepping and corridor tests of sensorimotor function (Schallert et al., 2000,
Dowd et al., 2005) beginning 8 weeks after stereotaxic surgery and repeated every four
weeks for 20 weeks. Here, animals injected with AAV-αSyn had no functional deficits
in the corridor or stepping tests at any time point compared to AAV-Cont animals.
However, there was subtle sensorimotor dysfunction seen in AAV-αSyn animals in the
whisker test at 16 and 20 weeks compared to AAV-Cont animals, but this effect was not
seen in animals injected with AAV-αSyn+AAV-GDF5. These results are in contrast to
those found by Decressac et al (2011) where AAV-αSyn transduced animals displayed
increased amphetamine-induced rotations at only 8 weeks post injection. Similarly, in
another study, intranigral AAV-αSyn overexpression was found to significantly affect
performance in the cylinder and stepping test 8 weeks post stereotactic surgery (Gombash
et al., 2013). The discrepancies in the behavioural findings of this study compared to
Decressac et al and Gombash et al were initially thought to be due to differences in the
virus preparation. In this study, viruses were prepared using a SYN1 promoter and a
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) to enhance
expression. While, in the contrasting studies, a cytomegalovirus (CMV) enhancer hybrid
synthetic chicken β-actin (CBA) promoter was used. However, in an additional study by
Decressac et al (2012) AAV-αSyn with synapsin-1 and WPRE enhancer were used and
again reported a significant effect on performance in the stepping test 3 weeks postsurgery and moreover, after 8 weeks there was significant motor dysfunction recorded in
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the stepping, cylinder and rotation test (Decressac et al., 2012b). In addition, the authors
reported a loss of over 50% of dopamine neurons from the SN after 8 weeks. However,
in contrast, a study carried out using a similar virus found a non-significant 10% loss in
dopaminergic neurons after AAV-αSyn injection to the SN at the same 8 week time point
(Su et al., 2017). As is now known, motor impairments arise when there is a 50% loss of
dopaminergic neurons and an 80% loss of striatal fibres (Cheng et al., 2010). In this study,
α-synuclein overexpression resulted in a ~36% loss of TH+ neurons from the SN and
~45% loss in striatal integrity. Therefore, the inconsistency perhaps lies with the efficacy
of the vector combination given i.e. AAV2/6 combined with AAV2/5 packaging units
and perhaps a stronger behavioural phenotype would be realised using a higher titre of
the virus.
Collectively, this study shows that long-term delivery of AAV-GDF5 to the SN is
safe and provides targeted delivery of GDF5 to TH+ neurons. In addition, AAV-GDF5
did not affect motor function or induce weight loss in adult rats. AAV-αSyn delivery to
the SN caused a significant reduction in TH+ number and striatal fibre density, that was
not seen in animals co-transduced with AAV-GDF5. In addition, α-synuclein induced
subtle sensorimotor function at the later time points which was attenuated by AAVGDF5. Finally, the overexpression of α-synuclein did not affect the BMP receptors or
effector molecules required for GDF5 signalling. In conclusion, GDF5 has now been
shown to exert neuroprotective effects against MPP+, 6-OHDA and α-synuclein in vitro
models of PD as well as the α-synuclein in vivo model of the disease. Moving forward, it
will important to evaluate whether there are neurorestorative effects of GDF5 in the αsynuclein animal model after degeneration of the nigrostriatal system has already
developed.

120

Chapter 5.0

Gene co-expression analysis of the human substantia nigra
identifies BMP2 as a neurotrophic factor that can promote
neurite growth in cells overexpressing wild-type or A53T synuclein.

5.1 Aims of Study
•

Identify BMP family members that co-express with markers of dopaminergic neurons in
the SN

•

Test the lead BMP ligand against 6-OHDA, MPP+ and the overexpression of WT and
mutant A53T α-synuclein in SH-SY5Y cells

•

Assess the neurotrophic ability of the lead BMP ligand against these cellular models of
PD in primary VM cultures

Work featured in this chapter has been published in the following paper:
Goulding SR, Sullivan AM, O'Keeffe GW, Collins LM. Gene co-expression analysis of
the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote
neurite growth in cells overexpressing wild-type or A53T α-synuclein. Parkinsonism
Relat Disord. 2019 Jul;64:194-201. doi: 10.1016/j.parkreldis.2019.04.008. Epub 2019
Apr 11. PMID: 31000327
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5.2 Abstract
Introduction: -synuclein-induced degeneration of dopaminergic neurons has been
proposed to be central to the early progression of PD. This highlights the need to identify
factors that are neuroprotective or neuroregenerative against -synuclein-induced
degeneration. GDF5 is a member of the BMP family and is neuroprotective against αsynuclein in vivo. Thus, this study hypothesized that other members of the BMP family
have the potential to protect these cells against -synuclein.
Methods: To identify the most relevant BMP ligands, unbiased gene co-expression
analysis was used to identify all BMP family members having a significant positive
correlation with five markers of dopaminergic neurons in the human SN. The ability of
lead BMPs to promote neurite growth was tested in SH-SY5Y cells and in primary VM
cultures of dopaminergic neurons, treated with either 6-OHDA or MPP+, or
overexpressing WT or A53T -synuclein.
Results: Only the expression of BMP2 was found to be significantly correlated with
multiple dopaminergic markers in the SN. BMP2 treatment promoted neurite growth in
SH-SY5Y cells and in dopaminergic neurons. Moreover, BMP2 treatment promoted
neurite growth in both SH-SY5Y cells and VM neurons, treated with the neurotoxins 6OHDA or MPP+. Furthermore, BMP2 promoted neurite growth in cells overexpressing
WT or A53T--synuclein. Finally, this study found that GDF5 upregulated the
expression of BMP2 in dopaminergic neurons both in vitro and in vivo.
Conclusion: These findings are important given that clinical trials of two neurotrophic
factors, GDNF and neurturin, have failed to meet their primary endpoints. These findings
are therefore a key first step in rationalising the further study of BMP2 as a potential NTF
in -synuclein-based translational models of PD.
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5.3 Introduction
The degeneration of midbrain dopaminergic neurons leading to the loss of striatal
innervation is central to the progression of PD (O'Keeffe and Sullivan, 2018). -synuclein
has been linked to PD since a number of mutations, such as the A30P (Kruger et al., 1998)
or A53T mutation in SNCA (Polymeropoulos et al., 1997), as well as triplications
(Singleton et al., 2003) or duplications (Chartier-Harlin et al., 2004) of SNCA, are
associated with autosomal dominant PD, while SNCA is also a susceptibility gene for
sporadic PD (International Parkinson Disease Genomics et al., 2011). In addition, synuclein is the main component of Lewy bodies and Lewy neurites, which are
pathological hallmarks of PD (Spillantini et al., 1997). Overexpression of α-synuclein in
individual cultured midbrain dopaminergic neurons has been shown to reduce neurite
growth (Koch et al., 2015). This is also supported by the reduced connectivity and spine
formation (Oliveira et al., 2015), and decreased neurite length and axonal degeneration
(Lin et al., 2016b), found in iPSC-derived neurons with SNCA triplication. Moreover
iPSC-derived dopaminergic neurons carrying the A53T mutation also develop neurite
degeneration (Kouroupi et al., 2017). These studies show that -synuclein can lead to
axonal and somal degeneration and highlight the need to identify factors that can promote
dopaminergic neurite growth in neurons carrying an -synuclein load.
BMPs are a group of 15 structurally-related proteins that are members of the TGF superfamily of ligands (Hegarty et al., 2014c). The BMPRs (BMPR2 with BMPR1A
or BMPR1B) are expressed in embryonic and adult rat dopaminergic neurons (Hegarty
et al., 2014a). Adult male BMPR2 dominant-negative mice display an almost complete
loss (~90%) of striatal innervation, with reduced locomotor activity (Chou et al., 2008a).
Previous studies have shown that BMP treatment increases dopaminergic neuron number
in midbrain cultures in vitro (Jordan et al., 1997, Reiriz et al., 1999). Additionally, BMP
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treatment, or overexpression of a constitutively-active BMPR1B, promotes neurite
growth in SH-SY5Y cells (Hegarty et al., 2013b), and in primary cultures of midbrain
dopaminergic neurons through the canonical Smad signalling pathway (Hegarty et al.,
2014a, Hegarty et al., 2013a, Hegarty et al., 2013b). Moreover, knockdown of a negative
regulator of BMP-Smad signalling during development promotes dopaminergic neurite
growth and leads to dopaminergic hyperinnervation of the striatum (Hegarty et al.,
2017c).
In chapter 3.0, a member of the BMP family known as GDF5 was shown to confer
protection to a model of dopaminergic neurons and primary VM cultures against MPP+
and 6-OHDA induced axon, soma and cell degeneration as well as WT α-synuclein
induced axon degeneration. Moreover, in chapter 4.0 delivery of AAV-GDF5 to the adult
rat SN was shown to exert neuroprotective effects in the AAV-Syn animal model of
PD. Additionally, mediators of the BMP-Smad signalling were found to be unaffected by
the overexpression of AAV-αSyn in vivo. Given these important findings, this study
sought to identify the expression profiles of individual BMPs in midbrain dopaminergic
neurons, and to test the neurotrophic ability of lead BMP ligands against cells
overexpressing -synuclein.

124

5.4 Results
5.4.1 Co-expression analysis of the human SN identifies an association
between BMPs/BMPRs and markers of dopaminergic neurons.
An unbiased co-expression analysis was conducted to identify all BMP genes that were
co-expressed with five markers of midbrain dopaminergic neurons in the human SN:
ALDH1A1, NR4A2/Nurr1, KCNJ6/Girk2, TH and LMX1B (Fig. 5.1A, B) (Ramasamy et
al., 2014). These analyses revealed significant positive correlations only for a specific
ligand and receptors of the BMP subfamily, namely BMP2, BMPR2, BMPR1A and
BMPR1B, from the lists of co-expressed genes (Fig. 5.1B-F). While all of the BMPRs
were positively correlated with four markers of Purkinje neurons in the human
cerebellum (PDE1A, CBLN1, PDE9A, CALB1), BMP2 was not (Fig. 5.1G). BMP2 was
also expressed at significantly higher levels in the SN than in the putamen or cerebellum
(Fig. 5.1H). Gene expression data from age- and gender-matched samples in GSE:49036
(Dijkstra et al., 2015) was also examined for BMP2 and BMPR expression in the SN of
patients at distinct stages of PD. These analyses showed a significant downregulation of
BMP2 in the SN of PD patients at Braak stage 5/6 compared to controls (Fig. 5.1I), while
no significant differences were observed for BMPR1B (data not shown) or BMPR2 (Fig.
5.1J). These data suggest that BMP2-BMPR signalling may play a functional role in
dopaminergic neurons in the human SN.

5.4.2 rhBMP2 promotes neurite growth in SH-SY5Y cells in a dosedependent manner and activates Smad signalling.
To establish the effects of rhBMP2 on individual neuronal cells, SH-SY5Y cells were
initially used. SH-SY5Y cells were treated with 0-200ng/ml concentrations of rhBMP2
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for 24 h (Fig. 5.2A) or 48 h (Fig. 5.2B, C). The total neurite length was used as a readout
of neurotrophic action and was measured at each time point. Statistical analysis revealed
that the effect of rhBMP2 on neurite growth is dose-dependent, with 50ng/ml rhBMP2
promoting the greatest increase in neurite growth at both 24 and 48h. To determine if
50ng/ml rhBMP2 could activate the Smad signalling pathway, a phospho-Smad ELISA
kit was used as before in chapter 3.0. Here, SH-SY5Y cells were treated with 50ng/ml
rhBMP2 for 2 h and processed for the ELISA. Statistical analysis demonstrated a
significant increase in phospho-Smad after treatment with 50ng/ml rhBMP2 for 2 h (Fig.
5.2D, E). These results are in agreement with previous findings that rhBMP2 activates
Smad-signalling and elicits neurotrophic effects on SH-SY5Y cells (Hegarty et al.,
2013b) and provides further knowledge of the most potent concentration of rhBMP2 for
neurite growth promotion.

5.4.3 MPP+ and 6-OHDA elicit concentration-dependent neurotoxic
effects on SH-SY5Y cells.
In order to test the ability of rhBMP2 against cellular models of PD, the next step was to
determine a concentration of the neurotoxins MPP+ and 6-OHDA that would elicit a
significant decrease in neurite length and cell viability in SH-SY5Y cells. Here, SHSY5Y cells were treated daily with increasing concentrations of MPP+ (0-1mM) or 6OHDA (0-15µM) for 72 h. The effect of both neurotoxins was analysed using neurite
length analysis and an MTT assay was used to measure cell viability, whereby a decrease
in absorbance is indicative of a reduction in cell viability. Increasing concentrations of
both MPP+ and 6-OHDA led to significant decreases in neurite length at all
concentrations tested for MPP+ (Fig. 5.3A, B) and at 10 and 15µM concentrations of 6OHDA (Fig. 5.3D, F). In addition, 1 and 1.5mM concentrations of MPP+ produced a
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substantial decrease in cell viability (Fig. 5.3C) while 10 and 15µM concentrations of 6OHDA also proved detrimental to cell viability (Fig. 5.3E). Given that 1mM MPP+ and
15µM 6-OHDA induced statistically significant decreases in both neurite length and cell
viability, these concentrations were used in further experiments.

5.4.4 rhBMP2 promotes neurite growth and survival, in 6-OHDA- and
MPP+-treated SH-SY5Y cells.
To determine if rhBMP2 treatment could promote neurite growth in cells treated with 6OHDA or MPP+, SH-SH5Y cells were treated with 50 ng/ml rhBMP2 and cultured with
or without 1mM MPP+ or 15µm 6-OHDA for 72 h. Here, rhBMP2 promoted neurite
growth while treatment with MPP+ or 6-OHDA led to a significant decrease in neurite
length compared to the untreated control (Fig. 5.4A, B). However, when cells treated with
6-OHDA or MPP+ were co-treated with rhBMP2, there was no significant difference in
neurite length compared to the untreated control indicating a protective effect of rhBMP2
(Fig. 5.4A, B). The viability of the cells was also analysed via MTT assay and showed
that MPP+ and 6-OHDA significantly decreased cell survival compared to the control
(Fig. 5.4C). However, when co-treated with rhBMP2, the groups were not significantly
different from the untreated control (Fig. 5.4C), despite the fact that a decrease was still
present. These data show that rhBMP2 can protect both against the degenerative effects
of MPP+ and 6-OHDA in SH-SY5Y cells.

5.4.5

rhBMP2

promotes

neurite

growth

in

SH-SY5Y

cells

overexpressing WT--synuclein or mutant A53T-α-synuclein.
Given that the majority of PD cases involve the cellular accumulation of -synuclein,
this study next sought to investigate whether rhBMP2 could promote neurite growth in
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cells overexpressing WT- or A53T--synuclein. To do this SH-SH5Y cells were
transfected with a control-GFP plasmid, or plasmids expressing GFP-tagged WT-synuclein or A53T--synuclein. Quantification of α-synuclein overexpression was
confirmed by western blotting and immunocytochemistry which revealed strong
expression of -synuclein in cells transfected with either WT- or A53T--synuclein-GFP
(Fig. 5.5A, B). Furthermore, quantification of GFP-positive neurites showed that both
WT- and A53T--synuclein overexpression induced significant decreases in neurite
length compared to the untreated GFP control, while rhBMP2 promoted neurite length
(Fig. 5.5C, D). In addition, rhBMP2 co-treatment was found to protect neurite growth
against the effects of both WT- and A53T--synuclein-overexpression in these cells (Fig.
5.5C, D). These data highlight that rhBMP2 exerts neurotrophic effects in neuronal cells
overexpressing -synuclein.

5.4.6 rhBMP2 protects cultured midbrain dopaminergic neurons
against 6-OHDA and MPP+.
Although SH-SY5Y cells are catecholaminergic, and are widely used in cellular models
of PD, they do not recapitulate all the features of dopaminergic neurons. For this reason,
the effects of rhBMP2 in primary cultures established from the E14 rat VM were
examined. Firstly, a dose response experiment was performed to confirm the best
concentration of MPP+ and 6-OHDA that would induce axon degeneration in primary
dopaminergic neurons in these cultures after 72 h in vitro. Here, it was determined that
all doses tested after had a detrimental effect on neurite growth after 72h. Therefore, in
keeping with chapter 3.0, 5µM MPP+ or 6-OHDA was used in subsequent experiments
(Fig. 5.6A, B). Here, 50ng/ml rhBMP2 treatment induced significant increases in
dopaminergic neurite growth, while MPP+ and 6-OHDA caused a significant reduction
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compared to the untreated control (Fig. 5.6C, D). However, co-treatment with rhBMP2
completely prevented the 6-OHDA or MPP+-induced degeneration (Fig. 5.6C, D). The
effect of MPP+ and 6-OHDA on somal area was then examined and a substantial
reduction in somal size was found, which was not seen in cultures co-treated with
rhBMP2 (Fig. 5.6E). After assessing cell viability, both neurotoxins were found to cause
a significant decrease in the number of TH+ neurons, which was partially rescued by
rhBMP2 (Fig 5.6F, H), while the total cell number was unaffected (Fig. 5.6G), indicating
a partial neuroprotective effect of rhBMP2. Collectively these data show that rhBMP2
promotes neurite growth and partially protect primary midbrain dopaminergic neurons
against 6-OHDA- and MPP+-induced degeneration.

5.4.7 rhBMP2 promotes neurite growth in WT--synuclein- and A53T-synuclein- overexpressing cultured midbrain dopaminergic neurons.
To investigate if rhBMP2 could also promote neurite growth in neurons overexpressing
WT- or mutant A53T--synuclein, E14 rat VM cultures were transfected with both WT-synuclein-GFP and A53T--synuclein-GFP overexpression plasmids, or with a
control-GFP plasmid. Immunocytochemistry (Fig. 5.7A) and subsequent quantification
of -synuclein staining (given the transfection efficiency was not sufficient for western
blotting) showed that E14 VM cultures transfected with either the WT--synuclein-GFP
or A53T--synuclein-GFP plasmid showed strong expression of -synuclein compared
to cells transfected with the control plasmid (Fig. 5.7B) . While the overexpression of
WT--synuclein-GFP or A53T--synuclein had no significant effect on somal area
compared to the control-GFP group (Fig. 5.7C), both WT--synuclein-GFP and A53T-synuclein-GFP resulted in a significant decrease in neurite length compared to controls
(Fig. 5.7D, E). In contrast, WT--synuclein-GFP or A53T--synuclein-GFP expressing
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cells that were also treated with rhBMP2 were not significantly different from the
controls. These data show that WT- or A53T--synuclein reduced neurite growth without
affecting somal area, and that rhBMP2 can promote neurite growth in cultured midbrain
dopaminergic neurons overexpressing WT- or A53T--synuclein.

5.4.8 GDF5 upregulates BMP2 in SH-SY5Y cells and in the adult rat
SN.
Chapter 3.0 highlighted the neuroprotective effects of GDF5 against cellular models of
PD and chapter 4.0 revealed GDF5 exerts neuroprotection in vivo against the AAV-αSyn
rat model of PD. However, given that BMP2 was the only member of the BMP family
found to be co-expressed with five key markers of dopaminergic neurons in the SN (Fig.
5.1) and given its neurotrophic effects against cellular models of PD (Fig. 5.3-5.7), the
hypothesise arose that the neurotrophic action of GDF5 may be partially mediated via the
increased expression of BMP2. To test this hypothesis, SH-SY5Y cells were cultured
with or without 50ng/ml rhGDF5 for 24 h. RNA was then prepared for RT-qPCR analysis
of BMP2 expression. RT-qPCR analysis showed that transcripts for BMP2 were
significantly upregulated after rhGDF5 treatment compared to the untreated control (Fig.
5.8A). To substantiate this finding, SN tissue from animals unilaterally injected with
either an AAV-Control or AAV-GDF5 vector for 20 weeks were immunofluorescently
stained for BMP2 and TH (Fig. 5.8B). The expression of BMP2 within TH+ neurons was
then quantified and expressed as a percentage of the contralateral intact side (Fig. 5.8C).
This analysis revealed a significant increase in BMP2 expression in AAV-GDF5 animals
compared to AAV-Control animals. These findings therefore add significant weight to
the potential contribution of BMP2 to the neurotrophic actions of GDF5 in vivo.
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5.5 Figures and Figure Legends

Fig. 5.1 BMP2-BMPRs are co-expressed with dopaminergic neuron markers in the
human SN. A, B Pearson correlation analysis showing the r values and false discovery
rate (FDR)-corrected p-values (in parentheses) from the SN (n=99). C-F Graphs showing
the correlation between BMPR2, BMPR1B, BMPR1A, BMP2 and ALDH1A1 expression
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in the SN. All data are 2log expression values. G Results of the Pearson correlation
analysis showing the r values and FDR-corrected p-values (in parentheses) of the
correlation of BMPR2, BMPR1B, BMPR1A and BMP2 with four Purkinje neuron
markers. H Box plot showing BMP2 expression in the human SN (n=99), putamen (n =
121) and cerebellum (n = 121) (*** p < 0.001 and ### p < 0.001 vs. SN). I, J 2log
expression values of I BMP2 and J BMPR2 in the SN of PD at distinct Braak stages of
PD, and in age-matched controls (*p < 0.05 vs. Control). H-J One-way ANOVA with
post-hoc Tukey’s test. Raw data was obtained from B-H GSE:60863 and I, J GSE:49036
and analysed using the R2: Genomics analysis and visualisation platform
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi).
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Fig. 5.2 rhBMP2 promotes neurite growth in SH-SY5Y cells in a dose-dependent
manner and activates Smad signalling. Graphs showing the neurite length of SH-SY5Y
cells treated with 0-200ng/ml rhBMP2 for A 24 h and B 48 h. C Representative
photomicrographs of SH-SY5Y cells treated with 0-200ng/ml rhBMP2 for 48 h. D
Quantification of phospho-Smad expression and E Representative photomicrographs of
SH-SY5Y cells treated with 50ng/ml rhBMP2 for 2 h and immunocytochemically stained
for phospho-Smad 1/5. Scale bar = 50µm. All data are presented as mean ± SEM from at
least three experiments. (* p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as indicated.
One-way ANOVA with Tukey’s post-hoc test (A, B) or Unpaired Student’s t-test (C)).
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Fig. 5.3 MPP+ and 6-OHDA elicit concentration-dependent neurotoxic effects on
SH-SY5Y cells. A Representative photomicrographs B Neurite length and C Cell
viability of SH-SY5Y cells following 72h daily treatment with increasing concentrations
of MPP+. D Neurite length E Cell viability and F Representative photomicrographs of
SH-SY5Y cells following 72h daily treatment with increasing concentrations of 6-
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OHDA. Scale bar = 50μm. All data are presented as mean ± SEM from at least three
experiments. (**p < 0.01, ***p < 0.001 vs. control or as indicated. One-way ANOVA
with Tukey’s post-hoc test).
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Fig. 5.4 rhBMP2 promotes neurite growth in MPP+-treated, 6-OHDA-treated SHSY5Y cells. Graph of A Neurite length, B Representative photomicrographs and C Cell
viability and of SH-SY5Y cells treated with 1mM MPP+ or 15μM 6-OHDA cultured with
or without 50ng/ml rhBMP2 for 72 h. Scale bar = 100μm. All data are presented as mean
± SEM from at least three experiments. (* p < 0.05, **p < 0.01, ***p < 0.001 vs. control
or as indicated. One-way ANOVA with Tukey’s post-hoc test).
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Fig. 5.5 rhBMP2 promotes neurite growth in WT and A53T -synucleinoverexpressing SH-SY5Y cells. A Representative images of SH-SY5Y cells transfected
with constructs expressing GFP (Control-GFP) or A53T-α-synuclein-GFP (αSynA53TGFP) immunocytochemically stained for α-synuclein protein at 24h, scale bar = 10μm;
quantification of this expression is shown in B. C Total neurite length and D
Representative images of transfected SH-SY5Y cells expressing either control-GFP or
αSynA53T-GFP and cultured with or without 50ng/ml rhBMP2 for 72h. Scale bar =
50μm. All data are presented as mean ± SEM from at least three experiments. (* p < 0.05,
**p < 0.01, ***p < 0.001 vs. control or as indicated. One-way ANOVA with Tukey’s (A,
B, C, G) or Dunnett’s (F) post hoc test).
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Fig. 5.6 rhBMP2 promotes neurite growth and partially protects against
dopaminergic neuron loss in MPP+-treated and 6-OHDA-treated primary cultures
of rat VM. Total neurite length of dopaminergic neurons in E14 VM cultures following
72h treatment with A 6-OHDA or B MPP+, at the concentrations indicated. C Total
neurite length and D Representative photomicrographs of dopaminergic neurons in E14
VM cultures treated with 50ng/ml rhBMP2 and cultured with or without 5µM MPP+ or
5μM 6-OHDA for 72 h. Scale bar = 50μm. E Somal area, F TH+ neurons as a percentage
of total cells and G number of cells per field of view, in primary cultures of the E14 rat
VM treated with 50ng/ml rhBMP2 and cultured with or without 5μM MPP+ or 5μM 6OHDA for 72h. H Representative photomicrographs of TH/DAPI-stained E14 VM
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cultures, treated as indicated. Scale bar = 50µm. All data are presented as mean ± SEM
from at least three experiments. (* p < 0.05, **p < 0.01, ***p < 0.001 vs. control or as
indicated. One-way ANOVA with Tukey’s post-hoc test).

Fig. 5.7 rhBMP2 promotes neurite growth in WT -synuclein- and A53T synuclein-overexpressing cells in primary cultures of E14 rat VM. A Representative
images of primary cultures of E14 rat VM transfected with constructs expressing GFP
(Control-GFP), -synucleinWT-GFP (-synWT-GFP) or -synuclein A53T-GFP (synA53T-GFP), then immunocytochemically stained for -synuclein at 72h. Scale bar =
10μm. Quantification of B -synuclein expression and C cell somal area in cultures
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transfected with Control-GFP, -synWT-GFP and -synA53T-GFP. D Representative
images (Scale bar = 50μm) and E quantification of total neurite length of E14 VM
cultures transfected with Control-GFP, -synWT-GFP and -synA53T-GFP and
cultured with or without 50ng/ml rhBMP2 for 72h. All data are presented as mean ± SEM
from at least three experiments. (*** p < 0.001 vs. control or as indicated. One-way
ANOVA with Tukey’s post-hoc test).
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Fig. 5.8 GDF5 upregulates the expression of Bmp2 transcripts in SH-SY5Y cells and
BMP2 protein expression in TH+ neurons of the adult rat SN. A Real time PCR data
showing expression of transcripts for Bmp2 in SH-SY5Y cells after 24h with and without
treatment of 50ng/ml rhGDF5. B Representative images of BMP2 expression in TH+
neurons in the adult rat SN of animals who received an AAV-Control or AAV-GDF5
vector and immunocytochemically stained for the expression of BMP2 (green) and TH
(red). Scale bar = 25µm. C Quantification of BMP2 expression in the SN of AAV-Control
or AAV-GDF5 animals, expressed as a percentage of the contralateral side. Data are
mean ± SEM from n=8 rats (*p < 0.05, **p<0.01; Student’s t-test).

141

5.6 Discussion
The BMP family exerts a broad range of biological functions depending on the tissue
type and cellular context (Nishimura et al., 2012, Wu et al., 2016, Hegarty et al., 2014a,
Jordan et al., 1997, Farkas et al., 1999, Yan et al., 2016). In recent years BMPs have
emerged as potent neurotrophic factors for midbrain dopaminergic neurons and can
promote dopaminergic neuronal survival, axonal growth and protect against neurotoxic
insult (Krieglstein et al., 1995, Jordan et al., 1997, Hegarty et al., 2014a, O'Keeffe et al.,
2017). The axon growth promoting effects of BMPs are particularly interesting given that
axonal degeneration is increasingly recognised as being central to early nigrostriatal
degeneration in PD (Burke and O'Malley, 2013, O'Keeffe and Sullivan, 2018, Dijkstra et
al., 2015), suggesting that BMPs may be useful in protecting the nigrostriatal pathway in
PD. In chapters 3.0 and 4.0, this thesis presented evidence of the potent neurotrophic
effects on midbrain dopaminergic neurons of a member of the BMP family, GDF5, in
cellular models of PD and in the α-synuclein rat model of PD. This promising discovery
is particularly important given the failure of GDNF to promote dopaminergic survival
using the same animal model (Decressac et al., 2011). In light of this novel finding, a
number of key questions arose; 1) which BMPs are functionally associated with midbrain
dopaminergic neurons in the adult SN, and 2) can these BMPs protect dopaminergic
neurons against neurotoxin-, and in particular, -synuclein-induced degeneration.
In the present study, only the expression of the BMP ligand, BMP2, and its
receptors, BMPR1A, BMPR1B and BMPR2, were shown to be positively correlated with
five key markers of dopaminergic function in the human SN, suggesting a functional
relationship between this BMP member and midbrain dopaminergic neurons. The study
also highlights that BMP2 is highly expressed in the SN compared to the putamen or
indeed the cerebellum, an area known to be particularly responsive to BMPs (Alder et al.,
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1999). In agreement with this, previous studies have shown the expression of transcripts
for BMP2, BMPR1B and BMPR2 receptors in the rat midbrain from E12, a period where
neurotrophic support is critical, prior to target innervation (Hegarty et al., 2014a).
Furthermore, BMP2 expression is identified to be significantly downregulated in the SN
in PD patients at Braak stage 5/6, while there are no significant changes in the expression
of its receptors. The findings of these studies suggested that endogenous BMP signalling,
perhaps mediated by BMP2, may promote midbrain dopaminergic neuronal survival
and/or maintain dopaminergic axonal integrity in the adult brain.
Using SH-SY5Y cells as an initial cellular model, the functional role of BMP2 was
examined and found that similar to rhGDF5, rhBMP2 exerts a concentration-dependent
effect on neurite growth, with 50ng/ml rhBMP2 exerting the greatest increase at both 24
and 48h time points. In support of this, rhBMP2 has previously been shown to enhance
axonal outgrowth in both SH-SY5Y cells and in dopaminergic neurons in primary E14
VM cultures (Reiriz et al., 1999, Jordan et al., 1997, Hegarty et al., 2014a, Hegarty et al.,
2013b, Nakamura et al., 2003). 50ng/ml rhBMP2 was also shown to initiate activation of
the canonical BMP-Smad signalling pathway in SH-SY5Y cells after 2hr, analysed
through the increased expression of phospho-Smad. This is in agreement with previous
studies showing that rhBMP2 is dependent on the canonical Smad signalling pathway to
elicit neurotrophic action (Boergermann et al., 2010, Yu et al., 2008).
Given that rhBMP2 promotes neurite length in SH-SY5Y cells, the effect of
rhBMP2 on cellular models of PD was examined next. A dose response of the wellestablished dopaminergic neurotoxins MPP+ and 6-OHDA was firstly carried out to
determine a concentration of either neurotoxin that would cause neurite as well as cell
degeneration. Here, 1mM MPP+ and 15µM 6-OHDA were found to cause significant
reductions in neurite length while also decreasing cell viability after 72h.
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However,

when either neurotoxin was co-treated with rhBMP2 for 72h, the degeneration of neurite
length and cell viability was no longer realised and instead were maintained at the same
level as an untreated control. To then establish the potential of rhBMP2 against αsynuclein, SH-SY5Y cells were transfected with either WT α-synuclein (αSynWT-GFP)
or mutant A53T-α-synuclein (αSynA53T-GFP). The overexpression of α-synuclein was
quantified by western blot and immunocytochemistry compared to a control-GFP
plasmid. In addition, the overexpression of WT- and A53T--synuclein-GFP in SHSY5Y cells caused a significant decrease in neurite length after 72h, consistent with
chapter 3.0 and previous findings (Koch et al., 2015, Oliveira et al., 2015), which was
not seen when the groups were co-treated with rhBMP2.
However, while SH-SY5Y cells are widely-used as an in vitro model of
dopaminergic neurons, they are ultimately catecholaminergic cells and thus do not
replicate all of the features of dopaminergic neurons. To address this, primary cultures of
E14 rat VM were used. A dose-response for MPP+ and 6-OHDA was initially carried out
and confirmed that 5µM MPP+ and 6-OHDA induced axonal degeneration in TH+
neurons, as in chapter 3.0. rhBMP2 treatment was found to promote neurite length of TH+
neurons, consistent with previous findings showing rhBMP2 can promote survival and
growth in rodent neurons (Jordan et al., 1997, Reiriz et al., 1999, Hegarty et al., 2014a).
In addition, rhBMP2 protected dopaminergic neurons against MPP+- and 6-OHDAinduced axonal degeneration. Furthermore, MPP+ caused a reduction to cell soma size,
and both MPP+ and 6-OHDA reduced numbers of TH+ neurons, both of which were
partially protected by rhBMP2. In support of these findings, rhBMP2-treatment has also
been shown to increase the survival of transplanted E14 VM dopaminergic neurons and
to decrease motor deficits, in 6-OHDA-lesioned rat models of PD (Espejo et al., 1999).
Collectively, these data show that rhBMP2 can protect dopaminergic neurons against
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neurotoxin-induced injury and thus may have significant potential as an NTF for use in
PD therapy.
While MPP+ and 6-OHDA are very useful neurotoxins for modelling PD, they do
not mimic the α-synuclein accumulation that is central to disease progression (Stefanis,
2012). Therefore, E14 VM cultures were transfected with WT- and A53T-α-synuclein
and found a decrease in neurite length, in agreement with a previous study using E14 rat
dopaminergic neurons (Koch et al., 2015). Here, rhBMP2 was found to promote neurite
growth against this α-synuclein-induced axonal degeneration. In addition, while both
WT- and A53T- α-synuclein had significant effects on neurite length, neither WT- or
A53T-α-synuclein had an effect on somal size, which is in agreement with chapter 3.0
and a previous study (Koch et al., 2015). This is significant as it is increasingly recognised
that the degenerative aetiology of PD may occur at both somal and axon levels (Burke
and O'Malley, 2013). Indeed, there have been several studies describing axonal
degeneration using iPSC-derived dopaminergic neurons isolated from patients with PD.
Specifically, iPSCs derived from PD patients with SNCA triplications displayed
decreased neuronal differentiation, activity and neurite outgrowth compared to control
iPSCs (Oliveira et al., 2015), as well as atypical neurite length and axonal fragmentation
(Lin et al., 2016b). Additionally, it has also been shown that PD patient iPSC-derived
dopaminergic neurons display phenotypic characteristics of PD, including Lewy-like
neurites comprised of pathological α-synuclein, protein aggregation, atypical neurite
outgrowth, and fragmented axons containing swollen varicosities of α-synuclein or Tau,
and have a reduced capability to form synapses (Kouroupi et al., 2017). These data agree
with previous in vivo studies showing that transgenic mice expressing human α-synuclein
develop synaptic dysfunction in striatal dopaminergic terminals and display an agedependent reduction in dopamine release (Garcia-Reitbock et al., 2010, Hunn et al.,
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2015). Therefore, given this mounting evidence in support of the role of α-synuclein in
axonal degeneration in PD, it is important to identify neurotrophic factors that can protect
against α-synuclein-induced axonal degeneration.
Chapter 3.0 and chapter 4.0 have given evidence to show that a member of the
BMP family, GDF5, has potent neurotrophic capabilities against in vitro models of PD
as well in vivo against the α-synuclein rat model of PD, in addition to previous findings
(Krieglstein et al., 1995, Sullivan et al., 1997, O'Keeffe et al., 2004a, Wood et al., 2005,
O'Sullivan et al., 2010, Costello et al., 2012). However, in this study only the expression
of BMP2 was found to be correlated with five key markers of dopaminergic neurons in
the SN. Interestingly, both GDF5 and BMP2 activate BMP-Smad signalling through
preferential binding to BMPR1B and BMPR2 receptors (Hegarty et al., 2014a), both of
which are also co-expressed with the five markers of dopaminergic neurons. Therefore,
this study sought to establish whether a link existed between GDF5, BMP2 and Smad
signalling. RT-PCR confirmed that rhGDF5 upregulated the expression of BMP2
transcripts in SH-SY5Y cells. In addition, animals who had received intranigral injection
of AAV-GDF5 had a significantly increased presence of BMP2 in TH+ neurons compared
to AAV-Control animals, further highlighting an important association exists between
GDF5 and BMP2. This finding is particularly interesting given the fact that AAV-GDF5
was neuroprotective against AAV-αSyn, suggesting that AAV-BMP2 may also offer
significant protection to dopaminergic neurons.
In summary, this study identified that BMP2 is co-expressed with midbrain
dopaminergic neuronal markers in the human SN and is downregulated in PD, and that
treatment with rhBMP2 can promote dopaminergic neurite growth and protect against
neurotoxin- and α-synuclein-induced degeneration in a model of dopaminergic neurons
and in primary cultures of dopaminergic neurons. In addition, GDF5, which was
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previously shown to be neuroprotective against the AAV-αSyn rat model of PD, was
shown to upregulate the expression of BMP2 in dopaminergic neurons and in the SN of
AAV-GDF5 treated animals. These findings are important given that clinical trials of two
dopaminergic NTFs, GDNF and neurturin, in PD patients have failed to meet their
primary endpoints (Hegarty et al., 2017a, Whone et al., 2019a, Whone et al., 2019b,
Warren Olanow et al., 2015). In light of this, the findings in our study are an important
first step in rationalising the further study of BMP2 as a potential neuroprotective therapy
using -synuclein-based translational models of PD.
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Chapter 6.0

Quinacrine and Niclosamide promote neurite growth in
midbrain dopaminergic neurons through the canonical BMPSmad pathway and protect against neurotoxin and synuclein-induced neurodegeneration.

6.1 Aims of Study
• Investigate the effect of Quinacrine and Niclosamide on SH-SY5Y cells and primary VM
cultures

• Identify the effect of Quinacrine and Niclosamide on the canonical Smad signalling
pathway

• Determine the effect of Quinacrine and Niclosamide against cellular models of PD in
primary VM cultures of dopaminergic neurons

• Evaluate the potential effect of Quinacrine and Niclosamide in primary dopaminergic
neurons transduced with AAV2/6-α-synuclein
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6.2 Abstract
Introduction: PD is a neurological disorder affecting over 10 million people worldwide.
Currently, the available treatment options are solely symptomatic and do not slow or stop
disease progression. This highlights the need to identify factors that are neuroprotective
or neuroregenerative against the progressive dopaminergic degeneration. This thesis
identified a member of the BMP family, known as BMP2, whose expression is
significantly correlated with that of several key markers of dopaminergic neurons in the
human SN and whose transcripts are downregulated in PD. In addition, chapter 5.0
showed that treatment with rhBMP2 is neuroprotective against dopaminergic
degeneration in in vitro models of Parkinson’s disease.
Methods: Using SH-SY5Y cells and primary E14 VM cultures, this study investigated
the neurotrophic profile of two FDA-approved drugs, Quinacrine and Niclosamide, that
have previously been shown to be modulators of BMP2 expression.
Results: Here, Quinacrine and Niclosamide were found to promote neurite length in both
SH-SY5Y cells and in primary cultures of dopaminergic neurons. In addition, the
neurotrophic action of Quinacrine and Niclosamide was shown to be mediated through
the activation of the canonical Smad signalling pathway. Finally, these two drugs were
demonstrated to be neuroprotective against in vitro models of Parkinson’s disease
including AAV-mediated delivery of α-synuclein.
Conclusion: Collectively this study identifies two drugs, that are safe for use in patients,
that can mimic the effects of endogenous BMP2 and activate BMP-Smad signalling. This
study therefore demonstrates the feasibility of using small molecule compounds to target
BMP-Smad signalling to protect dopaminergic neurons in patients with Parkinson’s
disease.
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6.3 Introduction
PD is a common bradykinetic disorder characterised by the progressive degeneration of
midbrain dopaminergic neurons, and the accumulation of intracellular aggregates of synuclein which are known as Lewy bodies and Lewy neurites (Lees et al., 2009). In
recent years there has been considerable interest in developing NTF therapy for PD. This
involves the delivery of NTF genes, or the recombinant proteins to the brain to protect
midbrain dopaminergic neurons from degeneration (Kelly et al., 2015). Despite initial
success in animal’s models and in open label trials (Choi-Lundberg et al., 1997,
Kordower et al., 2000, Kordower et al., 2006, Ramaswamy et al., 2007, Su et al., 2009,
Gill et al., 2003, John T. Slevin et al., 2005), randomised controlled trials of GDNF and
a related factor Neurturin failed to meet their primary end points (Lang et al., 2006, Patel
et al., 2005, Olanow et al., 2003, Warren Olanow et al., 2015, Whone et al., 2019a, Whone
et al., 2019b). As such there has been increasing interest in identifying other NTFs that
are capable of protecting dopaminergic neurons from degeneration. However, the
challenge surrounding NTFs is that they require direct administration to the brain as they
are rapidly metabolised in vivo and are unable to cross the blood brain barrier in adequate
doses (O'Keeffe et al., 2017). One strategy to overcome this problem may be to identify
small molecule drugs or biologics that are capable of crossing the blood brain barrier and
selectively activating the downstream targets of specific neurotrophic factors.
BMPs are a group of neurotrophic factors that like GDNF, are also members of the
TGF- superfamily (for review see O'Keeffe et al., 2017). Additionally, gene coexpression analysis of the human SN in chapter 5.0 identified that BMPRs and the BMP2
ligand display a co-expression pattern with multiple markers of dopaminergic neurons in
the human SN, suggesting a functional role for BMPs in this neuronal population.
Moreover, rhBMP2 promoted neurite growth in SH-SY5Y cells and dopaminergic

150

neurons after treatment with the neurotoxins 6-OHDA and MPP+, or in those
overexpressing -synuclein. In addition, AAV-mediated delivery of the BMP ligand
GDF5 was neuroprotective against α-synuclein overexpression in vivo and was shown to
upregulate the expression of BMP2 in the SN in Chapter 4.0. These data suggest that
clinically-approved drugs that modulate BMP2 expression or the BMP2 signalling
pathway, may be a novel class of compounds for protecting dopaminergic neurons.
In a recent study, Ghebes et al carried out a screen of 1280 commercially available
FDA-approved compounds in primary human tendon–derived cells to identify those
capable of modulating the BMP2 signalling pathway, which is essential for tendon and
ligament repair (Ghebes et al., 2017).

This analysis identified two drugs called

Niclosamide and Quinacrine that modulated the BMP2 pathway using a BMP2 reporter
cell line (Ghebes et al., 2017). Niclosamide is an anthelmintic agent that has been used
clinically to treat tape worm infections (Chen et al., 2018), while Quinacrine has a long
history of clinical use in the treatment of malaria (Ehsanian et al., 2011). Given that
Niclosamide and Quinacrine were found to modulate BMP2 signalling in primary tendon
cells (Ghebes et al., 2017), and since rhBMP2 protects dopaminergic neurons in primary
cultures of the rat VM from neurotoxin- and -synuclein-induced degeneration, this study
hypothesised that Niclosamide and Quinacrine may have neurotrophic and
neuroprotective effects on dopaminergic neurons in in vitro models of PD.
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6.4 Results
6.4.1 SH-SY5Y cells as a tool to study drugs affecting BMP-Smad
signalling.
This study initially used SH-SY5Y cells as they are a widely used model of dopaminergic
neurons and are a useful drug screening tool of relevance to PD (Xie et al., 2010, Xicoy
et al., 2017). These cells express high levels of BMPR1B (Fig. 6.1A), BMPR2 (Fig. 6.1B)
and Smad1/5/8 (Fig. 6.1C). These cells respond to a BMP stimulus evidenced by the fact
that treatment with rhBMP2 led to a significant increase in phospho-Smad1/5 activation
(Fig. 6.1D, E) and an increase in neurite growth which was used as a readout of
neurotrophic action at an individual cell level (Fig. 6.1F, G). Moreover, a functional link
between an increase in pSmad1/5 levels and neurite growth was demonstrated by the fact
that pre-treatment with dorsomorphin, a small molecule inhibitor of type-1 BMPRs (Yu
et al., 2008), prevented the effects of rhBMP2 on pSmad1/5 and on neurite growth (Fig.
6.1F, G). Collectively these data show that SH-SY5Y cells are a suitable tool to study the
potential effects of Quinacrine and Niclosamide on the BMP-Smad pathway and on
neurite growth.

6.4.2 Quinacrine and Niclosamide promote neurite growth in SH-SY5Y
cells.
Given that rhBMP2 is known to promote axon length in a number of neuronal cell types,
including dopaminergic neurons (Jordan et al., 1997, Reiriz et al., 1999, Hegarty et al.,
2013b), and that Quinacrine and Niclosamide have been shown to upregulate BMP2
expression in tendon tissue (Ghebes et al., 2017), the ability of both compounds to
promote neurite growth as a readout of neurotrophic action in SH-SY5Y cells was next
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tested. To do this, a dose-response experiment was performed in which SH-SY5Y cells
were treated daily with 0-10nM concentrations of either Quinacrine or Niclosamide or
with 50ng/ml rhBMP2 as a positive control for 72 h. Comparable results were found for
both compounds whereby a concentration of 1 or 10nM Niclosamide (Fig. 6.2A, C) or
Quinacrine (Fig. 6.2D, F) significantly increased neurite length relative to untreated
controls and to a similar extent to that of rhBMP2. Cell viability was also examined, and
it was found that there were no significant differences in cell viability in those groups
treated with up to 10nM Niclosamide (Fig. 6.2B, C) or Quinacrine (Fig. 6.2E, F) relative
to the untreated controls. Collectively these data show that Quinacrine and Niclosamide
promote neurite growth and do not induce any adverse effects on cell viability in SHSY5Y cells, which rationalised their further study in primary dopaminergic neurons.

6.4.3 Neurotrophic effects of Quinacrine and Niclosamide on primary
midbrain dopaminergic neurons.
Although SH-SY5Y cells are a useful screening tool, they do not recapitulate all features
of dopaminergic neurons. Therefore, a dose-response experiment was performed in
which increasing concentrations (0-10nM) of Quinacrine and Niclosamide were applied
to primary cultures of the E14 rat VM for 72h. In this experiment, concentrations of 0.110nM Quinacrine (Fig. 6.3A, C) or Niclosamide (Fig. 6.3D, F) induced a significant
increase in dopaminergic neurite growth relative to untreated controls, and at a
comparable level to neurite growth induced by rhBMP2. Given that a 10nM concentration
of Niclosamide or Quinacrine exerted the maximal increase in neurite length, TH+ cell
survival was also examined using this concentration and found that both compounds did
not negatively affect the cell viability of dopaminergic neurons (Fig. 6.3B, C, E, F).
Collectively, these data show that Quinacrine and Niclosamide are well tolerated by
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dopaminergic neurons and are capable of eliciting phenotypic changes that are similar to
those induced by the NTF rhBMP2. These data suggests that the effects of Quinacrine
and Niclosamide may be mediated through the canonical BMP-Smad signalling pathway.

6.4.4 Quinacrine and Niclosamide activate BMP-Smad-dependent
transcription in SH-SY5Y cells.
Given the finding that Quinacrine and Niclosamide activated the BMP2 pathway in
tendon cells (Ghebes et al., 2017), this suggested that Quinacrine or Niclosamide may
activate the canonical BMP-Smad signalling to promote neurite growth in dopaminergic
neurons. To investigate this possibility, a reporter assay in which a BMP responsive
element (BRE) drives the expression of GFP was used in which an increase in
intracellular GFP expression indicates increased BMP-Smad-dependent transcription
(Fig. 6.4A), as described in previous studies (Hegarty et al., 2017c, Hegarty et al., 2014a).
To do this SH-SY5Y cells were transiently transfected with 250ng of the BRE-GFP
reporter plasmid. At 24h post-transfection, 10nM of Niclosamide or Quinacrine, or
50ng/ml rhBMP2 (as a positive control) was added to the culture medium. Here, the
addition of 10nM Quinacrine or Niclosamide significantly increased the expression of
GFP, compared to untreated controls and was comparable to the increase induced by
rhBMP2 after 24 h (Fig. 6.4B, C). These data show that Quinacrine and Niclosamide
stimulate a Smad-dependent transcriptional response in SH-SY5Y cells.
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6.4.5 Quinacrine and Niclosamide increase phospho-Smad levels which
are required for their neurite growth promoting effects in cultured
dopaminergic neurons.
Given that Quinacrine and Niclosamide activate BMP-Smad dependent transcription in
SH-SY5Y cells (Fig. 6.4), the functional relevance of this was examined in primary
dopaminergic neurons. The same reporter assay could not be performed as the
transfection efficiency of primary cultures is very low, which is compounded by them
being mixed cultures, therefore a modified approach was used. As phospho-Smad levels
are indicative of BMP-Smad pathway activation, dopaminergic neurons were
immunocytochemically stained for TH and pSmad-1/5/8 which allowed us to analyse
phospho-Smad levels in dopaminergic neurons. In this experiment, treatment of E14 VM
cultures with 10nM Quinacrine or 10nM Niclosamide for 24h led to significant increases
in pSmad-1/5/8 levels in TH+ neurons, which was completely prevented by pre-treatment
with the BMPR inhibitor, dorsomorphin (Fig. 6.5A, D). Similarly, Quinacrine- and
Niclosamide-induced increases in neurite growth were prevented by pre-treatment with
dorsomorphin (Fig. 6.5B, C). Collectively these data show that both Quinacrine and
Niclosamide mediate their phenotypic effects on dopaminergic neurons via the BMPSmad signalling pathway. As BMPs have been shown to have neuroprotective effects on
dopaminergic neurons (Jordan et al., 1997, Reiriz et al., 1999, Krieglstein et al., 1995,
Hegarty et al., 2013b), this suggested that Quinacrine and Niclosamide may protect
against dopaminergic degeneration.
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6.4.6 Quinacrine and Niclosamide protect dopaminergic neurons from
MPP+ and 6-OHDA-induced degeneration
In chapter 5.0, rhBMP2 was shown to protect dopaminergic neurons from
neurodegeneration induced by the dopaminergic neurotoxins, MPP+ and 6-OHDA.
Therefore, we next tested whether Quinacrine and Niclosamide could also protect
dopaminergic neurons against 6-OHDA- and MPP+-induced degeneration. To do this,
primary cultures of E14 rat VM were treated with 10nM of Quinacrine or Niclosamide
and cultured with or without 5µM 6-OHDA or MPP+, for 72 h. For Niclosamide, a twoway repeated measures ANOVA revealed a significant effect of both neurotoxins (F(1,
3) = 169.9, p = 0.0010) on neurite length, but no effect of Niclosamide (F(1.234, 3.701)
= 4.449, p = 0.1072) and no interaction between Niclosamide and the neurotoxins
(F(1.326, 3.978) = 0.5978, p = 0.5291). Furthermore, post-hoc testing using an
uncorrected Fisher’s LSD test revealed a significant reduction in neurite length of MPP+
(p = 0.0095) and 6-OHDA (p = 0.0018) versus the control (Fig. 6.6A, B). While no
significant difference was found for MPP+ (p = 0.5321) and 6-OHDA (p = 0.1662)
cultures co-treated with Niclosamide. For Quinacrine, a two-way repeated measures
ANOVA revealed a significant interaction between Quinacrine x Neurotoxins (F(1.44,
4.32) = 10.52, p = 0.0247) and both neurotoxins (F(1, 3) = 161.6, p = 0.0011) on neurite
length, but no effect of Quinacrine alone (F(1.049, 3.146) = 2.081, p = 0.2429).
Furthermore, post-hoc testing using an uncorrected Fisher’s LSD test revealed a
significant reduction in neurite length of MPP+ (p = 0.0008) and 6-OHDA (p = 0.0273)
versus the control (Fig. 6.6C, E). While no significant difference was found for MPP+ (p
= 0.7516) and 6-OHDA (p = 0.7713) cultures co-treated with Quinacrine.
We next sought to determine whether Quinacrine and Niclosamide can protect TH+
neuron number against the neurotoxins MPP+ or 6-OHDA. Here, a two-way repeated
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measures ANOVA revealed a significant effect of the neurotoxins (F(1, 2.001) = 23.03,
p = 0.0408) and the drug compounds (F(1.183, 2.366) = 21.16, p = 0.0316) on TH+ neuron
number, however there was no significant interaction between the drug compounds and
the neurotoxins on TH+ cell number (F(1.293, 2.585) = 1.22, p = 0.3863). In addition,
post-hoc testing using an uncorrected Fisher’s LSD test revealed a significant reduction
in neurite length of MPP+ (p = 0.0097) and 6-OHDA (p = 0.0263) versus the control (Fig.
6.6D). While no significant difference was found for MPP+ (p = 0.1210) and 6-OHDA (p
= 0.0.964) cultures co-treated with Niclosamide and no significant difference was found
for MPP+ (p = 0.1167) and 6-OHDA (p = 0.3655) cultures co-treated with Quinacrine.
Collectively, these data show that Quinacrine and Niclosamide can protect dopaminergic
neurons against neurotoxin-induced degeneration.

6.4.7 AAV-mediated delivery of α-synuclein to primary dopaminergic
neurons induces axon degeneration in an MOI-dependent manner.
The next goal was to develop an in vitro model of α-synucleinopathy in primary
dopaminergic neurons in order to test the hypothesis that Quinacrine and Niclosamide
could protect against α-synuclein-induced neurodegeneration. In order to determine the
effect of AAV-mediated delivery of α-synuclein in vitro, primary cultures of the E14 rat
VM were transduced with increasing MOIs of an AAV vector carrying the human αsynuclein transgene (AAV-αSyn) for 5 DIV (Fig. 6.7). Cultures were then
immunocytochemically stained for α-synuclein and TH which demonstrated that αsynuclein was expressed in TH+ cells at each MOI tested (Fig. 6.7A). To assess the effect
of AAV-αSyn on neurite length, E14 VM cultures were transduced with either an AAVGFP vector or AAV-αSyn at increasing MOIs for 5 DIV. Quantification of TH+ cells
expressing α-synuclein revealed that the effect of AAV-αSyn-induced axon degeneration
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was MOI-dependent. (Fig. 6.7B, C). In this experiment, transduction with AAV-αSyn led
to a significant decrease in neurite length only at an MOI of 2.0×105 when compared to
AAV-GFP transduced TH+ cells. This experiment therefore showed that AAV-mediated
delivery of α-synuclein successfully transduces TH+ neurons and induced axondegeneration in these dopaminergic neurons.

6.4.8 Quinacrine and Niclosamide protect dopaminergic neurons from
AAV-α-synuclein-induced axon degeneration.
In chapter 5.0 it was shown that rhBMP2 was protective against axon-degeneration
induced by the overexpression of both WT and mutant A53T α-synuclein plasmids in
E14 VM cultures. To assess whether Quinacrine and Niclosamide could also protect
against α-synuclein-induced degeneration, E14 VM cultures were transduced with AAVGFP or AAV2-αSyn at an MOI of 2.0×105. To assess whether treatment with Quinacrine
or Niclosamide could protect dopaminergic cells from α-synuclein-induced degeneration,
Quinacrine or Niclosamide were administered using two different treatment paradigms
in this model. In the first experiment, primary cultures of the E14 rat VM were transduced
with either AAV-GFP or AAV-αSyn vectors and treated daily thereafter for 10 DIV in a
concurrent treatment paradigm. A two-way ANOVA revealed a significant α-synuclein
x drug interaction on the numbers of TH+ dopaminergic neurons in these cultures (F(2, 10)
= 5.388, p = 0.0258). Post-hoc testing showed that α-synuclein resulted in a significant
reduction in dopaminergic neuron number (p = 0.0015), that was not seen in cultures
treated with Quinacrine (p = 0.4409) or Niclosamide (p = 0.4409) (Fig. 6.8A).
Dopaminergic neurite length was also examined, and showed a significant effect of αsynuclein (F(1, 4) = 9.656, p = 0.0360) and drug treatment (F(2, 8) = 21.37, p = 0.0006), with
no significant interaction (F(2, 8) = 1.861, p = 0.2170). Post-hoc testing showed that α-
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synuclein resulted in a significant reduction in dopaminergic neurite length (p = 0.0315),
that was not seen in cultures treated with Quinacrine (p = 0.4922) or Niclosamide (p =
0.4922) (Fig. 6.8B). These data show that concurrent treatment with Quinacrine or
Niclosamide prevents α-synuclein-induced reductions in dopaminergic neuron number
and neurite length.
Experiment 2 involved a delayed drug treatment paradigm. Primary cultures of the
E14 rat VM were transduced with the AAV-GFP or AAV-αSyn vectors and left for 5
days. The cultures were then treated with Quinacrine or Niclosamide on day 5 and daily
thereafter for an additional 5DIV (10 days total). A two-way ANOVA showed a
significant α-synuclein x drug interaction on the numbers of TH+ dopaminergic neurons
in these cultures (F(2, 10) = 6.420, p = 0.0161). Post-hoc testing revealed that α-synuclein
resulted in a significant reduction in dopaminergic neuron number (p = 0.0016), that was
not seen in cultures treated with Quinacrine (p = 0.5259) or Niclosamide (p = 0.7871)
(Fig. 6.8C). An examination of dopaminergic neurite length revealed a significant effect
of α-synuclein (F(1, 4) = 13.83, p = 0.0205) and drug treatment (F(2, 8) = 43.65, p < 0.0001)
with no significant interaction (F(2, 8) = 4.103, p = 0.0594) (Fig. 4D, E). Post-hoc testing
showed that α-synuclein resulted in a significant reduction in dopaminergic neurite length
(p = 0.0040), that was not seen in cultures treated with Quinacrine (p = 0.1278) or
Niclosamide (p = 0.4256). These data show that Quinacrine or Niclosamide, when given
to neurons with an established α-synuclein load, can prevent α-synuclein-induced
reductions in dopaminergic neuron number and neurite length.
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6.5 Figures and Figure Legends

Fig. 6.1 SH-SY5Y cells as a tool to study drugs affecting BMP-Smad signalling.
Representative photomicrographs showing immunocytochemical staining for A
BMPR1B, B BMPR2 and C Smad1/5/8 expression in SH-SY5Y cells. D Representative
photomicrographs of immunocytochemical staining of phospho-Smad and E Intensity of
phospho-Smad as measured using ELISA in SH-SY5Y cells after treatment with 50ng/ml
rhBMP2 with and without 1µg/ml dorsomorphin for 2 h. F Total neurite length and G
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Representative photomicrographs of SH-SY5Y cells after treatment with 1µg/ml
dorsomorphin with and without 50ng/ml rhBMP2 for 24 h. Scale bar = 25µm. All data
are presented as mean ± SEM from at least three experiments. (* p < 0.05, ** p < 0.01,
***p < 0.001 vs. control; +++ p < 0.001 vs rhBMP2. One-way ANOVA with Tukey’s
post-hoc test).

Fig. 6.2 Niclosamide and Quinacrine promote neurite growth in SH-SY5Y cells. A
Total neurite length B Total cell number and C Representative photomicrographs of SHSY5Y cells following treatment with Niclosamide at the concentrations indicated for 72h.
D Total neurite length E Total cell number and F Representative photomicrographs of
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SH-SY5Y cells following treatment with Quinacrine at the concentrations indicated for
72h. Scale bar = 50 µm. All data are presented as mean ± SEM from at least three
experiments. (*p < 0.05, ** p < 0.01, *** p < 0.001 vs. control. One-way ANOVA with
Tukey's post-hoc test).

Fig. 6.3 Neurotrophic effects of Quinacrine and Niclosamide on primary midbrain
dopaminergic neurons. A Total neurite length B TH+ neurons expressed as a percentage
of the control and C Representative photomicrographs of E14 VM TH+ neurons following
treatment of Niclosamide at the concentrations indicated for 72h. D Total neurite length,
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E TH+ neurons expressed as a percentage of the control and F Representative
photomicrographs of E14 VM TH+ neurons following treatment of Quinacrine at the
concentrations indicated for 72h. Scale bar = 50 µM. All data are presented as mean ±
SEM from at least three experiments. (*p < 0.05, **p < 0.01, ***p < 0.001 vs. control.
One-way ANOVA with Tukey's post-hoc test).

Fig. 6.4 Niclosamide and Quinacrine activate BMP-Smad dependent transcription
in SH-SY5Y cells. A Schema showing BRE-GFP reporter system. B BRE-driven GFP
expression expressed as a percentage of untreated control cells and C Representative
photomicrographs of SH-SY5Y cells following 24h treatment of 10nM Niclosamide or
Quinacrine or 50ng/ml rhBMP2. Scale bar = 10 µM. All data are presented as mean ±
SEM from three experiments. (*p < 0.05, ***p < 0.001 vs. control or as indicated. Oneway ANOVA with Tukey's post-hoc test).
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Fig. 6.5 Quinacrine and Niclosamide increase phospho-Smad levels which are
required for their neurite growth promoting effects in cultured dopaminergic
neurons. A Phospho-Smad activation and B Total neurite length of TH+ neurons in E14
VM cultures following 24h treatment of 10nM Niclosamide or Quinacrine with or
without 1µg/ml dorsomorphin. C, D Representative photomicrographs of E14 VM cells,
immunocytochemically stained for C TH and D pSmad1/5/8, following 24h treatment of
10nM Niclosamide or Quinacrine with or without 1µg/ml dorsomorphin. Scale bar = 50
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µM. All data are presented as mean ± SEM from at least three experiments. (*** p <
0.001 vs. control; # p < 0.05, ### p < 0.001 vs Quinacrine; $$ p < 0.01 vs Niclosamide.
One-way ANOVA with Tukey's post-hoc test).

Fig. 6.6 Quinacrine and Niclosamide protect dopaminergic neurons from MPP+ and
6-OHDA-induced degeneration. A Representative photomicrographs and B Total
neurite length of E14 VM cultures after 72 h treatment with 10nM Niclosamide with or
without 5µM MPP+ or 6-OHDA. C Total neurite length and E Representative
photomicrographs of E14 VM cultures after 72 h treatment with 10nM Quinacrine with
or without 5µM MPP+ or 6-OHDA. D Numbers of TH+ neurons as a percentage of the
control in E14 VM cultures after 72 h treatment with 10nM Quinacrine or Niclosamide
with or without 5µM MPP+ or 6-OHDA. Scale bar = 50 µM. All data are presented as
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mean ± SEM from at least three experiments. (* p < 0.05, ** p < 0.01, *** p < 0.001 vs.
control; Two-way repeated measures ANOVA with Uncorrected Fisher’s LSD post-hoc
test).

Fig. 6.7. AAV-mediated delivery of α-synuclein to primary dopaminergic neurons
induces axon degeneration in an MOI-dependent manner. A Representative
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photomicrographs of E14 VM cultures after transduction with AAV2/6-GFP or AAV2/6α-synuclein and immunocytochemically stained for TH and α-synuclein, counterstained
with DAPI. B Graph of and C Representative photomicrographs of TH+ neurons
transduced with AAV2/6-GFP or AAV2/6-α-synuclein at the MOI’s indicated for 5 DIV.
Scale bar = 50µm. All data are presented as mean ± SEM. (** p < 0.01 vs. AAV-GFP.
Student’s t-test).

Fig. 6.8 Quinacrine and Niclosamide protect midbrain dopaminergic neurons
against α-synuclein-induced axon degeneration. A DA neuron number and B DA
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neurite length of E14 TH+ neurons transduced with AAV-GFP or AAV-α-synuclein and
cultured with or without 10nM Quinacrine or Niclosamide daily for 10 DIV. C DA
neuron number and D DA neurite length and E Representative photomicrographs of E14
TH+ neurons infected with AAV-GFP or AAV-α-synuclein and cultured with or without
10nM Quinacrine or Niclosamide after 5 DIV daily up to 10 DIV. Scale bar = 50µm. All
data are presented as mean ± SEM from at least three experiments. (* p < 0.05, ** p <
0.01 vs. control; Two-way ANOVA with Holm-Sidak’s post hoc test).

6.6 Discussion
NTF therapy has attracted significant interest as a potential disease-modifying approach
for the treatment of PD. However, the application of neurotrophic factors in a clinical
setting currently requires direct administration to the brain via invasive surgery and has
had limited success to date (Nutt et al., 2003, Patel et al., 2005, Whone et al., 2019a,
Whone et al., 2019b). BMP2 has been shown to have potent neurotrophic effects on
dopaminergic neurons (Jordan et al., 1997, Krieglstein et al., 1995, Hegarty et al., 2013b).
Similar to other members of the BMP family, BMP2 exerts its effects via the canonical
Smad signalling pathway (Hegarty et al., 2014a, Weiss and Attisano, 2013). Therefore,
the identification of small molecule compounds, capable of crossing the blood brain
barrier, that could modulate the expression of BMP2 and/or BMP-Smad signalling in
dopaminergic neurons has potential therapeutic relevance for PD. The clinical application
of such agents through non-surgical routes would be hugely advantageous from a safety
perspective and allow wider application to patients. The FDA approved small molecule
drugs, Quinacrine and Niclosamide, have been shown to upregulate BMP2 expression in
a dose-dependent manner in a BMP2 reporter cell line and in human tendon-derived
tissue (Ghebes et al., 2017). Given the substantial evidence in chapter 5.0 in support of
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BMP2 as an NTF for dopaminergic neurons, this study investigated the effect of
Quinacrine and Niclosamide on dopaminergic neurons using SH-SY5Y cells and cultures
of the E14 rat VM.
Firstly, SH-SY5Y cells were verified as an appropriate tool to screen drug
compounds for neurotrophic ability and for activation of the canonical Smad signalling
pathway. SH-SY5Y cells were shown to express high levels of BMP2’s receptors,
BMPR1B and BMPR2, as well as Smad-1, -5 and -8, the effector molecules involved in
initiating Smad signalling (Wrana and Attisano, 2000). In addition, SH-SY5Y cells
treated with rhBMP2 resulted in the activation of the Smad pathway, as shown by
increased phospho-Smad activation, as well as increased neurite length, and both of these
effects were supressed by co-treatment with dorsomorphin. This finding is supported by
several studies showing that rhBMP2 preferentially binds to BMPRI receptors (Weber et
al., 2007, Mueller and Nickel, 2012, Wang et al., 2014) to activate canonical Smad
signalling in C2C12 cells (Heinecke et al., 2009), SH-SY5Y cells (Hegarty et al., 2013b,
Hegarty et al., 2017b) and primary VM dopaminergic neurons (Hegarty et al., 2014a). In
this study, both Quinacrine and Niclosamide were also found to promote neurite growth
in SH-SY5Y cells and in cultured dopaminergic neurons, to the same extent as rhBMP2.
Neither of these two compounds affected cell viability, rationalising their safe application
to dopaminergic neurons. In contrast to this finding, exposure to 5µM Quinacrine induced
the cell death of human tendon cells after 7 DIV (Ghebes et al., 2017), however the
concentration of Quinacrine used on dopaminergic neurons in this study was significantly
lower at 10nM. In addition, Quinacrine and Niclosamide were also found to activate the
Smad signalling pathway, as evidenced by upregulated Smad dependent transcription in
SH-SY5Y cells, and increased phospho-Smad levels in cultured dopaminergic neurons.
This effect on Smad signalling was not seen in human tendon cells (Ghebes et al., 2017),
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however in that study the cells were exposed to Quinacrine an Niclosamide for 2h in
contrast to the 24h timepoint used in this study. Moreover, the effects of both Quinacrine
and Niclosamide on neurite length and on phospho-Smad levels were blocked by
dorsomorphin, showing that they were mediated through activation of the canonical
Smad signalling pathway. This is consistent with findings showing BMP neurotrophic
effects were prevented by the use dorsomorphin which demonstrated their dependence
on the canonical Smad signalling pathway to elicit neurotrophic action. (Hegarty et al.,
2014a, Hegarty et al., 2013b)
Chapter 5.0 showed that rhBMP2 promotes TH+ cell survival and neurite length
against the selective dopaminergic neurotoxins MPP+ and 6-OHDA in cultures of the E14
VM. In this study Quinacrine and Niclosamide also demonstrated significant
neuroprotection against MPP+- and 6-OHDA-induced neurite degeneration and cell
death. In support of this finding, Quinacrine has previously been shown to protect striatal
dopamine

levels

in

vivo

against

6-OHDA

and

1-methyl-4-phenyl-1,2,3,6-

tetrahydropyridine (MPTP) striatal lesioning in Wistar rats and C57BL mice, respectively
(Tariq et al., 2001). In the MPTP study, adult male mice were administered four different
doses of Quinacrine via intraperitoneal (i.p.) injection 30 min prior to the administration
of 30mg/kg MPTP daily for 5 days. Mice were sacrificed on day 5 and striata were
collected for HPLC analyses. For the 6-OHDA study, Wister rats were administered four
different doses of Quinacrine via i.p. injection 30 min prior to a unilaterally 6-OHDA
lesion to the right striatum and were treated daily thereafter for 4 days. On day 5 animals
were sacrificed and striata were collected for HPLC analyses. In both studies, they found
MPTP and 6-OHDA significantly reduced striatal dopamine and glutathione (GSH),
which was attenuated by co-treatment with Quinacrine in a dose-dependent fashion. In
addition, Niclosamide fully prevented the degeneration induced by MPP+ and 6-OHDA
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on neurite length, and was protective against the effect of MPP+, but not 6-OHDA, on
TH+ cell survival. These findings demonstrate that Quinacrine and Niclosamide can
protect midbrain dopaminergic neurons against neurotoxin-induced dopaminergic
degeneration, which is the clinical hallmark of PD.
Chapter 5.0 also showed that rhBMP2 is protective against axon-degeneration
induced by the overexpression of both WT and mutant A53T α-synuclein plasmids in
E14 VM cultures. Therefore, in this experiment E14 VM cultures were transduced with
an AAV2/6-α-synuclein vector at an MOI that induced axon degeneration in
dopaminergic neurons. The approach to this study was two-fold; could Quinacrine and
Niclosamide protect nerve terminals from α-synuclein, and if so, could these compounds
restore dopaminergic nerve terminals after degeneration had already occurred. Treatment
with Quinacrine or Niclosamide at the time of AAV2/6-α-synuclein infection
significantly protected TH+ neurons against α-synuclein-induced axon degeneration.
Moreover, treatment with Quinacrine or Niclosamide 5 days after the AAV2/6-αsynuclein infection, when degeneration had already occurred, significantly rescued TH+
neurons against α-synuclein-induced degeneration. These findings are particularly
noteworthy as axon degeneration is thought to be a central early pathological event that
precedes symptom onset and initiates nigrostriatal neuron loss in PD (Kordower et al.,
2013, O'Keeffe and Sullivan, 2018). Thus, the advent of new therapeutics that can
substantially restore dopaminergic nerve terminals within the nigrostriatal pathway is of
huge significance.
In addition to its effects on BMP signalling in dopaminergic neurons, it is worth
noting that Quinacrine has also been shown to be a potent non-selective inhibitor of
phospholipase A2 (PLA2) (Tariq et al., 2001, Talk et al., 1997). PLA2 is an important
enzyme in the inflammatory response and within the brain, PLA2 regulates the conversion
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of arachidonic acid into proinflammatory mediators and its reabsorption into the
membrane (Farooqui et al., 2006). When PLA2 activity becomes disrupted, abnormally
high amounts of proinflammatory mediators are produced, resulting in oxidative stress
and neuroinflammation analogous to neurological diseases such as PD (Farooqui et al.,
2006). PLA2 is also known to play a role in regulating the synaptic release of dopamine
within the adrenal medulla (Kudo et al., 1996). A study investigating the effect of PLA2
on animal behavioural demonstrated that rats who received a unilateral intranigral lesion
of PLA2 displayed significantly increased apomorphine-induced rotational behaviour,
suggesting that PLA2 can cause severe inhibition of dopamine release within the
nigrostriatal pathway (Brunner and Gattaz, 1995). In support of this, another study
observed that mice deficient in group IV cytosolic PLA2 are resistant to the degenerative
effects of the dopaminergic neurotoxin MPTP (Klivenyi et al., 1998). These studies
support the hypothesis that inhibitors of PLA2, like Quinacrine, could be a promising lead
for the treatment of neurological disorders. Interestingly, it has been shown that TGF-β
signalling in mesangial cells, leading to the activation of Smad proteins, attenuates PLA2
signalling (Xin et al., 2004). Consequently, further work is needed to clarify whether a
relationship exists between BMP-Smad signalling and PLA2 activity in dopaminergic
neurons, which may further elucidate the mechanism of action of Quinacrine.
Similarly, Niclosamide is also known to modulate several cell signalling cascades
including Wnt/β-catenin, mTOR, JAK/STAT3 and NF-κB and can cause mitochondrial
depolarisation through the uncoupling of oxidative phosphorylation (Chen et al., 2018,
Kadri et al., 2018, Alasadi et al., 2018). This is interesting as PINK1, a mitochondrial
serine/threonine-protein kinase, regulates mitochondrial homeostasis and is activated by
mitochondrial depolarisation (Kazlauskaite and Muqit, 2015). Furthermore, point
mutations in the PINK1 gene are responsible for autosomal recessive forms of early onset
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PD (Valente et al., 2004). Niclosamide treatment has also been shown to indirectly
activate endogenous PINK1 signalling in cultured cortical neurons (Barini et al., 2018).
These findings suggest a possible therapeutic role for Niclosamide to slow the
progression of PD neuropathology through the activation of PINK1, as well as BMP
signalling.
In summary, this study has shown that the FDA-approved drugs Quinacrine and
Niclosamide elicit positive phenotypic changes in both SH-SY5Y cells and primary
cultures of dopaminergic neurons. Specifically, these drugs confer neurotrophic effects
on SH-SY5Y cell and cultured dopaminergic neurons by stimulating the canonical BMPSmad signalling pathway. Furthermore, Quinacrine and Niclosamide have been shown
to be protective against MPP+- and 6-OHDA-induced dopaminergic degeneration and can
protect and restore dopaminergic axon degeneration caused by AAV-α-synuclein. Further
work is needed to examine the effects of Quinacrine and Niclosamide in in vivo models
of PD such as the AAV-α-synuclein rat model and to further explore the mechanism of
action of these compounds. However, collectively this study adds considerable evidence
to the potential use of these small molecule drugs to target and protect dopaminergic
neurons and justifies their further investigation as a potential therapeutic agents for
neuroprotection in PD.
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Chapter 7.0

AAV-BMP2 causes the loss of dopaminergic striatal terminals
and exacerbates α-synuclein-induced motor deficits in the αsynuclein rat model of Parkinson’s disease.

7.1 Aims of Study
• Evaluate AAV-BMP2 in primary dopaminergic neurons
• Investigate the long-term effects of AAV-mediated delivery of BMP2 in vivo
• Determine if there is a neuroprotective effect of AAV-BMP2 against α-synuclein
overexpression

• Determine the effect of α-synuclein and AAV-BMP2 on motor behaviour
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7.2 Abstract
Introduction: The use of viral vectors to achieve long-term, targeted delivery of NTFs
to the brain of PD patients is an area of growing interest. However, the first clinical trials
using gene delivery of Neurturin to the putamen and SN, has had disappointing outcomes
to date. BMP2 is a member of the BMP family and represents a novel NTF for
dopaminergic neurons. This study therefore evaluated the neuroprotective effect of
intranigral gene delivery of AAV-BMP2 in the α-synuclein pre-clinical model of PD.
Methods: 80 adult female SD rats were used over two experiments. In experiment 1;
animals received a unilateral injection of an AAV-Cont+AAV-Cont or AAVBMP2+AAV-Cont vector combination into the SN. In experiment 2; animals received an
AAV-aSyn+AAV-Cont or an AAV-aSyn+AAV-BMP2 vector combination into the SN.
Behavioural tests of sensorimotor function were carried out at 16, 20 and 24 weeks, prior
to post-mortem analysis of a-synuclein pathology and nigrostriatal integrity at 24 weeks.
Results: Intranigral delivery of AAV-BMP2 induced a substantial loss of striatal fibres
and striatal dopamine levels at 24 weeks post-surgery. AAV-BMP2 animals also
presented with extensive forelimb akinesia as measured by the stepping test of motor
function. In addition, when given in combination with AAV-αSyn, AAV-BMP2
exacerbated the functional deficits induced by α-synuclein overexpression.
Conclusions: Intranigral AAV-BMP2 is not protective against α-synuclein and is toxic
to striatal terminals at the viral titre used in this study. More work is now needed to
evaluate the safety and effective viral load of AAV-BMP2 in vitro and in vivo in order to
rationalise the further development of BMP2 for the treatment of PD.
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7.3 Introduction
The current available therapies for the treatment of PD are solely symptomatic and
therefore do not slow or stop the degeneration of dopaminergic neurons or the
accumulation of α-synuclein (Raza et al., 2019). Therefore, there is an urgent need for
disease modifying therapies that can replace the dopaminergic neurons that have been
lost or regenerate those that remain. In reference to the latter, one promising therapeutic
intervention is the application of NTFs. However, the administration of NTFs to the brain
has thus far proven difficult given the rapid metabolism of neurotrophic factors in vivo,
coupled with insufficient spread to the target area (Lang et al., 2006).
The advent of gene therapy using viral vectors to deliver a gene of interest into the
brain has the potential to overcome these hurdles and achieve long-term, targeted delivery
of neurotrophic factors (Lundstrom, 2018). There are several candidate NTFs that have
achieved promising results in pre-clinical models using AAV or LV vectors including
GDNF (Chen et al., 2008, Decressac et al., 2011, Lu-Nguyen et al., 2014), Neurturin
(Gasmi et al., 2007, Herzog et al., 2007, Kordower et al., 2006, Bartus et al., 2011), CDNF
(Cordero-Llana et al., 2015, Bäck et al., 2013, Ren et al., 2013), MANF (Cordero-Llana
et al., 2015, Hao et al., 2017), and VEGF (Tian et al., 2007). However, the vast majority
of these studies have evaluated the effect of the viral delivery of NTFs against MPTP and
6-OHDA lesioned animal models. While these animal models are indeed useful, they do
not accurately mimic the α-synuclein pathophysiology that is central to PD progression
(Stefanis, 2012, Ko and Bezard, 2017). Related to this is the recent failure of AAV-GDNF
to protect dopaminergic neurons against a novel α-synuclein model of PD (Decressac et
al., 2011), despite extensive pre-clinical evidence of GDNF neuroprotection against the
classical toxin models of the disease. In addition, clinical trials using AAV-mediated
delivery of Neurturin to the brain has thus far failed to reach its primary end-points
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(Marks et al., 2010, Warren Olanow et al., 2015). This failure emphasises the need to
evaluate potential NTFs against an α-synuclein model to justify the further development
of these therapies.
In chapter 4.0, the potential of intranigral AAV-mediated delivery of GDF5 in the
α-synuclein animal model of PD was investigated. In that study, AAV-GDF5 exerted
potent neuroprotection to dopaminergic neurons and their striatal terminals against αsynuclein and attenuated the motor deficits induced by the α-synuclein overexpression.
GDF5 is a member of the BMP family, which is known to harbour several other NTFs
for dopaminergic neurons, including BMP2 (Jordan et al., 1997, Reiriz et al., 1999,
Hegarty et al., 2014a, Hegarty et al., 2014c). As seen in chapter 5.0, BMP2 was the only
ligand in the BMP family that was found to be co-expressed with five key markers of
dopaminergic neurons within the SN and moreover, the expression of BMP2 was shown
to be downregulated in late stage PD, while the expression of its target receptors remained
unchanged. rhBMP2 was demonstrated to promote TH+ cell viability against MPP+ and
6-OHDA and was neuroprotective against MPP+ and 6-OHDA induced somal and axonal
degeneration. Moreover, rhBMP2 was shown to promote neurite length in dopaminergic
neurons overexpressing WT and mutant A53T α-synuclein. In addition, GDF5 was
shown to upregulate the expression of BMP2 both in vitro and in vivo, suggesting that
BMP2 may contribute to the neurotrophic actions of GDF5. In light of the growing
evidence in support of BMP2, this study aimed to evaluate the neurotrophic potential of
intranigral delivery of AAV-BMP2 in the α-synuclein animal model of PD.
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7.4 Results
7.4.1 AAV2/5-BMP2 transduces TH+ neurons and promotes neurite
growth.
Owing to the substantial neurotrophic effects achieved with rhBMP2 in chapter 5.0 in
vitro, to test the potential ability of AAV-BMP2 to integrate into TH+ neurons in vivo,
E14 VM cultures were transduced with an AAV-BMP2 vector using an MOI of 5×104
for 10 DIV. The cultures were then immunocytochemically stained for BMP2 and TH
which showed strong expression of the AAV-BMP2 vector throughout the VM culture
and notably, inside TH+ neurons (Fig. 7.1A). In order to assess the effect of AAV-BMP2
on TH+ neurons, E14 VM cultures were transduced with an AAV-GFP control vector or
AAV-BMP2 vector for 10 DIV. Neurite length and TH+ cell survival were then analysed
as a readout of neurotrophic potential. Here AAV-BMP2 was found to have significantly
increased neurite length compared to AAV-GFP (Fig. 7.1B, C). In addition, there was no
change in TH+ neuron viability in cultures transduced with AAV-BMP2 compared to
AAV-GFP cells (Fig. 7.1D). These preliminary results indicated that the AAV-BMP2
viral vector can successfully transduce TH+ neurons and can mediate neurotrophic effects
on neurites without adversely affecting cell survival.

7.4.2 Experimental Design
Having shown the transduction of TH+ neurons by the AAV-BMP2 vector in vitro, an in
vivo experiment was then carried out. The approach to this animal study was modelled
on chapter 4.0. However, given the lack of a substantial behavioural phenotype after αsynuclein overexpression, the viral titre of each vector was increased 1.5-fold. In
experiment 1, the safety and efficacy of AAV-mediated delivery of BMP2 to the SN was
evaluated. Animals received a unilateral injection of either an AAV2/5-Cont+AAV2/6-
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Cont (AAV-Cont) or an AAV2/5-BMP2+AAV2/6-Cont (AAV-BMP2) vector
combination into the SN (Fig. 7.2A). Concurrently, experiment 2 assessed whether BMP2
could offer neuroprotection against the neurodegeneration induced by the overexpression
of human WT α-synuclein. Here, animals received a unilateral injection of an AAV2/6αSyn+AAV2/5-Cont (AAV-αSyn) or an AAV2/6-αSyn+AAV2/5-BMP2 (AAVαSyn/BMP2) vector combination into the SN (Fig. 7.2B). In both cases, behavioural
testing was carried out at four-weekly intervals beginning 16 weeks after stereotactic
surgery (Fig. 7.2C). This 16 week time-point was based on evidence from the AAVGDF5 study in which a behavioural phenotype became apparent only at 16 weeks postsurgery. Animals were sacrificed at 24 weeks and analysed for transgene overexpression
and nigrostriatal integrity.

7.4.3 Intranigral delivery of AAV-BMP2 leads to substantial loss of TH+
striatal fibres at 24 weeks post-surgery.
In experiment 1, the safety and efficiency of intranigral AAV-mediated delivery of BMP2
was evaluated relative to animals who had received an AAV-Cont vector. After 24 weeks,
animals were sacrificed and assessed for nigrostriatal integrity by immunohistochemical
staining for TH (Fig. 7.3B, F). To confirm the expression of the BMP2 transgene, SN
sections from AAV-BMP2 animals were also immunohistochemically stained for BMP2
and TH which showed strong expression of BMP2 within TH+ neurons in the ipsilateral
SN (Fig. 7.3A). Quantification of the number of TH immunoreactive neurons in the SN
showed no significant difference between AAV-BMP2 and AAV-Cont animals (Fig.
7.3B, C). However, analysis of TH staining as a percentage of the contralateral intact
striatum revealed a significant loss of ~40% TH+ fibres in the ipsilateral striatum of AAVBMP2 animals compared to a reduction of ~18% in AAV-Cont animals after 24 weeks
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(Fig. 7.3D, F). In addition, HPLC analysis of dopamine levels in the striatum
demonstrated a significant loss of ~33% of striatal dopamine in AAV-BMP2 animals
relative to those injected with an AAV-Cont vector (Fig. 7.3E). The initial results of this
study therefore indicate that AAV-BMP2, at least at the titre used in this study, leads to
chronic degeneration of nigrostriatal TH+ fibres.

7.4.4 Intranigral AAV-αSyn delivery induces strong overexpression of
α-synuclein in the SN and Striatum.
Concurrently, in experiment 2, animals received a unilateral intranigral injection of an
AAV-αSyn vector and concomitantly either an AAV-Cont or an AAV-BMP2 vector (Fig.
7.4). To confirm overexpression of the α-synuclein transgene, SN and striatal sections
from AAV-αSyn and AAV-αSyn/BMP2 animals were immunohistochemically stained
for α-synuclein (Fig. 7.4A). Quantification of α-synuclein staining revealed wide-spread
expression of α-synuclein throughout the dorsolateral striatum (Fig. 7.4A, B) and the SN
(Fig. 7.4D) at 24 weeks post-surgery. In addition, the level of α-synuclein expression did
not differ between AAV-αSyn and AAV-αSyn/BMP2 animals. To confirm the targeted
delivery of α-synuclein to TH+ neurons, SN sections from AAV-αSyn animals were also
immunohistochemically stained for α-synuclein and TH which showed α-synuclein
overexpression within TH+ neurons (Fig. 7.4C). These results demonstrate that intranigral
delivery of AAV-αSyn penetrates dopaminergic neurons and AAV-BMP2 does not
attenuate the expression of α-synuclein.
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7.4.5 AAV-BMP2 does not protect dopaminergic neurons from the rat
AAV-αSyn model of PD.
At 24 weeks post-surgery, animals in experiment 2 were sacrificed and assessed for
nigrostriatal integrity. To determine the neurodegeneration induced by the
overexpression of α-synuclein and whether AAV-BMP2 was neuroprotective against this
degeneration, the number of TH+ neurons in the ipsilateral SN were measured against the
contralateral side. At 24 weeks post injection of AAV-αSyn, there was ~23% loss of TH+
neurons compared to the intact side (Fig. 7.5A, C). While animals injected with AAVαSyn/BMP2 experienced ~20% loss of TH+ neurons compared to the intact side (Fig.
7.5A, C). In addition, quantitative analysis of TH+ striatal fibre density showed the
overexpression of α-synuclein induced a ~35% loss in TH immunoreactivity in the
ipsilateral striatum compared to the intact side (Fig. 7.5B, D) while co-delivery of AAVαSyn with AAV-BMP2 led to ~39% loss in TH+ striatal density in the ipsilateral striatum
compared to the intact side (Fig. 7.5B, D). Moreover, analysis of striatal dopamine levels
using HPLC analysis revealed that intranigral delivery of AAV-αSyn in combination with
AAV-BMP2 induced a further ~22% reduction in striatal dopamine compared to AAVαSyn alone (Fig. 7.5E), however this result was not statistically significant (p<0.08).
Collectively, these data indicate that AAV-BMP2, at the titre tested in this study, is not
neuroprotective against α-synuclein overexpression.
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7.4.6 Long-term viral-mediated overexpression of WT -synuclein in
the rat SN leads to sensorimotor impairments that are exacerbated by
AAV-BMP2.
To determine the effect of α-synuclein overexpression on motor behaviour and whether
this could be prevented by AAV-BMP2, animals underwent a battery of behavioural tests
including the whisker, stepping and cylinder tests of sensorimotor function beginning at
16 weeks post-surgery and repeated again at weeks 20 and 24. Firstly, using a two-way
repeated measures ANOVA the effect of AAV-BMP2 and time on motor function were
examined relative to AAV-Cont animals (Fig. 7.6A-C). In the whisker test, neither AAVBMP2 (F(1, 22) = 2.752; p=0.1114) nor time (F(2, 44) = 2.482; p=0.7813) had an effect on
performance relative to control animals (Fig. 7.6A). In addition, neither AAV-BMP2 (F(1,
22)

= 0.4017; p=0.5327) nor time (F(2, 44) = 2.098; p=0.1349) had an effect on the cylinder

test relative to control animals (Fig. 7.6C). However, there was a significant effect of
AAV-BMP2 (F(1, 22) = 31.44; p<0.0001) but not time (F(2, 44) = 0.3075; p=0.7369) on
performance in the stepping test (Fig. 7.6B). Post-hoc analysis using a Bonferroni
correction showed that AAV-BMP2 animals performed significantly worse than controls
in the stepping test at all time points examined; 16 weeks (p=0.0008), 20 weeks
(p=0.0005) and 24 weeks (p=0.0121) (Fig. 7.6B).
The effect of α-synuclein overexpression and time on motor performance relative
to control animals were also analysed using a two-way repeated measures ANOVA (Fig.
7.6D-F). In the whisker test, time (F(2, 44) = 3.621; p=0.0350) but not AAV-αSyn (F(1, 22)
= 0.3256; p=0.5740) had an effect on performance relative to control animals (Fig. 7.6D).
While in the cylinder test neither AAV-αSyn (F(1, 22) = 2.279; p=0.1454) nor time (F(2, 44)
= 0.5089; p=0.6047) had an effect on performance relative to control animals (Fig. 7.6F).
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However, there was a significant effect of AAV-αSyn (F(1, 22) = 9.659; p=0.0051) but not
time (F(2, 44) = 1.158; p=0.3234) on performance in the stepping test (Fig. 7.6E). Post-hoc
analysis using a Bonferroni correction revealed that AAV-αSyn animals performed
significantly worse than control animals at the 16 week timepoint (p=0.0379), but not at
the 20 week (p=0.4867) or 24 week (p=0.1002) timepoint (Fig. 7.6E).
Given the effects of AAV-Syn and AAV-BMP2 were predominantly seen in the
stepping test, the four groups were then directly compared at the 24 week time point (Fig.
7.6G). A one-way ANOVA at 24 weeks revealed there was a significant effect in the
cylinder test with a post-hoc Tukey test showing a significant reduction in the number of
placings of AAV-αSyn, AAV-BMP2 as well as AAV-αSyn/BMP2 animals relative to
AAV-Cont animals (Fig.7.6G). Moreover, compared to AAV-Cont animals, the effect of
AAV-BMP2 (p=0.0046) and AAV-αSyn/BMP2 (p<0.0001) were worse than that of
AAV-αSyn alone (p=0.0336) however AAV-BMP2 and AAV-αSyn/BMP2 were not
significantly different from AAV-αSyn. Collectively these data show that intranigral
AAV-BMP2 caused significant impairments to forelimb behaviour relative to AAV-Cont
animals. In addition, while intranigral AAV-Syn led to significant impairments in some
aspects of forelimb function relative to AAV-Cont animals, this was in these cases
exacerbated by co-delivery of AAV-BMP2.
In addition, given that weight loss has previously been shown to be an adverse
effect of GDNF (Nutt et al., 2003, Manfredsson et al., 2009), the average weight of the
animals in each group at 24 weeks was analysed by one-way ANOVA and showed there
were no differences in weight relative to AAV-Cont animals (Fig. 7.6H). This result
indicates that the overexpression of BMP2 or α-synuclein caused no adverse effect on
weight.
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7.5 Figures and Figure Legends

Fig. 7.1 AAV-BMP2 co-expresses with TH+ neurons and promotes neurite growth.
A Representative photomicrographs of BMP2 expression in TH+ neurons. Scale bar =
25µm. B Graph of neurite length C Representative photomicrographs D Graph of total
TH+ neurons expressed as a percentage of total cells after transduction with either AAVGFP or AAV-BMP2 for 10 DIV. Scale bar = 50µm. All data are presented as mean ±
SEM from at least three experiments. (***p < 0.001 vs. control. Unpaired Student’s ttest).
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Fig. 7.2 Experimental Design. A In Experiment 1, animals received a unilateral injection
of an AAV-Cont+AAV-Cont or AAV-BMP2+AAV-Cont vector combination into the
SN. N=20 per group. B In Experiment 2, animals received a unilateral injection of an
AAV-αSyn+AAV-Cont or AAV- αSyn+AAV-BMP2 vector combination into the SN.
N=20 per group. C Schema showing the study timeline for each experimental group from
0-24 weeks, including behavioural testing and post-mortem assessment measure. IHC =
Immunohistochemistry.
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Fig. 7.3 Intranigral delivery of AAV-BMP2 leads to substantial loss of TH+ striatal
fibres at 24 weeks post-surgery. A Representative photomicrographs showing
expression of the BMP2 transgene (green) in TH+ neurons (red) in the ipsilaterally
(injected) SN at 24 weeks’ post-injection of the AAV-BMP2 vector. Scale bar = 50µm.
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B Representative photomicrographs of AAV-Control (Black) and AAV-BMP2 (Pink)
TH-stained sections through SN on the ipsilateral side. Scale bar = 200µm. C, D,
Graph showing TH immunoreactivity in C the SN and B the striatum expressed as a
percentage of the intact side. E Graph of HPLC data showing striatal dopamine (DA)
levels expressed as a percentage of the intact side. F Representative photomicrographs of
TH-stained sections through the striatum on the ipsilateral side and the contralateral intact
side. Scale bar = 1mm. All data are presented as mean ± SEM and analysed by a Student’s
t-test; *p< 0.05, ***p < 0.001 vs control.
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7.4. Intranigral AAV-αSyn delivery induces strong overexpression of α-synuclein in
the SN and Striatum. A Representative photomicrographs and B Quantification of αsynuclein expression in the striatum of AAV-αSyn and AAV-αSyn/BMP2 animals 24
weeks post-surgery. Scale bar = 1mm. C Representative images of the SN of AAV-αSyn
animals immunofluorescently stained for α-synuclein and TH. Scale bar = 50µm. D
Quantification of α-synuclein expression in the SN. All data are presented as mean ±
SEM and analysed by a Student’s t-test.
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Fig. 7.5 AAV-BMP2 does not protect dopaminergic neurons from the rat AAV-αSyn
model of PD. A, B Representative photomicrographs of TH staining in A the ipsilateral
SN and B the striatum in animals injected with AAV-Syn with either an AAV-Cont
(purple) or AAV-BMP2 (pink) vector into the SN. Scale bar in A = 200µm; in B = 1mm.
C, D Quantification of TH immunoreactivity expressed as a percentage of the
contralateral intact side in C the SN and D the striatum for both experimental groups. E
Graph of HPLC data showing striatal dopamine (DA) levels expressed as percentage of
the intact side. All data are presented as mean ± SEM and analysed by a Student’s t-test.
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Fig. 7.6 Long-term viral-mediated overexpression of WT -synuclein in the rat SN
leads to subtle sensorimotor impairments that are not protected by AAV-BMP2. AF Graphs showing the results of the A, D whisker, B, E stepping and C, F cylinder tests
at four weekly intervals from 16 weeks up to 24 weeks after stereotactic injection with
A-C an AAV-Cont+AAV-Cont (Black) or AAV-BMP2+AAV-Cont (Pink) or D-F an
AAV-αSyn+AAV-Cont (Purple) or AAV-αSyn+AAV-BMP2 (Purple/Pink) vector into
the SN. G Graph showing the combined experimental results of the stepping test at 24
weeks post stereotactic injection into the SN with AAV-Cont+AAV-Cont, AAVBMP2+AAV-Cont, AAV-αSyn+AAV-Cont or AAV-αSyn+AAV-BMP2, as indicated.
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H Graph showing the final weight of animals in all experimental groups (N=20). All data
are mean ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001 vs control; A-F two-way ANOVA
with post-hoc Bonferroni’s test; G one-way ANOVA with post-hoc Tukey’s test (n=12
per group)).

7.6 Discussion
The application of dopaminergic NTFs as a therapeutic intervention for PD is a key area
of interest (Sullivan and O’Keeffe, 2016). However, neurotrophic factors themselves are
not ideal candidates as they are rapidly metabolised in the brain by endogenous enzymes.
Gene therapy using viral vectors to transfer the gene of interest into specific regions of
the brain serves to circumvent this issue to achieve long-term, targeted delivery of
neurotrophic factors (Axelsen and Woldbye, 2018, Lundstrom, 2018). Given the
successful outcome of AAV-GDF5 exerting neuroprotection against the α-synuclein rat
model of PD in chapter 4.0, this study aimed to evaluate the potential of intranigral
delivery of AAV-BMP2 against the same animal model of the disease.
E14 VM cultures were initially transduced with AAV-BMP2 for 10 DIV and
immunocytochemical staining revealed strong expression of BMP2 inside TH+ neurons.
In addition, AAV-BMP2 promoted neurite length of TH+ neurons and did not affect the
number of TH+ neurons in culture compared to the AAV-GFP control, indicating the
safety and efficacy of AAV-BMP2 in E14 VM cultures. The approach to the animal study
was then consistent with the AAV-GDF5 study in chapter 4.0. The safety and proficiency
of intranigral delivery of AAV-BMP2 was assessed. Immunofluorescent staining for
BMP2 and TH immunoreactivity showed strong expression of the transgene within
dopaminergic neurons in the ipsilateral SN. Nigral integrity was assessed after 24 weeks
and showed there was no significant change in the number of TH+ neurons in the
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ipsilateral SN of AAV-BMP2 relative to AAV-Cont animals. However, analysis of
striatal integrity showed a substantial loss of TH+ fibres in AAV-BMP2 animals relative
to AAV-Cont animals, which was substantiated by HPLC analysis showing a significant
reduction in dopamine levels within the striatum. However, it is also worth noting that
AAV-Cont animals in this study had ~20% fewer TH+ neurons in the SN and ~14% fewer
TH+ striatal fibres compared to AAV-Cont animals in the GDF5 study, likely to be a
consequence of the increased viral titre used in this study. Moreover, while no difference
was identified in the whisker and cylinder motor tests in animals injected with AAVBMP2 compared to AAV-Cont animals, analysis of the stepping test revealed substantial,
long-lasting impairments of the contralateral paw of AAV-BMP2 animals, at all of the
time points tested. The results of this study therefore indicate that while intranigral
delivery of AAV-BMP2 did not negatively affect dopaminergic neurons in the SN, it had
a detrimental effect on dopaminergic terminals in the striatum and induced forelimb
akinesia in affected animals.
In a concurrent study, the consequences of viral mediated α-synuclein
overexpression in the SN and whether co-delivery with AAV-BMP2 could protect
dopaminergic neurons from α-synuclein induced neurodegeneration was assessed.
Intranigral AAV-αSyn caused widespread expression of α-synuclein in the dorsolateral
striatum and midbrain and was co-expressed in TH+ neurons within the ipsilateral SN.
The level of α-synuclein overexpression was consistent in AAV-αSyn and AAVαSyn/BMP2 animals, demonstrating that AAV-BMP2 does not quell the expression of αsynuclein. Additionally, after assessing nigrostriatal integrity, the number of TH+ neurons
in the ipsilateral SN as well as TH+ fibre density in the ipsilateral striatum were found to
be the same for both AAV-αSyn and AAV-αSyn/BMP2 animals, however co-delivery
with AAV-BMP2 did appear to worsen the loss of striatal fibres.
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Interestingly, the degenerative effect of AAV-BMP2 in this study appears to be
localised to striatal terminals and not dopaminergic neurons themselves, as evidenced by
the consistent number of TH+ neurons in the ipsilateral SN of AAV-BMP2 and AAVCont animals. In addition, the number of TH immunoreactive neurons in the ipsilateral
SN of AAV-αSyn animals was no different to that of AAV-αSyn/BMP2 animals
suggesting that the loss of TH+ neurons from the SN was a result of α-synuclein
overexpression alone. However, that BMP2 induces the degeneration of striatal terminals
is inconsistent with a previous study that showed BMP2-treated foetal mesencephalic
cells (FMCs) transplanted into the striatum of 6-OHDA lesioned rats increased the
number and morphology of dopaminergic neurons and reduced apomorphine-induced
rotations in adult rats (Espejo et al., 1999). These results are also unprecedented given
the substantial in vitro evidence in support of the neurotrophic effects of BMP2 (Jordan
et al., 1997, Reiriz et al., 1999, Hegarty et al., 2014a, Hegarty et al., 2013b, Stull et al.,
2001, Yan et al., 2016), coupled with the fact that AAV-GDF5, which was
neuroprotective in the α-synuclein model of PD, upregulates the expression of BMP2 in
the adult rat SN. Taking everything into account, it appears likely that the problem may
lie with the AAV-BMP2 virus itself, in that the viral titre used in this study may have
been too potent and better results may be achieved using a refined viral load.
The apparent toxicity of AAV-BMP2 on striatal terminals could also be a result of
increased astroglial activation resulting in a heightened immune response. Astrocytes
play a crucial role in the maintenance of brain and CNS homeostasis as well as in
neurogenesis and synaptogenesis and have been heavily implicated in neurodegenerative
disorders (Bélanger and Magistretti, 2009, Phatnani and Maniatis, 2015). Indeed, high
concentrations of BMP2 has previously been shown to significantly increase both the
number and phenotype of astroglial cells in primary VM cultures (Reiriz et al., 1999) and
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promotes the differentiation of oligodendroglial-astroglial progenitor cells into astrocytes
(Mabie et al., 1997). Astrocytes are immunocompetent cells and act as important
regulators of inflammation within the brain. When astrocytes become activated, known
as astrogliosis, this stimulates an immune response in which immune modulators
including cytokines and growth factors are released with potential neurotoxic effects
(Bélanger and Magistretti, 2009, Farina et al., 2007). These include the release of
potentially harmful reactive oxygen species (ROS) and the formation of glial scars,
thought to disrupt axon regeneration and neurite outgrowth (Sofroniew, 2005). Thus, the
disappointing outcome of intranigral AAV-BMP2 in this study may in part be due to an
increased astroglial response induced by the high viral titre of BMP2.
In addition, the level of α-synuclein-induced degeneration in this study was shown
to be less than that achieved in the GDF5 study in chapter 4.0. In the GDF5 study, αsynuclein overexpression caused a significant loss of ~36% of TH+ neurons from the SN
and ~45% loss in striatal fibre density. Yet in this study using a higher viral titre, αsynuclein overexpression induced a loss of ~23% of TH+ neurons from the SN and ~36%
loss in striatal fibre density. These results are surprising, and the reason is so far unclear
but may be caused by increased transduction competition between AAV-αSyn and AAVCont vectors in TH+ neurons in the SN. However, efficient co-delivery of multiple AAV
vectors has been achieved previously (Muramatsu et al., 2002, Shen et al., 2000, During
et al., 1998). Although in these studies, the genes shared a common goal to convert TH
into dopamine and thus recognising competing vectors in this case would prove difficult.
In addition, in these successful studies, the vectors have been delivered to the striatum
rather than the SN. Moreover, the overexpression of α-synuclein in this study did not
affect the sensorimotor function of animals in the whisker test, as seen in the GDF5 study.
However, AAV-αSyn did have a significant reduction in the number of placings with the
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contralateral paw in the stepping test, which was found to be aggravated by co-delivery
with AAV-BMP2. Given that α-synuclein overexpression did not affect performance in
the corridor test of lateralised response in the GDF5 study, this test was replaced by the
cylinder test of independent forelimb use in this study (Olsson et al., 1995). The cylinder
test is recommended as the best measure of lateralised sensorimotor behaviour in lesioned
rats (Björklund and Dunnett, 2019) however no change in the number of placings of
AAV-αSyn, or indeed AAV-BMP2 animals, was detected in this study. In addition,
similar to the GDF5 study, the behavioural results of animals injected with α-synuclein
in this study are in direct contrast with the behavioural phenotype achieved by Decressac
et al in a previous study at only 3 weeks post-surgery (Decressac et al., 2012b).
Collectively, the results of this study indicate that while AAV-BMP2 did not affect
dopaminergic neurons in the SN, the viral titre used proved to be toxic to striatal fibres
and striatal dopamine levels resulting in impaired motor function, perhaps mediated by
increased astroglial activation. AAV-BMP2 was not neuroprotective against α-synuclein
and instead exacerbated the α-synuclein-induced neurodegeneration and motor deficits.
Further work is now needed to investigate this potential immune response and to assess
the extent of neuroinflammation within the striatum. Moving forward with BMP2 gene
therapy, it will be important to decipher a safe and efficacious viral load of AAV-BMP2
through additional safety studies conducted both in vitro and in vivo and analysed over
various timepoints. As for the future use of the AAV-αSyn viral vector in animal models,
it is clear that more work is needed to ensure an efficient transduction of TH+ cells in the
SN that lead to a concrete, consistent behavioural phenotype in order to justify the further
use of this animal model.
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Chapter 8.0

Discussion
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8.1 Summary, Final Discussion and Future Work
The initial objective of this thesis was to investigate the efficacy of GDF5 and BMP2
in in vitro models of PD using SH-SY5Y cells and dopaminergic neurons in primary
cultures of E14 VM cultures. The second objective of this thesis was to establish the
potential of gene therapy using viral mediated delivery of GDF5 or BMP2 to protect
dopaminergic neurons in the SN and their axons projecting to the striatum, in the αsynuclein rat model of PD. The final aim of this thesis was to identify clinically
approved drugs, capable of crossing the blood brain barrier, that could potentially
modulate BMP signalling in dopaminergic neurons for use as a novel therapeutic
approach in PD.
In chapter 3.0 and chapter 5.0, this thesis demonstrated that GDF5 and BMP2,
respectively, exerted neurotrophic effects in a number of in vitro models of PD,
including in cells overexpressing WT and mutant α-synuclein expression plasmids.
However, at the time these studies were performed, the AAV-mediated in vitro model
of α-synucleinopathy developed in chapter 6.0, was not yet established. This model is
particularly useful given that the restorative effect of potential factors can be
determined after α-synuclein induced axonopathy has already occurred, as seen by the
neuroprotective effects of delayed treatment of Quinacrine and Niclosamide.
Therefore, going forward it will be important to examine the effects of both GDF5
and BMP2, and indeed other BMP ligands and potential molecules, on dopaminergic
neurons using this in vitro model. In addition, while it is now abundantly clear that
GDF5 and BMP2 promote the neurite growth of dopaminergic neurites given the
findings in this thesis and those contained in previous studies (Reiriz et al., 1999,
Hegarty et al., 2014a, Hegarty et al., 2013b, Jordan et al., 1997, Goulding et al., 2019,
O'Keeffe et al., 2004a), a better understanding of the molecular mechanisms mediating
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these effects are needed. Some recent work has shed some new light on this, however.
The Zinc finger E-box-binding homeobox (Zeb)2 (also known as Smad-interacting
protein-1 (Sip1)) transcription factor has recently been identified as a negative
regulator of Smad signalling in midbrain dopaminergic neurons (Hegarty et al.,
2017c). Zeb2 was identified from a PCR screen probing for novel regulators of
midbrain dopaminergic axon growth and was shown to be temporally regulated in the
developing midbrain in conjunction with several components of BMP signalling
during initial axon growth and striatal innervation. Moreover, Zeb2 overexpression in
E14 VM neurons significantly reduced phospho-Smad levels, while knockdown of
Zeb2 correlated with a significant increase in phospho-Smad expression as well as
neurite growth promotion which was shown to be dependent on the activation of BMP
signalling. These results were mirrored in vivo whereby Zeb2 knockout mice
demonstrated dopaminergic hyperinnervation of the striatum (Hegarty et al., 2017c).
More recently, my work contributed to a newly published study which
identified serine threonine receptor-associated protein kinase (STRAP) and
nucleoside diphosphate kinase (NME)1 proteins as regulators of GDF5-induced
neurite growth (Anantha et al., 2020). In this study, STRAP and NME1 were identified
through an untargeted proteomic screen of SH-SY5Y cells after treatment with GDF5.
Gene co-expression analysis of the neurotypical human SN also identified a coexpression pattern of STRAP and NME1 with multiple markers of dopaminergic
neurons (Anantha et al., 2020). Moreover, analysis of the SN of PD patients
demonstrated a significant loss of NME1 compared with controls. Furthermore, in
vitro studies revealed that gene knockdown of STRAP and NME1 in SH-SY5Y cells
prevented GDF5 induced increases in neurite growth, while treatment with
recombinant NME1 was capable of increasing neurite growth in SH-SY5Y cells and
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TH+ neurons in E14 VM cultures. In addition, AAV-mediated delivery of GDF5 to
the SN of adult rats significantly increased the expression of NME1 in TH+ neurons
(Anantha et al., 2020). When considered in the context of this thesis, this suggests that
the beneficial effects of AAV-GDF5 in the rat α-synuclein model in vivo (Goulding
et al. 2020 in press) may be due at least in part to upregulation of NME1 in vivo
(Anantha et al. 2020), however this requires experimental validation.
Beyond dopaminergic neurons, GDF5 has also been shown to enhance the
dendritic complexity in cultured rat hippocampal pyramidal neurons (Osório et al.,
2013). In this study, GDF5 was shown to regulate dendritic growth and morphology
through the upregulation of the hairy enhancer of split (HES)5 transcription factor, as
gene knockdown of HES5 completely prevented GDF5-mediated dendritic growth.
While GDF5 null mice exhibited significantly shorter and less complex dendritic
arbours, suggesting a crucial role for GDF5 in modulating dendritic growth in vivo
(Osório et al., 2013). Moreover, intracerebral infusion of GDF5 has been shown to
protect hippocampal neurons against kainic acid-induced degeneration (Zhao et al.,
2017). Collectively, these findings suggest that downstream effectors of GDF5 and
the BMP-Smad signalling pathway represent targets that are worthy of investigation
as potential disease-modifying therapeutic targets for PD. Future work on translating
these findings including identifying potential small molecule inhibitors of Zeb2 or the
investigation of the therapeutic potential of NME1 in vivo, possibly via viral mediated
delivery to the SN in animal models of PD, will be important.
In addition to downstream effectors, the identification of small molecule drugs
or biologics that are capable of initiating Smad pathway activation in dopaminergic
neurons holds significant potential and chapter 6.0 provides proof of principle of this
concept. Quinacrine and Niclosamide are FDA approved, clinically available drugs
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that were shown to modulate BMP2 expression in human tendon cells (Ghebes et al.,
2017). In chapter 6.0, both Quinacrine and Niclosamide demonstrated potent neurite
growth promoting effects in midbrain dopaminergic neurons against several in vitro
models of PD including AAV-mediated delivery of α-synuclein, through the
activation of the canonical Smad signalling pathway. In support of the use of small
molecule drugs as therapies for PD, additional small molecules compounds which
target and inhibit α-synuclein oligomer formation have also been shown to attenuate
axonal degeneration in iPSCs expressing A53T-α-synuclein (Kouroupi et al., 2017).
While other recent studies have identified small molecule compounds that can inhibit
α-synuclein misfolding and aggregation (Tóth et al., 2019, Perni et al., 2017, Pujols et
al., 2018), restore α-synuclein-impaired phagocytosis, block the cellular transmission
of α-synuclein (Tóth et al., 2019) and prevent the degeneration of dopaminergic
neurons (Pujols et al., 2018). Such findings highlight the potential of a combination
therapy using small molecule compounds, with each drug targeting a specific facet of
the α-synuclein pathology in PD.
The use of small molecule drugs such as Quinacrine and Niclosamide is also
quite significant from a patient safety perspective given that Quinacrine and
Niclosamide are readily available for systemic administration, completely bypassing
the need for invasive surgeries. However, to translate these findings into clinical trials,
pre-clinical evaluation of efficacy, toxicity, pharmacokinetic as well as
pharmacodynamic studies are required. To this effect, there have been some studies
examining the bioavailability of both Quinacrine and Niclosamide in animal models.
As mentioned in chapter 6.0, 6-OHDA-lesioned rats or MPTP-lesioned mice treated
daily with an intraperitoneal injection of 10, 30 or 60mg/kg Quinacrine daily for 5
days partially protected striatal dopamine levels and no adverse effects were noted by
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the authors (Tariq et al., 2001). However, systemic delivery of Quinacrine to the brain
is challenging due to its rapid efflux by the P-glycoprotein transporter which is found
in the endothelial cells of the CNS (Dohgu et al., 2004). To combat this issue, one
study reported that 10mg/kg Quinacrine given in combination with 100mg/kg
Cyclosporine A, a P-glycoprotein inhibitor, by oral gavage resulted in a 6-fold
increase in quinacrine accumulation within the brain compared to Quinacrine alone
(Ahn et al., 2012). However, this study noted that Quinacrine was effectively cleared
from the CNS some hours after administration and suggests that higher or more
frequent dosing regimens may be required to elicit beneficial changes within the brain
(Ahn et al., 2012).
In addition, Niclosamide has a poor solubility profile which hampers its
systemic bioavailability when administered orally (Whitesell, 1998). While there have
been no studies investigating the pharmacokinetics of Niclosamide in the brain, some
studies have evaluated methods of delivery to increase the bioavailability of
Niclosamide. In one such study, a 100mg/kg of a nano-suspension of Niclosamide
administered via oral gavage has been evaluated in mice for the treatment of ovarian
cancer (Lin et al., 2016a). Here the treatment regimen consisted of 5 times weekly for
4 weeks and post-mortem analysis indicated no adverse effects of Niclosamide on
weight, renal and hepatic function and histological analysis of vital tissue, including
the brain, showed no impairments, suggesting the safety of nano-formulated
Niclosamide in animals. In addition, the salt form of Niclosamide known as
Niclosamide Ethanolamine (NEN), which has increased water solubility, is known to
have an excellent safety profile as long-term oral treatment with high doses of NEN
in rats and dogs did not show any adverse effects even after one year (Hecht and
Gloxhuber, 1962, Andrews et al., 1982). Oral NEN has also been shown to be safe
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and effective in an animal model of type-2 diabetes (Tao et al., 2014). In addition,
Niclosamide has also been evaluated as an anticancer agent for glioblastoma, the most
common and aggressive malignant brain tumour in adults (Davis, 2016, Wieland et
al., 2013). Here, severe combined immunodeficient (SCID) mice were given an
intraperitoneal injection of 30mg/kg Niclosamide 3 times daily for 5 days and no
adverse effects were noted by the authors (Wieland et al., 2013). While these results
are indeed encouraging, it is clear that much work is needed to develop and evaluate
the safety profile and targeted efficacy of both drugs within the brain parenchyma
before evaluating their potential use in pre-clinical models of PD.
In chapter 7.0, the therapeutic efficacy of AAV-mediated delivery of BMP2 to
the SN was investigated and revealed that AAV-BMP2 had a detrimental effect on
striatal dopamine levels and TH+ striatal fibres, which led to consistent contralateral
forelimb akinesia in the stepping test. Moreover, AAV-BMP2 exacerbated the
pathological and behavioural effects of α-synuclein overexpression. The outcome of
this study was particularly disappointing given the positive findings for BMP2 in vitro
reported in chapter 5.0 and indeed elsewhere (Goulding et al., 2019, Goulding et al.,
2020, Hegarty et al., 2014a, Hegarty et al., 2013b, Espejo et al., 1999, Jordan et al.,
1997, Yan et al., 2016). In addition to the evidence that AAV-GDF5 upregulated the
expression of BMP2 in vivo, as seen in chapter 4.0. The reason for this outcome is
unclear but it seems likely to be due to the viral titre used in the study causing a protein
overload and an increased immune response. This has been seen previously with
adenoviruses whereby viral loads exceeding 1.0×108 vg/ml were associated with
chronic inflammation and vector mediated cytotoxicity (Thomas et al., 2001, Puntel
et al., 2010). In addition, viral transduction with GFP has been linked with cellular
toxicity, oxidative stress and immunogenicity, compounding its use as a molecular tag
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in vivo (Ansari et al., 2016, Goto et al., 2003, Stripecke et al., 1999, Koprich et al.,
2010). Moreover, while AAV vectors are associated with an excellent safety profile
in a clinical setting (Kelly et al., 2015), high doses of AAV vectors delivered to the
CNS via direct injection has led to toxicity in animal models (Haery et al., 2019,
Colella et al., 2017). In one particular study, the use of Cre-dependent ‘helper’ AAVs
for monosynaptic tracing was evaluated through stereotactic delivery to the
somatosensory cortex (Lavin et al., 2020). Here, the authors found that high titres of
the AAV vectors were associated with severe toxicity due to the high expression of
the ‘helper’ genes, which was not seen in diluted preparations that were optimised at
specific concentrations (Lavin et al., 2020). In addition, toxicity associated with
AAV-mediated transgene delivery to the retina has been shown to be entirely
dependent on the viral titre used, and is completely prevented at low doses (Khabou
et al., 2018). More relevant to PD, high doses of GDNF have been associated with
chronic adverse effects experienced by participants in a previous clinical trial (Nutt et
al., 2003, d'Anglemont de Tassigny et al., 2015) These findings, together with the
results of AAV-BMP2 in chapter 7.0, indicate that the dosing threshold of AAVBMP2 requires careful consideration and optimisation prior to further evaluation in
pre-clinical models, which is currently ongoing. In addition, evaluation of the innate
and adaptive immune response to the viral load, and to the vector itself, requires
further characterisation (Mingozzi and High, 2013, Colella et al., 2017).
In chapter 4.0, it was demonstrated that AAV-GDF5 protects dopaminergic
neurons and their axons as well as striatal dopamine levels in the α-synuclein animal
model of PD. In addition, AAV-GDF5 attenuated the motor deficits induced by αsynuclein overexpression. However, only a subtle behavioural phenotype was seen in
this model after 16 weeks compared to other studies using a similar viral construct and
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viral titre (Decressac et al., 2012b, Decressac et al., 2011). Additional limitations of
this model include the slow rate at which neurodegeneration develops and the level of
α-synuclein expression required to bring about this degeneration, which far exceeds
that seen in the human disease by almost 5-fold (Decressac et al., 2012c, Duffy et al.,
2018). Therefore, in developing this finding it will be important to determine the
effectiveness of AAV-GDF5 in an α-synuclein model with more robust motor
impairments. One such model includes the use of preformed α-synuclein fibrils (PFFs)
injected into the brain (Gómez-Benito et al., 2020). The use of PFFs is based on the
evidence that when α-synuclein protofibrils are injected into the brain, they act as
‘seeds’ which trigger the aggregation, hyperphosphorylation and ubiquitination of
endogenous α-synuclein (Luk et al., 2012, Patterson et al., 2019). These aggregates
have been shown to contain phosphorylated α-synuclein and are spread throughout
dopaminergic cell somas and neuronal processes (Luk et al., 2012, Paumier et al.,
2015, Chu et al., 2019). In addition, the morphology of these α-synuclein aggregates
is akin to that of human Lewy bodies and several studies have given additional
evidence of colocalization with markers of Lewy bodies (Wakabayashi et al., 2013,
Paumier et al., 2015, Chu et al., 2019). However, similarly to the AAV-α-synuclein
model, a limitation of this model is the slow development of neurological changes
within the brain and the onset of motor deficits (Luk et al., 2012, Paumier et al., 2015,
Peelaerts et al., 2015). To combat this, one study has evaluated a combined approach
in which AAV-α-synuclein and PFFs, at doses mimicking that found in human PD
pathology, were compared with the injection of AAV-α-synuclein or PFFs alone
(Thakur et al., 2017). In the combined study, AAV6-α-synuclein was unilaterally
injected into the SN and VTA first, followed four weeks later by unilateral injection
of PFFs into the same sites. The results of this study showed that the combined model

204

induced a profound loss of dopaminergic neurons, triggered the formation of Lewylike aggregates as well as fibrillar inclusions in dopaminergic cell soma and processes,
and induced a long-lasting inflammatory response, just 3 weeks post PFF injection
(Thakur et al., 2017). These neurological changes were significantly worse than those
achieved by AAV-α-synuclein or PFF alone. Moreover, the authors noted significant
impairment in the contralateral forelimb of animals who received the combined model
only 3 weeks post-injection compared to AAV-α-synuclein or PFF only and this
deficit was even more pronounced after 12 weeks (Thakur et al., 2017). These results
indicate that the concurrent use of AAV-α-synuclein and PFFs can reproduce the
cardinal features of human PD, which other α-synuclein models have failed to
replicate.
An additional model being evaluated to provide a more faithful representation
of PD involves the viral mediated overexpression of mutant A53T-α-synuclein, which
has been shown to induce nigrostriatal degeneration, Lewy-like pathology as well as
motor deficits in mice (Ip et al., 2017). In this study, AAV1/2-A53T-α-synuclein was
unilaterally injected into the SN. Behavioural output was then measured via the
cylinder test at 5 and 9 weeks post-surgery which revealed a significant asymmetry of
forepaw use, with animals favouring the ipsilateral side as early as 5 weeks (Ip et al.,
2017). At 10 weeks post-surgery, there was a significant loss of TH+ striatal fibres and
a substantial reduction in striatal dopamine levels as well as the dopaminergic
metabolite DOPAC. The number of TH immunoreactive neurons in the SN was also
dramatically reduced compared to control animals (Ip et al., 2017). This novel model
of α-synuclein pathology therefore also fulfils several criteria required for robust preclinical testing of disease-modifying therapies, such as AAV-GDF5.
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Additionally, given that AAV-mediated viral delivery of GDF5 was
neuroprotective when given at the same time as the α-synuclein insult, going forward
it will also be important to evaluate the neurorestorative properties of GDF5 in vivo
after α-synuclein-induced degeneration has already developed. This is critical because
at the time of onset of motor symptoms in PD, it is estimated that over 30% of
dopaminergic neurons have been lost from the SN but ~70% of striatal fibres have
also degenerated (Cheng et al., 2010). Relevant to this, a recent study has
demonstrated that the level of neuroprotection granted by LV-mediated delivery of
GDNF to the 6-OHDA-lesioned striatum was subject to the degree of nigrostriatal
degeneration (Quintino et al., 2019). While GDNF provided neuronal and behavioural
protection to animals when expressed at the time of lesion, expression of GDNF in
animals lesioned with 6-OHDA 6 weeks prior, offered no neurorestorative effects in
terms of dopaminergic neuronal rescue or a reversal of motor deficits (Quintino et al.,
2019). These findings align with the lacklustre results of previous GDNF clinical
trials, the nature of which involves participants already experiencing profound
nigrostriatal deterioration (Kordower et al., 1999, Lang et al., 2006, Nutt et al., 2003,
Whone et al., 2019a, Whone et al., 2019b). Related to this, studies with GDF5 in the
6-OHDA animal model have previously shown a partial protective effect on
dopaminergic neurons in the SN when given one week after 6-OHDA lesion, however
no protective effect was seen when given two weeks after the lesion (Hurley et al.,
2004).
Therefore, careful consideration also needs to be given to the type of patients
that may ultimately benefit from GDF5 therapy. It is widely hypothesised that the
failure of GDNF and Neurturin in clinical trials to date may be correlated with the fact
that the majority of patients enrolled in these trials were at advanced stages of PD
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(Sullivan and O’Keeffe, 2016, Hegarty et al., 2017a, Kirik et al., 2017, Bartus and
Johnson, 2017, Kordower and Bjorklund, 2013). This idea is supported by segregated
clinical data from individual participants from the recent AAV-Neurturin trials.
Analysis of this data demonstrated that patients who had received the intervention less
than 5 years after diagnosis benefitted the most, while those who had received AAVNeurturin more than 10 years post-diagnosis experienced no clinical benefit (Warren
Olanow et al., 2015, Bartus, 2015, Marks et al., 2010). This lack of clinical efficacy
may be attributed to the chronic axonal degeneration which occurs early in PD (Cheng
et al., 2010). NTF signalling requires communication between neuronal cells and their
axonal terminals innervating their target structures (Ito and Enomoto, 2016).
Therefore, at advanced stages of PD, it is possible that an inadequate number of axons
are available for the transport of NTFs. In support of this, post-mortem studies
conducted on some of the participants from the GDNF and Neurturin trials have
shown there to be a substantial loss of dopaminergic terminals in the putamen (Bartus,
2015, Love et al., 2005). Equally, the limited number of axons remaining may
themselves be undergoing the degenerative process which would significantly impact
on their capability to effectively transport proteins such as NTFs, which is supported
by evidence of impaired axonal transport in axons prior to their degeneration (Roy et
al., 2005, De Vos et al., 2008, Chung et al., 2009). In light of this evidence, patients
at earlier stages of PD, when the nigrostriatal system is not yet fully compromised,
may be more likely to benefit from potential GDF5 gene therapies in the future.
An interesting approach to evaluate the neurorestorative approach of GDF5
while the nigrostriatal system is undergoing degeneration may involve the study
paradigm used in the Quintino et al study described earlier. In this study GDNF was
under the control of a destabilising domain (DD) which allowed for the regulation of
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gene expression at a post-translational level (Tai et al., 2012, Iwamoto et al., 2010).
GDNF was expressed as a fusion protein coupled with a coding sequence for a DD,
which marks the fusion protein for degradation. Thus, expression of the GDNF-DD
fusion protein in the brain resulted in full proteasomal degradation. However, systemic
delivery of trimethoprim (TMP) blocks this proteasomal recognition, allowing for the
regulated and stable expression of GDNF (Quintino et al., 2019). This approach could
potentially be used to regulate the expression of, and further evaluate, AAV-mediated
delivery of BMP2 in future studies. In addition, the study paradigm provides a novel
approach to evaluate the neuroprotective and neurorestorative properties of NTFs in
animal models of PD that could be replicated with α-synuclein rather than 6-OHDA.
An additional benefit of using this animal model is that only one stereotactic surgery
is required, as the fusion protein can be delivered at the same time as the insult and
will only become active in the brain upon TMP administration. This would then allow
for the regulation and assessment of GDF5 gene therapy when the nigrostriatal system
has significantly deteriorated and thus give important insights into the therapeutic
window of GDF5 neuroprotection and potential neurorestoration. Moreover, this
approach could potentially be used to deliver NTFs, with controlled expression, in a
clinical setting.
Finally, in chapters 3.0 and 4.0 it was demonstrated that the overexpression of
α-synuclein did not affect the expression of the BMPRs and Smad mediators required
by both GDF5 and BMP2 to activate the canonical signalling pathway, both in vitro
and in vivo. In addition, animals overexpressing α-synuclein and GDF5 had
significantly increased levels of phospho-Smad expression compared to animals
overexpressing α-synuclein alone, suggesting target engagement and the integrity of
the BMP-BMPR-Smad signalling pathway. However, whether α-synuclein affects
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BMP-BMPR-Smad mediated transcription remains elusive. One way to determine this
would be to overexpress α-synuclein in SH-SY5Ys and E14 VM cultures and in
parallel, transfect these cultures with a Smad luciferase assay, such as the BRE-GFP
reporter assay used in chapter 6.0. This would allow for the evaluation of the effect of
α-synuclein overexpression on Smad dependent transcription after treatment with
GDF5, BMP2 as well as Quinacrine and Niclosamide which also mediate their
neurotrophic action exclusively through this pathway.
However, while transcripts for the BMPRs and Smad effector molecules were
found to be unaffected by α-synuclein in chapter 4.0, transcripts for RET, the coreceptor required for GDNF and Neurturin induced signalling, was shown to be
significantly downregulated after 20 weeks (Goulding et al., 2020 in press). While
this finding agrees with that previously shown (Decressac et al., 2012a), the reduction
in RET found in this study after 20 weeks was significantly less than that seen after 2
weeks in the previous study. In addition, it has been reported that α-synuclein leads to
the downregulation of Nurr1 (Decressac et al., 2012a, Jia et al., 2020), a critical factor
for the survival of dopaminergic neurons (Saucedo-Cardenas et al., 1998, Jiang et al.,
2005, Jankovic et al., 2005). However, a separate study found no evidence for a
reduction in Nurr1 in PD patients or after α-synuclein overexpression in mice (Su et
al., 2017). Collectively, given the evidence it would appear that the level of αsynuclein in the host brain may play a key role in regulating Nurr1 and RET
expression and potentially explains why Neurturin was found to be most beneficial in
patients more recently diagnosed with PD (Marks et al., 2010, Warren Olanow et al.,
2015, Bartus, 2015) when the α-synuclein load in the brain is not saturating. One way
to perhaps test this theory would be to design an in vivo study in which different groups
of animals received increasing titres of α-synuclein (Fig. 8.1). This would allow for
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the evaluation at specific time points of whether α-synuclein load affects Nurr1 and
RET, as well as mediators of the BMP-Smad signalling pathway and beyond. This
information could lead to major breakthroughs in developing targeted NTF therapies
for patients at all stages of PD.

Fig. 8.1 Schematic of potential in vivo study to evaluate the effect of α-synuclein
overexpression on signalling mechanisms in dopaminergic neurons. Cohorts of
rats receive an intranigral injection of α-synuclein at increasing titres A, B or C.
Animals from each cohort are sacrificed at timepoints beginning 4 weeks postinjection up to 52 weeks. Nigrostriatal integrity is evaluated as well as transcripts for
effector molecules required for specific pathway activation including RET, BMPRs,
Smad1/5 etc. Created with Biorender.com.
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8.2 Conclusion
The concept of NTF therapy and whether it remains a viable approach for the
treatment of PD has recently been called into question (Barker et al., 2020). This thesis
has demonstrated novel neurotrophic action of BMP2 and GDF5 including the
protection of dopaminergic cell bodies and their axons against several in vitro models
of PD. This thesis has also shown profound neuroprotection in vivo with GDF5 against
the degenerative effects of α-synuclein on the nigrostriatal pathway in the α-synuclein
pre-clinical model of the disease. Moreover, the overexpression of α-synuclein was
demonstrated to not affect the expression of the mediators required for the activation
of the canonical Smad signalling pathway both in vitro and in vivo. Therefore, the
collective findings in this thesis would suggest that NTF therapy using BMP ligands
is a viable approach and the evidence for GDF5 in vivo provides justification for the
further development of GDF5 gene therapy as a disease-modifying intervention for
PD. Finally, this thesis has demonstrated that the small molecule drugs, Quinacrine
and Niclosamide, have potent neurotrophic action against cellular models of PD as
well as neurorestorative properties in dopaminergic neurons against α-synucleininduced axonal degeneration in vitro. The effects of these compounds was shown to
be dependent on the activation of the canonical Smad signalling pathway. Therefore,
the findings in this thesis highlight the potential of using these small molecule drugs
to target the BMP-Smad signalling pathway in dopaminergic neurons as a novel
therapeutic approach for neuroprotection in PD.
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